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Murine gammaherpesvirus 68 (MHV-68) is a lymphotropic virus which infects wild
murid rodents and can readily infect experimental mice. Thus, MHV-68 is an
invaluable small animal model for elucidating gammaherpesvirus pathogenesis and
immune evasion strategies. The MHV-68 genome has been fully sequenced (Virgin et
al., 1997) and comparative sequence analysis has shown that it is more closely related to
Kaposi's sarcoma-associated herpesvirus (KSHV) and herpesvirus saimiri (HVS) than
Epstein-Barr virus (EBV). There are at least 80 open reading frames (ORFs) within the
genome, many of which are present in other gammaherpesviruses. There are, however,
4 ORFs, termed M1-M4, which are unique to MHV-68. Gammaherpesviruses have the
propensity to abduct immunomodulatory elements, therefore it is likely that such
elements will be encoded within the MHV-68 genome. One such candidate is the M4
gene. The aim of the project was to functionally characterise the M4 gene and elucidate
its role in the pathogenesis of MHV-68.
Half of the M4 protein was expressed in a bacterial expression system and the purified
protein was used to generate anti-sera. Immunoprecipitation studies demonstrated the
M4 sera bound to a protein of ~44kDa, the predicted size of the M4 product. Analysis
of M4 transcription in vitro showed that the gene was transcribed both early, prior to
DNA synthesis, and late in the virus lifecycle.
The M4 gene was cloned into a mammalian expression construct and transfected into
COS-7 cells. Cells containing the construct were selected under G418 (neomycin
derivative) antibiotic selection. However, we were unable to demonstrate that the COS-
7 cells expressed the M4 protein.
The M4 gene was inserted into MHV-76, a virus which lacks part of the left hand end of
the genome including the M4 gene, generating a M4 knock-in (M4KI) recombinant
virus. Apart from this deletion, MHV-76 harbours the full contigency of MHV-68
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genes. Polymerase chain reaction (PCR) and Southern analysis were used to
demonstrate the presence of the M4 gene in the M4KI virus. Reverse trancription-PCR
(RT-PCR) and northern analysis were used to show that the M4KI virus was expressing
M4 RNA in vitro. The M4KI virus was used for comparative studies with MHV-76,
which lacks the M4 gene, and MHV-68, which contains the M4 gene. The growth
kinetics ofMHV-76 are similar to MHV-68 in vitro but in contrast the virus appears to
be cleared more efficiently in vivo in the lungs of mice. The establishment of latency is
also impaired in the spleens of MHV-76-infected mice (Macrae et al., 2001). In vitro
studies revealed the M4KI virus growth kinetics were similar to MHV-68 and MHV-76.
Infection of BALB/c mice with the M4KI virus revealed that it replicates in the lung
with the same kinetics as MHV-76. Thus, compared to MHV-68, MHV-76 and M4KI
virus titres rise slightly faster, and levels of virus are reduced or cleared quicker. M4KI
virus infective centres were much reduced in the mediastinal lymph nodes in comparison
to MHV-76 and MHV-68, and were not detectable in the spleen. Thus, the M4 gene
product, in the context of the MHV-76 genome prevented the establishment of
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Herpesviruses are complex, enveloped viruses which contain a large double-stranded
DNA genome. Analysis of most vertebrates has yielded at least one herpesvirus
(Roizman et al., 1992). Hosts include lower vertebrates such as bony fish, reptiles and
amphibians, and higher vertebrates such as birds and mammals. Each herpesvirus is
usually limited to a single species in natural infections (Minson et al., 1989). This high
degree of host specificity implies that the members of the herpesvirus family, of which
there are over 100, have evolved in close association with their hosts.
1.1.1 Morphology
The architecture of a typical member of the herpesvirus family consists of a core which
contains viral DNA which is present as a toroid (Nazerian, 1974). The virion possesses
an icosadeltahedral capsid which is 100-110 nm in diameter containing 162 capsomeres.
A hole runs from the surface along the long axis and is 4 nm in diameter (Wildy et al.,
1963). The tegument is the term given to an asymmetric structure between the capsid
and envelope. Variation in the thickness of the tegument is usually determined by where
the virion is situated in the infected cell. This alterable thickness of the tegument
contributes in the size of herpesvirions which can range from 120 to 300 nm.
1.1.2 Classification
The original classification of herpesviruses was based on biological properties, but
current classification takes into consideration gene content and sequence similarities
(Roizman et al., 1981, 1992). The members of the family Herpesviridae are classified
into three subfamilies; the Alpha-, Beta-, and Gamma-herpesvirinae.
The Alphaherpesvirinae have a variable host range, grow relatively quickly in cell
culture, have a short reproductive cycle, and have the ability to establish latent infections
in nervous tissue. VZV (Varicella zoster virus), HSV-1 (herpes simplex virus type 1)
and HSV-2 (herpes simplex virus type 2) among others belong to the
Alphaherpesvirinae.
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The Betaherpesvirinae have a much more restricted host range, exhibit longer
reproductive cycles in cell culture, spread more slowly in cell culture and frequently
cause enlargement of infected cells. They include CMV (cytomegalovirus), HHV-6
(human herpesvirus type 6), and HHV-7 (human herpesvirus type 7). Viruses in this
subfamily are latent in tissues such as lymphoreticular cells, secretory glands and
kidneys.
The Gammaherpesvirinae have a host range that is commonly limited to the family
which the natural host is a member of. However, there are exceptions to the rule.
Members of this subfamily, such as EBV (Epstein-Barr virus), HVS (herpes virus
saimiri), MHV-68 (murine gammaherpesvirus-68), AHV-1 (alcelaphine herpesvirus 1)
and the more recently discovered KSHV (Kaposi's sarcoma-associated herpesvirus)
(Chang et al., 1994) are lymphotropic and tend to be specific for either T or B
lymphocytes. The gammaherpesvirus latent form is frequently maintained in lymphoid
tissue.
The three herpesvirus subfamilies have been subdivided into genera. The
Alphaherpesvirinae have currently been separated into two genera; the genus
Simplexvirus which includes HSV-1, and the genus Varicellovirus which includes VZV.
The Betaherpesvirinae have currently been separated into three genera; the genus
Cytomegalovirus which includes HCMV, the genus Muromegalovirus which includes
murine cytomegalovirus, and the genus Roseolovirus which include HHV-6. The
Gammaherpesvirinae have been separated into two genera; the genus
Lymphocryptovirus (gamma-1 herpesvirus) which includes EBV, and the genus
Rhadinovirus (gamma-2 herpesvirus) which includes HVS, KSHV, AHV-1 and MHV-
68.
An example of a herpesvirus which does not fit into the criteria of recognised
subfamilies is channel catfish virus (CCV). This virus is classified in the
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Alphaherpesvirinae. However , sequence analysis has not shown any significant genetic
relationship between CCV and alphaherpesviruses (Davison, 1992).
There are four common properties of herpesviruses. Firstly, enzymes such as DNA
polymerase and helicase which are involved in nucleic acid synthesis, and thymidylate
synthetase and thymidine kinase which are involved in DNA metabolism are produced
by all herpesviruses. Secondly, the nucleus is the compartment where viral DNA
synthesis and capsid assembly occurs. The capsid is always enveloped as it travels
through the nuclear membrane. Thirdly, the release of infectious progeny virus always
results in the death of the infected host cell. Lastly, herpesvirus genomes can remain
latent in their natural host cells. In latently infected cells, the viral genomes take the
form of closed circular molecules and there is a reduction in viral gene expression
(Roizman et al., 1992).
1.1.3 Conserved Genes
Herpesviruses possess linear double-stranded DNA genomes ranging from 125 to 230kb
and contain 70 to 200 genes. The nucleotide composition varies from 32% to 74% G +
C. The unique DNA of herpesvirus genomes contains reading frames which are closely
arranged and frequently overlap. There are genes orientated left and right and some
which contain splice sites. A widely differing pattern of repeated regions are commonly
found either within or at the ends of the genome (McGeoch, 1989, 1992, Roizman et al.,
1992).
Overall, the three subfamilies share about 40 conserved or core genes in common as
judged by their amino acid sequence comparisons. This strongly implies a common
evolutionary origin in that core genes are present as blocks which have been subjected to
rearrangement throughout the process of evolution (Davison et al., 1987, Chee et al.,
1990, Albrecht et al., 1992). Core genes are present in central processes such as
nucleotide metabolism, DNA replication, capsid structure, DNA packaging and virion
morphogenesis. The UL50 gene ofHSV-1, for example, is a core gene which functions
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as a deoxyuridine triphosphatase (McGeoch et al., 1994). This gene is non-essential,
that is, UL50 may be removed from the HSV-1 genome without affecting viral growth in
cell culture (McGeoch et al., 1994). Core genes do not necessarily correspond to
essential genes, however genes non-essential in tissue culture may be essential in vivo
e.g. UL39 and US2 (Roizman & Sears, 1996).
1.1.4 Unique Genes
Each individual herpesvirus encodes unique genes which have evolved to confer a
particular advantage to the virus. The unique genes serve as characteristics of particular
subfamilies but some genes are exclusive to a member of a subfamily. These genes are
responsible for aspects of the survival of each subfamily such as pathogenesis, latency
and immune evasion (Virgin et al., 1997, Albrecht et al., 1992, Russo et al., 1996, Baer
et al., 1984).
1.1.5 Gene Expression
In cells productively infected by a herpesvirus, viral gene expression occurs in a
sequential order in a cascade fashion. Groups of viral genes which are expressed are
termed immediate-early, early or late depending on when their encoded protein is
produced post-infection (Honess & Roizman, 1974). Immediate-early genes are defined
by their transcription after infection prior to viral protein synthesis, for example, the
ICP4 protein of HSV. Early genes are transcribed prior to DNA synthesis and their
products may be required to facilitate replication of the viral genome, for example
thymidine kinase and DNA polymerase. Late genes encode proteins produced after
DNA synthesis is initiated, for example structural proteins such as capsid proteins
(Roizman & Sears, 1996). Viral gene expression during latency occurs at a much lower
level than during lytic infection. In HSV, LATs (latency-associated transcripts) are
present abundantly in latently-infected neurons (Stevens et al., 1988, Krause et al.,
1988). During EBV latent infection, at least 11 EBV proteins are expressed (see section
1.2.3). Two genes encode Epstein-Barr virus early RNA (EBER 1 and EBER2), six
encode nuclear proteins (EBNAs 1, 2, 3a, b, c, and LP), and three encode integral
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membrane proteins (LMP 1, 2A, and 2B) (Kieff, 1996).
1.1.6 Lytic Replication
HSV is the most intensely studied of all herpesviruses and the large amount of
information known about herpesvirus lytic replication is predominantly from the HSV
work.
Initially, the virus enters a cell via attachment to cell surface receptors mediated by a
glycoprotein attachment pathway, resulting in a rapid fusion of the viral envelope with
the plasma membrane. The viral DNA is trafficked to the pores of the nucleus by its
surrounding viral capsid where it is released into the nucleus and immediately
circularises. The nucleus is the site where DNA synthesis proceeds. Sequential
expression of the cascade of immediate early, early and late genes ensues (described in
section 1.1.5). The virus encodes a number of proteins necessary for DNA synthesis
including the DNA polymerase. Replication occurs via a rolling circle mechanism
generating head to tail concatemers of unit length viral DNA which are cleaved and
packaged into preassembled capsids (Jacob & Roizman, 1977, Jacob et al., 1979). The
capsids containing the viral DNA acquire a new protein while viral glycoproteins and
tegument proteins accumulate in cellular membranes which attach onto the capsids. It is
uncertain how the virus acquires its final envelope membrane but it has been proposed
that after intranuclear assembly, the capsids acquire an envelope by budding through the
inner lamella of the nuclear membrane. The complete virion then passes through the
secretory pathway, and membrane glycoproteins are modified by the endoplasmic
reticulum (ER) and Golgi compartments (Johnson & Spear, 1982). An alternative
hypothesis suggests a two-step envelopment process in which the virus may acquire the
final envelope at the plasma membrane where glycoproteins have been trafficked to.
Recent mounting evidence strongly favours the two-step envelopment process. The
virus undergoes de-envelopment and then re-envelopment at a post-ER compartment
(Browne et al., 1996, Whiteley et al., 1999, Roller et al., 2000, Klupp et al., 2000).
Subsequently, the virus buds through the nuclear membrane resulting in an infectious
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mature virion (Roizman & Sears, 1996).
1.1.7 Diseases Associated with Alphaherpesviruses
Infection of an individual host for the first time by a herpesvirus can either be
symptomatic, or more commonly, clinically inapparent. Primary HSV infection
involves virus entry into sensory nerve endings and axonal transport to the neuronal cell
body where the latent infection is established. The majority of the adult population is
latently infected with HSV but most individuals appear asymptomatic. Individuals that
exhibit signs of primary HSV-1 infection present a condition termed acute
gingivostomatitis. Reactivation of HSV-1 which occur in a minority of infected
individuals result in recurrent lesions, termed 'cold sores'. HSV-2 primary infection can
cause aseptic meningtis and extragenital lesions, however, as with HSV-1, many
primary genital infections are inapparent. Secondary reactivating symptoms of HSV-2
present as genital lesions. Other diseases associated with HSV are infections of the eye
which can cause keratoconjuctivitis and invasion of the central nervous system which
presents as herpes encephalitis (Whitley, 1996).
VZV infection of an individual for the first time can cause varicella (chicken pox) and
reactivation results in zoster (shingles) (Mahalingam et al., 1999). Varicella occurs in
most individuals during their childhood and is usually an uncomplicated disease.
However, in immunocompromised patients, varicella is a severe and often life-
threatening disease. VZV also establishes a life long latent infection of sensory dorsal
root ganglia. Unlike HSV, VZV is disseminated, thus latency is established in multiple
ganglia. Zoster is frequent among the elderly. VZV can frequently cause complications,
such as post-herpetic neuralgia which involves severe debilitating chronic pain (Arvin,
1996).
1.1.8 Diseases Associated with Betaherpesviruses
CMV infection is acquired at an early age and is common in all populations. Primary
infection does not usually cause any symptomatic illness in normal healthy individuals,
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but has been associated with a mononucleosis syndrome. However, CMV is a major
cause of multi-organ disease in immunocompromised patients. Invasive CMV disease
can occur in newborn infants infected in utero, immunocompromised post-transplant
patients, and AIDS patients (Britt & Alford, 1996).
Studies with both HHV-6 and HHV-7 have been limited to primary infections of
children. Primary HHV-6 infection is the causative agent of exanthem subitum
(roseola), a common febrile illness that occurs in early childhood (Pellett & Black,
1996). HHV-7 appears to cause a very similar illness to that reported for HHV-6
(Frenkel & Roffman, 1996). Like CMV, infection of the immunocompromised and
AIDS patients can cause severe multi-organ involvement. However, these findings are
unclear and remain to be determined.
1.1.9 Diseases Associated with Gammaherpesviruses
Gammaherpesviruses cause significant disease in both humans and domestic cattle.
AHV-1 (alcelaphine herpesvirus-1) and OHV-2 (ovine herpesvirus-2) are non-human
gammaherpesviruses of economic importance in having a causal association with
malignant catarrhal fever (MCF), a fatal lymphoproliferative disorder of domestic
ruminants (Bridgen et al, 1989, Plowright et al, 1960). In humans, EBV the prototypic
gammaherpesvirus (see section 1.2) and the more recently discovered KSHV (Kaposi's
sarcoma-associated herpesvirus) (see section 1.4) have received the greatest interest due
to their association with disease in humans. Herpesvirus saimiri (HVS) has also been
well studied due to its oncogenic properties in marmosets and cottontail rabbits
(Medvezcky et al., 1989, Wright et al., 1977). Herpesvirus sylvilagus infects cottontail
rabbits (Hinze, 1971) and is of interest as this infection resembles infectious
mononucleosis in man and has analogy to EBV infection (Medveczky et al., 1984,
Kramp et al., 1985).
1.2 Epstein-Barr Virus
In the majority of cases primary EBV infection occurs in childhood and is clinically
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inapparent. Over 90% of the human population are asymptomatic carriers and it is
generally thought and accepted that EBV is orally transmitted. The individuals who do
not encounter the symptom-free primary infection during their childhood undergo
delayed primary infection during their adulthood. Half of these cases are asymptomatic
whereas the other 50% result in infectious mononucleosis syndrome characterised by
lymphadenopathy, particularly in the cervical region. The strong cell mediated immune
response that occurs is thought to be the principal acute infection surveillance
mechanism (Tomkinson et al., 1987, Lynne et al., 1998).
Virus replication primarily occurs in oropharyngeal epithelial cells and possibly in B
lymphocytes in lymphoid-rich areas (Sixbey et al., 1984). After initial infection, virus
can frequently be detected in saliva for life (Yao et al., 1985). The major reservoirs for
EBV are in the B lymphocytes in the circulating blood and lymphoid and bone marrow
tissues (Decker et al., 1996, Khan et al., 1996). Resting B cells harbour EBV in a latent
state where the genome is maintained in a non-productively replicating form. Persistent
EBV infection is primarily controlled by CD8+ cytotoxic lymphocytes (CTL) as the
virus persists in a few circulating B lymphocytes (Murray et al., 1992). Sporadic
reactivation of EBV and its infection of cells is effectively controlled by the immune
surveillance of viral specific cytotoxic T cells (Moss et al., 1979, Rickinson et al., 1979,
Rickinson et al., 1980).
1.2.1 EBV-Associated Diseases
EBV manifests as a disease when the virus-host balance is disturbed and its association
with a number of malignancies has generated great interest in the pathogenesis of this
gammaherpesvirus. Reactivation of EBV is associated with diseases including Burkitt's
lymphoma, Hodgkin's disease, post-transplant lymphoma, T cell lymphomas and
nasopharyngeal carcinoma,
EBV emerged as a virus of immense interest when it was identified as the aetiological
link with endemic (African) Burkitt's lymphoma (BL) tumour samples (Epstein et al.,
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1964). Classic BL is B cell tumour found in equatorial African and Papau New Guinea
(Burkitt 1970) where it is a predominant childhood malignancy. Over 90% of endemic
BLs are EBV positive and though the role of EBV remains unclear, it is generally
accepted that the virus is one necessary element in the causation of disease. A sporadic
form of BL, with very similar clinical features to endemic BL, occurs with a greatly
reduced incidence in other regions of the world with only 20% of tumours containing
EBV DNA, although in others this can rise to 80% (Magrath, 1990). Both the endemic
and sporadic forms of BL show translocations involving c-myc, an oncogene, which
results in its deregulation (Leder et al., 1983, Klein & Klein, 1985, Bornkamm et al.,
1987, Rickinson & Kieff, 1996). These studies have implicated the virus in the chain of
events which leads to these c-myc translocations.
Organ graft patients who are immunosuppressed to prevent organ rejection are targets
for the development of post-transplant lymphomas (PTL) and lymphoproliferative
disease. The lymphoproliferative disease can also occur in AIDS patients. All EBV
latent genes are expressed in PTL and some AIDS lymphomas, which would suggest
that EBV has a significant role in the development of the lesions (Young et al., 1989,
Thomas et al., 1990, Gavioli et al., 1993).
EBV DNA has been detected in up to 50% of cases of Hodgkin's disease (HD), a
tumour which occurs worldwide. However, evidence is not sufficient to implicate EBV
in the aetiology of HD (Weiss et al., 1989, Herbst & Niedobitek, 1993, Rickinson &
Kieff, 1996). The condition is characterised by the presence ofmalignant multinucleate
Reed-Sternberg and mononucleate Hodgkin cells within the affected lymph node.
Mutations identified in cases of HD are limited but they have been observed in the
tumour suppressor gene p53 (Gupta et al., 1993, Niedobitek et al., 1993) and
retinoblastoma protein (Morente et al., 1997), indicating an involvement of these genes
in the development ofHD.
Different types of T cell lymphomas have been linked to EBV infection with a wide
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range of incidences, including angioimmunoblastic lymphadenopathy (Ott et al., 1992),
nasal lymphoma (Harabuchi et al., 1990) and peripheral T cell lymphoma (Jones et al.,
1988). Like many EBV-associated diseases, the role of the virus in the lesions is
unclear.
Nasopharyngeal carcinoma (NPC) is a malignancy which occurs rarely throughout the
world but is the major cause of death from cancer in southern China (Simons et al.,
1974). The tumour develops in the squamous epithelium in the posterior nasopharynx
(Raab-Traub, 1993). Studies have indicated the association of EBV with NPC and the
presence of the virus DNA in the malignant epithelial cells (Wolf et al., 1973).
Environmental co-factors, such as phorbol esters and nitrosamines (tumour promoting
chemicals) detected in Chinese salted fish have been linked to areas of high incidence of
NPC (Poirier et al., 1987).
Other EBV-associated malignancies include oral hairy leucoplakia in HIV carriers
(Greenspan at al., 1985) and extremely rare familial X-linked lymphoproliferative
disease (Sayos et al., 1998, Howie et al., 2000).
1.2.2 EBV Genome
The prototypical gamma-1 herpesvirus EBV occurs in over 90% of the world's
population. The discovery ofEBV as the possible causative virus in BL tumour samples
led to the cloning (Dambaugh et al., 1980) and sequencing (Baer et al., 1984) of EBV,
the first of any herpesvirus. The EBV genome is a linear double-stranded DNA of
172kb in length with a GC content of 60%. Long terminal repeats (LTRs) flank the
unique sequence which contains several internal repeats dispersed across the DNA. To
date, only two types of EBV have been defined, type 1 and type 2, also called type A
and type B, which have 70-85% DNA sequence homology (Sample et.al., 1990). The
differences in their genomes are primarily in the areas which encode the latency
associated nuclear proteins. EBV type 1 is more prevalent in western societies whereas
both types are isolated with an equal frequency in African countries (Zimber et al.,
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1986). Type 1 is able to transform cells better than type 2 which has been attributed to
variations in two latency associated genes (Rickinson et al., 1987, Rowe et al., 1989).
EBV unique genes and gammaherpesvirus specific genes are among the many open
reading frames (ORFs), of which there are over 90, encoded by the EBV genome. The
latency associated proteins (described in section 1.2.3) are unique to EBV as no
homologues have been described for any other herpesviruses.
A few examples of gammaherpesvirus specific genes encoded by the EBV genome are
as follows. A bcl-2 homologue is functionally active as an expressed early gene
(Henderson et al., 1993, Tarodi et al., 1994). The EBV R transactivator is expressed as
a immediate early gene responsible for regulating the expression of other lytically
expressed viral proteins (Ragoczy & Miller, 1999). ZEBRA (Z fragment EBV
reactivation antigen) is an immediate early gene associated with reactivation from
latency acting as a key transactivator for lytic virus replication (Packham et al., 1990).
A homologue of ZEBRA has been identified in KSHV.
Like many gammaherpesviruses, EBV encodes homologues of cellular genes, for
example the bcl-2 homologue and the interleukin-10 homologue, which is described
later in section 1.6.4.
The EBV genome encodes many glycoproteins including the important glycoprotein,
gp340/220 which mediates the virus attachment to the B cell surface by binding to
CR2/CD21 (Nemerow et al., 1987, Fingeroth et al., 1984). Binding of EBV to
CR2/CD21 on resting B cells results in B cell activation and proliferation (Sinclair et al.,
1994).
1.2.3 EBV Latency Genes
The establishment of latency in lymphocytes is critical for the survival and maintenance
of gammaherpesviruses within their host. Genes have been identified which are
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expressed during EBV latency. These include the six EBV nuclear antigens (EBNAs)
termed EBNA 1, 2, 3A, 3B, 3C, EP (leader protein), three latent membrane proteins
(LMP) termed LMP 1, 2A and 2B, two small EBV-encoded RNAs termed EBERs 1 and
2, and the BARTs (Kieff, 1996).
EBNA 1 is a DNA binding protein which binds sites in the latent viral origin of
replication. EBNA 1 is the only viral protein required for the maintenance of the viral
episome, the latent state of the genome (Yates et al., 1985). This latency protein also
binds non-specifically to DNA and is involved in the co-ordination of virus genome
replication with cell division. BYRF1 encodes the EBNA 2 protein, a transcription
factor which activates latent viral genes and cellular genes necessary for the
immortalisation of B lymphocytes in vitro (Cohen et al., 1989). EBNAs 3A, 3B and 3C
are encoded by BERF. Little is known about the three proteins, except that EBNA 3A
and 3C are required for B cell immortalisation (Tomkinson et al., 1993). The function
of EBNA LP, encoded by BWRF1, is unknown but there have been indications it may
bind to p53 and the retinoblastoma gene product which would propose it to be involved
in the regulation of cell proliferation (Szekely et al., 1993, Hammerschmidt & Sugden,
1989).
LMP 1 is a viral oncoprotein coded for by the BNLF1 ORF and is the most abundant
viral transcript present in latently infected B cells. The LMP 1 protein functions as a
cytoplasmic and membrane protein and is essential for B cell immortalisation (Kaye et
al., 1993). Recently, LMP 1 has been shown to exert immunosuppressive effects on T
lymphocytes in vivo and inhibit, as well as stimulate, gene expression (Dukers et al.,
2000, Sandberg et al., 2000). Furthermore, LMP-1 has been demonstrated to induce the
transporter associated with antigen processing 2 (TAP-2) gene which is associated with
and requires the expression of the interferon regulatory factor 7 (IRF-7) (Rowe et al.,
1995, Zhang & Pagano, 2001). The LMP 2A and 2B ORFs are situated at opposite ends
of the linear EBV genome in BARF1/BNRF1, and are only in entirety when an episome
is formed (Laux et al., 1988). Alternative splicing produces the two membrane proteins
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which are not required for B cell immortalisation. Little is known about their function.
LMP 2A may be involved in the inhibition of calcium mobilisation which is a process
associated with the viral lytic cycle and B cell activation (Miller et al., 1994, Crawford
& Ando, 1986).
EBERs 1 and 2 are coded for by BCRF1 and are transcribed but not translated. Their
RNAs are the most abundant in latently infected cells. The significance of the EBERs is
unknown. They are not required for immortalisation of B lymphocytes or for virus
replication but may be involved in the regulation of the protein kinase PKR. Recently,
the EBERs have been shown to contribute to the tumourigenic potential of BL cells
independent of a direct effect on apoptosis (Ruf et al., 2000).
BARTs are a complex family of transcripts of unknown function which are transcribed
from the BamHI A region of the genome (Brooks et al., 1993, Smith et al., 2000a).
1.2.4 EBV Latency Types
Three distinct types of latent EBV infection exist, termed I, II and III. The decision
where one cell type chooses one latency state over another is not fully understood. In
vitro studies have demonstrated it is possible to switch from one form of latency to
another, which indicates a transcriptional control mechanism may exist (Kerr et al.,
1992, Rowe et al., 1992).
The type III model of latent EBV infection is provided by in vitro transformed
lymphoblastoid cell lines (LCL). The full array of latency genes are transcribed which
are the six EBNAs, the three LMP, the two EBERs and the BARTs. This type of
expression is also observed in infectious mononucleosis, EBV positive lymphomas of
transplant patients, and nai've B cells of healthy tonsils (Tierney et al., 1994,
Laytragoon-Lewin et al., 1997, Joseph et al., 2000).
Latency type I was initially observed in EBV-positive Burkitt's lymphoma biopsies.
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This type of latency only expresses EBNA1, the EBERs and the BARTs (Rowe et al.,
1987, Brooks et al., 1993).
Nasopharyngeal carcinoma cells were the source of the first observations of latency type
II (Deacon et al., 1993, Brooks et al., 1992, Hamilton-Dutoit et al., 1993, Young et al.,
1988). This type of latency is also seen in Hodgkin's disease. Latency type II gene
expression includes EBNA1, the EBERs, the BARTs, LMP1 and/or LMP2A and/or
LMP2B (Hitt et al., 1989, Gilligan et al., 1991).
1.3 Herpesvirus Saimiri
Herpesvirus saimiri (HVS) is a T lymphotropic gamma-2 herpesvirus which causes an
asymptomatic infection in its natural host the squirrel monkey (<Saimiri sciureus).
However, in New World primates and cottontail rabbits, HVS infection results in rapidly
fatal T cell lymphomas (Wright et al., 1977, Medveczky et al., 1989). Transformation
of simian (Desrosiers et al., 1986) and human (Biesinger et al., 1990) T lymphocytes in
vitro can also occur due to infection with HVS. The level of oncogenicity and
transforming ability of HVS is accounted for by sequence divergence in the left end of
the long unique region of the viral genome and is the basis for classification of HVS into
subgroups A, B and C (Desrosiers et al., 1985, Medveczky et al., 1984, Desrosiers et al.,
1986, Szomolanyi et al., 1987, Murthy et al., 1989, Biesinger et al., 1990). Two genes
termed saimiri-associated protein (STP) and tyrosine kinase-interacting protein (TIP)
which reside in the variable left hand end of the HVS genome have been shown to be
necessary for oncogenesis (Duboise et al., 1998).
1.3.1 HVS Genome
The HVS genome consists of 112.9kb of unique DNA of low GC content (34.5%)
flanked by l,444bp multiple repeats of high GC content (70.8%) (Albrecht et al., 1992).
There are 76 ORFs encoded within the genome, 60 of which are homologous to genes in
other herpesviruses. Many cellular homologues are present which include D-type
cyclin, G protein-coupled receptor (Nicholas et al., 1992), dihydrofolate reductase
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(Trimble et al., 1988), thymidylate synthase (Bodemer et al., 1986), complement control
proteins (Albrecht et al., 1992b) and interleukin-17 (see section 1.6) (Spriggs, 1994).
1.4 Kaposi's Sarcoma-Associated Herpesvirus
KSHV (Kaposi's sarcoma-associated herpesvirus) is the most recently discovered
human herpesvirus (Ganem, 1997). This gamma-2 herpesvirus was first identified in a
Kaposi's sarcoma (KS) tumour of an individual infected with AIDS (Chang et al.,
1994). The discovery of the eighth human herpesvirus has led to its implication in the
pathogenesis of KS, a vascular tumour consisting of bundles of spindle cells which
produce proinflammatory and angiogenic factors. The KSHV genome has also been
detected in primary effusion B cell lymphomas (PEL) and multicentric Castleman's
disease (MCD) (Mesri et al., 1996; Renne et al., 1996a; Russo et al., 1996; Boshoff et
al., 1997, Cesarman et al., 1995a).
In contrast to other herpesviruses, this virus has a unusual distribution in the human
population. KSHV appears to have a more limited presence among the human
population appearing in clusters of well defined populations. Classic KS in elderly
Mediterranean men is usually indolent, human immunodeficiency virus (HlV)-negative
endemic KS occurs in certain African populations, HIV-associated KS is the leading
neoplasm of AIDS patients, and post-transplant KS has also been observed (Beral,
1991). Epidemiological studies support the theory that KSHV is predominantly sexually
transmitted (Gao et al., 1996, Kedes et al., 1996, Blackbourn et al., 1999). A high
prevalence occurs in gay and bisexual men with AIDS, a much lower frequency occurs
in individuals infected with HIV by heterosexual contact, and it rarely occurs in those
infected by blood donations or drug use (Beral et al., 1991). The incidence of childhood
KS has also led to the possibility of vertical transmission of KSHV (Ziegler &
Katongole-Mbidde, 1996). Saliva has also been observed to harbour KSHV and may be
involved in horizontal KSHV transmission (Blackbourn et al., 1998).
KS lesions are composed of endothelial cells and endothelial-like spindle cells (Boshoff
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et al., 1995, Staskus et al., 1997). In contrast to conventional cancers, KS is unusual in
that the lesions appear to be multifocal and appear to respond to extracellular growth
regulatory signals (Nakamura et al., 1988). Compared to the general population, AIDS
patients have a 20,000 times higher risk of KS which may be related to the growth
factors released from HIV-infected cells in addition to immunosupression (Ensoli et al.,
1990). Culturing of KSHV in vitro has proven to be difficult with very limited
replication achieved in fibroblastoid cells (Foreman, et al., 1997, Renne et al., 1996b,
1998). Like other gammaherpesviruses, KSHV establishes a latent infection
characterised by the expression of specific genes and the presence of the episomal form
of the genome (Russo et al., 1996, Renne et al., 1996a, Decker et al., 1996, Sarid et al.,
1998, Staskus et al., 1997, Zhong et al., 1996, Dupin et al., 1999). B cell lines have
been obtained from PEL patients which harbour KSHV in a latent state (Cesarman et al.,
1995b, Renne et al., 1996b).
1.4.1 KSHV Genome
Sequence analysis has been performed on a PEL cell line (Russo et al., 1996) and a KS
biopsy (Neipel et al., 1997) which has revealed that an identical KSHV sequence is
present in both pathologies. The KSHV genome consists of a 140.5kbp long unique
region (LUR) flanked by multiple GC rich terminal repeats of 801 bp. KSHV is more
closely related to HVS, as of the 81 ORFs the LUR encodes, 66 contain sequence
similarity to HVS ORFs (Russo et al., 1996).
A number of cellular genes have been pirated by KSHV including the D-type cyclin,
bcl-2 and FLICE inhibitor proteins (FLIP). The KSHV encoded D-type cyclin binds to
its activating cellular partner cyclin dependent kinase 6 (cdk6) (Godden-Kent et al.,
1997), a process not inhibited by normal cell cycle control mechanisms involving cdk
inhibitors (Swanton et al., 1997). This allows the viral cyclin to drive the cell through
checkpoints ensuring proliferation is achieved. The viral bcl-2 homologue can block
apoptosis as efficiently as its cellular counterpart which suggests it is present to ensure
survival and proliferation of cells which would otherwise succumb to cell death (Cheng
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et al., 1997, Sarid et al., 1997). The viral FLIPs may be involved in preventing
apoptosis in cells induced by death receptors and thereby enhance tumour progression
(Thome et al., 1997, Djerbi et al., 1999). Cytokine and chemokine elements, including
IL-6, GPCR, M1P-I, MIP-II, and MIP-III (see section 1.6.2 and 1.6.4) are also encoded
by the KSHV genome. The presence of regulatory genes is an advantage for the
survival of KSHV given that KS is largely a growth factor disorder which further
supports the role ofKSHV in malignant transformation.
Although many KSHV genes have cellular homologues, only a small number are
latently expressed in tumour tissues. The latency genes include kaposin A (ORFK12),
vFLIP (ORF71/K13), D-type cyclin (ORF72), LNA-1/LANA1 (ORF 73), and the most
recently discovered LNA-2/LANA2 (ORF 10.5) (Rainbow et al., 1997, Kellam et al.,
1997, Kedes et al., 1997, Dittmer et al., 1998, Sarid et al., 1999, Sadler et al., 1999,
Jenner et al., 2001, Rivas et al., 2001).
The main immunogenic latent nuclear antigen (LNA-1) is expressed in all three
malignancies associated with KSHV (Dupin et al., 1999). LNA-1 has been shown to
secure KSHV DNA to chromatin during mitosis (Ballestas et al., 1999, Cotter et al.,
1999), inhibit p53 transcriptional activity (Friborg et al., 1999) and interact with the
retinoblastoma protein-E2F pathway (Radkov et al., 2000). This supports a role for the
latent genes in combating host antiviral immune reponses and ensuring cell proliferation
(Djerbi et al., 1999).
1.5 A Gammaherpesvirus Animal Model
EBV is the prototypic and most widely studied member of the gammaherpesviruses. As
previously mentioned, the gammaherpesvirus subfamily also include HVS and KSHV.
Thus, this finding has heightened the level of interest in the studies of the pathogenesis
of gammaherpesviruses. Our goal is to fully elucidate the function and pathogenesis of
gammaherpesviruses in man. However, studies have been hampered by both EBV and
KSHV being species specific. In vivo experiments are restricted to the clinical
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presentation of the infection.
Animal models have been of great importance in studies of herpesvirus pathogenesis.
Limited gammaherpesvirus animal models exist which include HVS infection of
primates and rabbits, AHV-1 infection of rabbits, EBV infection of Old World primates
such as rhesus macaques, marmosets and cotton top tamarins (Moghaddam et al., 1997,
Finerty et al., 1992). New World primate infection with EBV does not establish a long-
term inapparent infection, an aspect essential for gammaherpesvirus latency studies
(Shope et al., 1973). No appropriate animal model exists for KSHV infection.
Flowever, herpesviruses related to KSHV have been isolated from rhesus monkeys,
macaques, African green monkeys, chimpanzees and gorillas (Desrosiers et al., 1997,
Rose et al., 1997, Searles et al., 1999, Alexander et al., 2000, Greensill et al., 2000).
Studies of EBV in severely combined immunodeficient (SCID) mice have been
performed for therapeutic reasons but these studies do not reflect the true nature of the
virus infection in its natural host (Mosier et al., 1988, Rowe et al., 1991, Johannessen &
Crawford, 1999). Rabbits are only useful as an animal model for non-human
gammaherpesviruses and are quite costly. There are many ethical issues concerned with
using primates and they are of limited availability and difficult to maintain. Murine
models of both human alphaherpesvirus and betaherpesvirus infection exist, however,
none exist for the study of gammaherpesvirus pathogenesis. A murine model is
desirable because of the large amount of information available on mouse genetics and
immunology, and because of the cost efficiency, breeding ability and ease of
maintenance ofmouse colonies.
The need for a gammaherpesvirus animal model has been filled by murine
gammaherpesvirus 68 (MHV-68), a virus which has comparable genetics and
pathogenesis to EBV. Characterisation of the infection of mice with MHV-68 has
shown that this is an invaluable model system. This system will be advantageous in the
observation of the true nature of gammaherpesvirus infection in vivo, the origin of
disease and the host response, including prophylactic immune mechanisms (Sunil-
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Chandra et al., 1992a, b, 1993, 1994a).
1.5.1 Murine Gammaherpesvirus-68 (MHV-68)
MHV-68 was one of five viruses isolated from free-living murid rodents in Slovakia
(Blaskovic et al., 1980). Contrary to EBV, this gammaherpesvirus undergoes a
productive infection in standard cell monolayer cultures. The virus is able to infect a
large variety of cell types from a number of different species (Ciampor et al., 1981,
Svobodova et al., 1982), including Baby Hamster Kidney (BHK) cells which are
typically used to quantitate infectious virus using a conventional plaque assay and
myeloma cell lines such as NSO's. One cell line termed Sll has been derived from a
tumour taken from a MHV-68 infected mouse. This cell line is of B cell origin and all
Sll cells are latently infected and bear the genome in a circular or episomal
conformation. Of the S11 cells, 2% at any one time undergo spontaneous reactivation to
become productively infected. The number of S11 cells undergoing productive infection
can be increased to around 10% following the addition of phorbol esters such as TPA
(Usherwood et al., 1996b). Sll cells appear to be morphologically similar to EBV-
positive lymphoblastoid cell lines (Rickinson & Kieff, 1996) and KSHV-positive B
lymphoma lines (Moore et al., 1996).
1.5.2 The MHV-68 Genome
The complete nucleotide sequence ofMHV-68 has been determined (Virgin et al., 1997,
Davison et al., unpublished results). The MHV-68 genome contains 118, 237 bp of
unique DNA of 46% GC content flanked by multiple copies of a 1213 bp terminal repeat
of 78% GC content. Within the unique region of the genome there are at least 80 open
reading frames (ORFs), many of which are homologues of other gammaherpesvirus
genes (see figure 1.5.2). Within those ORFs, 63 have been found to be homologues of
HVS genes. In addition, the homologues are present in the KSHV genome and many
but not all are in the EBV genome. From comparison of MHV-68 ORFs with their
homologues, it has been revealed that this genome is more closely related to HVS and
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to other herpesviruses, MHV-68 genes with cellular counterparts have been discovered
including a complement regulatory protein, a bcl-2 protein, a D-type cyclin, and a G-
protein coupled receptor.
As predicted, the ORF 4 gene has been shown to encode a functional inhibitor of
complement activation as measured by inhibition of C3 deposition on activated zymosan
particles (Kapadia et al., 1999). Further functions of ORF 4 have been suggested
including induction of intracellular signals (Kapadia et al., 1999). Recently an ORF 4
recombinant virus and its corresponding revertant was generated using a system with the
MHV-68 genome cloned as an infectious bacterial artificial chromosome (BAC) (Adler
et al., 2000). The deletion of ORF 4 revealed that it was not essential for replication of
MHV-68 in vitro. However, the recombinant virus demonstrated a delay in growth
which was further supported by use of the revertant virus (Adler et al., 2000).
Limited homology to bcl-2 family members has been observed with ORF Mil. Other
viral bcl-2 homologues contain both the BH1 and BH2 domains, which are important for
the function of bcl-2 (Kroemer, 1997), and studies have revealed they all have anti-
apoptotic activities in vitro (Cheng et al., 1997, Derfuss et al., 1998, Henderson et al.,
1993, Kawanishi, 1997, Nava et al., 1997, Sarid et al., 1997, Tarodi et al., 1994). On
the contrary, the MHV-68 bcl-2 homologue appears to harbour homology only for the
BH1 domain (Virgin et al., 1997) but has still been demonstrated to inhibit Fas- and
TNF-induced apoptosis (Wang et al., 1999, Roy et al., 2000) and be expressed during
virus persistence (Roy et al., 2000). Unlike the other viral bcl-2 homologues, the MHV-
68 bcl-2 homologue has been shown to be susceptible to caspase, an apoptosis-inducing
protease. Although the MHV-68 bcl-2 was susceptible its cleavage product functioned
similarly to the other unsusceptible viral bcl-2 homologues by preventing proapoptotic
activity (Bellows et al., 2000). It would appear that these properties of viral bcl-2
homologues assist virus propagation by facilitating host survival and overcoming
programmed cell death in both productively and persistently infected cells.
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Similar to KSHV and HVS (Li et al., 1997, Nicholas et al., 1992), a D-type cyclin
homologue is predicted to be encoded by ORF 72 ofMHV-68 (Virgin et al., 1997). The
MHV-68, KSHV and HVS cyclin homologues all share conserved residues, and both
KSHV and HVS homologs have been shown to be involved in binding to cyclin-
dependent kinase 6 (cdk6) (Godden-Kent et al., 1996, Li et al., 1997, Jung et al., 1994).
Studies with the MHV-68 cyclin homologue have demonstrated it has a role in
oncogenesis by inducing cell cycle progression in primary lymphocytes and transgenic
mice expressing the protein develop lymphoblastic lymphomas with age (van Dyk et al.,
1999). A recombinant virus lacking the MHV-68 cyclin homologue has recently been
generated showing growth of the cyclin-deletion mutant is efficient in vitro and with the
same kinetics as the wild type virus (Hoge et al., 2000). However, a replication
deficiency occurs upon acute infection in BALB/c mice and the recombinant virus can
also establish latency but reactivation is poor. This work was confirmed by the
restoration of wild-type phenotype using a revertant virus (Hoge et al., 2000). These
studies indicate there may be multiple roles for the MHV-68 D-type cyclin homologue
including oncogenesis, acute infection and efficient reactivation from latency.
ORF 74 has homology to genes encoding G-protein coupled receptors (GCR) and may
function as an IL-8 receptor. If ORF 74 is found to be a functional IL-8 receptor, it is
possible that host cytokines signalling through the viral GCR would affect the
pathogenesis of MHV-68. The MHV-68 GCR homologue is one of many
gammaherpesvirus GCR homologues discovered (see section 1.6.2). Other
immunomodulation genes have also been found and are described in section 1.6.
ORF 50 of MHV-68 is an immediate early gene which has homology, along with HVS
and KSHV, to the EBV Rta gene which is also gene 50 encoded. Both ORF 50 genes of
KSHV and EBV have been demonstrated to have a significant involvement in the
reactivation of latent virus (Lukac et al., 1998, Ragoczy et al., 1998, Sun et al., 1998,
Zalani et al., 1996). The MHV-68 encoded rta homolog has been characterised (Liu et
al., 2000) and has also been shown to play a central role in viral reactivation from
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latency (Wu et al., 2000).
Other MHV-68 ORFs have been found to be homologues of gammaherpesvirus
glycoproteins, for example, ORF 8, 22, 39, 47, and M7 are homologues of gB, gH, gM,
gL, and gpl50 (Efstathiou et al., 1990a, Efstathiou et al., 1990b, Stewart et al., 1994a,
Stewart et al, 1996, Pepper et al., 1996, Virgin et al., 1997). Studies have only been
performed on the MEIV-68 gB and gpl50 genes (Stewart et al., 1994a, Stewart et al.,
1996). Like the EBV-encoded gB, the MHV-68-encoded gB is not expressed on the
virion envelope or the cell membrane of infected cells. This is in contrast to the HSV-
encoded gB which is essential for initial attachment to a cell surface (Cai et al., 1988,
Spear et al., 1992, Shieh et al., 1992, Trybala et al., 1993, Laquerre et al., 1998). The
gpl50 gene of MHV-68 was selected for study as it is a potential homologue of
gp340/220, an abundant glycoprotein present on the surface of virions and a major
neutralising determinant of EBV (Nemerow et al., 1987).
1.5.3 MHV-68 Unique Genes
The MHV-68 genome harbours a number of unique ORFs, including M1-M4 and 8
tRNA-like structures (Bowden et al., 1997), that reside in the left hand end of the
genome and have no clear homology to genes present in the other gammaherpesviruses.
However, in the other gammaherpesviruses, virus-specific genes are located in similar
regions and have been shown to be associated with latency or transformation. This has
generated great interest in the putative gene functions of the genes at the left hand end of
the MHV-68 genome. The unique ORFs are predicted to encode proteins with a
minimum of 100 amino acids in length. Studies have shown that this left hand region,
along with others, is transcriptionally active during latency resulting in a further
heightened interest (Virgin et al., 1999a).
The 8 vtRNAs with significant homology to mammalian tRNAs are highly expressed
within splenic germinal centres of latently infected mice and are similar to the EBER
genes in that their biological function is unclear. The vtRNAs can act as a marker for
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virus latency and are considerably important for detecting latent virus (Bowden et al.,
1997, Simas et al., 1999). However, it is important to note that no homologues of the
other EBV latency genes have yet been found in MHV-68. The function of these
putative tRNA-like genes in viral pathogenesis is unclear as they are not aminoacylated,
hence may not have a functional role as tRNAs.
The Ml gene exhibits sequence homology to a poxvirus serine protease inhibitor, SPI-1,
the first observation of its kind among the herpesviruses, and homology to the M3 gene,
another unique gene of MHV-68 (Virgin et al., 1997, Simas et al., 1998). Poxvirus
serpins have been linked to a wide variety of functions including the regulation of host
cell range by altering apoptosis (Brooks et al., 1995). However, Ml does not appear to
harbour the active site of serpins, therefore it is unlikely to function as a serpin. Studies
in which the Ml gene was deleted had no effect on the primary infection or the
establishment of latency (Simas et al., 1998). However, disruption of Ml with a lacZ
expression cassette resulted in enhanced reactivation from latency, proposing Ml may
be involved in a pathway which functions to suppress virus reactivation (Clambey et al.,
2000).
The M2 gene has an unknown function but studies which have detected M2 viral
transcripts in latently infected mice and in latently infected cells in vitro have proposed
M2 is a latency-associated protein (Husain et al., 1999, Virgin et al., 1999). These
studies also identified an epitope in the M2 protein that is recognised by CD8+ T
lymphocytes which demonstrated this protein is a target for the host cytotoxic
lymphocyte response (Husain et al., 1999). The induction of the CD8+ T cell response
to the M2 antigen has been examined and has shown that the antigen-specific T cell
response contributes to the control of latently infected cells (Usherwood et al., 2000).
This finding provides vital clues and will assist the development of a long-term
prevention of gammaherpesvirus diseases.
The M3 gene lacks homology to all known genes including chemokine elements,
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however, it has recently been characterised and shown to encode an abundantly secreted
protein (van Berkel et al., 1999). Studies by two independent groups have demonstrated
the M3 protein binds a number of chemokines, blocks chemokine interactions with cells,
and prevents chemokine calcium signalling (Parry et al., 2000, van Berkel et al., 2000).
The M3 transcript is transcribed during latency (Simas et al., 1999, Virgin et al., 1999).
This finding along with its function as a chemokine binding protein allows us to predict
a role for M3 in establishing or reactivating latency and in immune evasion.
1.5.4 The M4 Gene
Apart from the sequence of the M4 gene, there is no information about this novel gene.
The start codon of the M4 gene is located 8598bp from the left hand end of the MHV-68
unique region and the predicted coding region is about 1.3kb in length (Virgin et al.,
1997). The encoded M4 protein is expected to have a molecular weight of 44.8kD. No
studies as yet have been performed to elucidate the function of the M4 protein. Viruses
have the propensity to harbour genes with an immunomodulatory role. Thus, it is
possible that M4 may function as a viral-encoded cytokine.
1.5.5 MHV-68 Latency-Associated Genes
MHV-68 latent gene expression is unclear due to sensitivity issues with the methods of
detection. Studies have been performed which have proposed candidate latency genes of
MHV-68 (Simas et al., 1999, Virgin et al., 1999). Candidate latency-associated genes
include, ORF M2, ORP M3, ORF M9, ORF Mil (bcl-2 homologue), ORF 72 (cyclin
homologue), ORF 73 (KSHV LANA homologue), ORF 74 (GCR homologue) and the 8
tRNAs. Initially, no other genes except the M3 gene was identified as a candidate
latency gene using in situ hybridisation (Simas et al., 1999). Further studies using
nested reverse transcriptase-PCR (RT-PCR) detected the other candidate latency genes
in addition to the M3 gene (Virgin et al., 1999). However, possible contamination of the
RT-PCR with viral lytic transcripts may have occurred. The M2 protein has been shown
to be latency-associated and has an epitope that is recognised by cytotoxic T
lymphocytes (Husain et al., 1999). Detection of candidate latency-associated genes in
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some cell types and not others have suggested, like EBV, there may be multiple forms of
MHV-68 latency (Husain et al., 1999).
None of the EBV latency-associated genes are conserved among the members of the
gammaherpesvirus family. In HVS, STP and TIP are transformation-associated gene
products which are not conserved in the gammaherpesviruses (Damania et al., 2000).
This supports the evidence that MHV-68 virus-specific genes are candidates for viral
latency.
1.5.6 Murine Gammaherpesvirus-76 (MHV-76)
MHV-76 is a second murine gammaherpesvirus which was isolated from a wood mouse
and recent studies have aroused great interest in this isolate. Sequence analysis of
MHV-76 revealed that the left hand end of the genome had been deleted including the
M1-M4 genes and the 8 tRNAs. Apart from this deletion, MHV-76 harbours the full
contingency ofMHV-68 genes. The growth kinetics of MHV-76 are similar to MHV-68
in vitro but in contrast it appears to be cleared more efficiently in vivo in the lungs of
mice (Macrae et al., 2001). Like MHV-68, MHV-76 establishes latency in the spleens
of infected mice but the ability to do this is reduced (Macrae et al., 2001). These
observations along with the M gene studies (see section 1.5.3) show the left hand end of
the genome is associated with the pathogenesis ofMHV-68 and in the establishment of
latency.
The discovery ofMHV-76 has provided us with a useful tool which we can manipulate
for molecular biology studies. Studies involving the replacement of each of the
individual deleted M genes at the left hand end would be desirable for in vitro and in
vivo studies and would provide an insight into the importance of this region.
1.5.7 MHV-68 Infection and Pathogenesis
Wild rodents are infected by a MHV-68-like virus, however, the mechanism of the route
of entry is not known (Blaskovic, 1984). From observation of other gammaherpesvirus
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infections, it is probable that the route of infection involves the rodents coming into
close proximity with each other, and thereby transmitting the virus via the respiratory
pathway.
In experimental studies using inbred mice, intranasal infection is the most common
method of infection with MHV-68 as this represents the most likely route of infection in
nature. Alternatively, the virus may also be spread through saliva between rodents.
Acute infection is established in the lungs and this was demonstrated by laboratory
strains of mice which were inoculated intranasally with 4xl05 p.f.u. of MHV-68. The
initial productive infection in the lung causes an interstitial and peri-bronchiolar
pneumonia (Blaskovic et al., 1984; Rajcani et al., 1985; Sunil-Chandra et al., 1992a).
This infection involves alveolar epithelial cells and mononuclear cells surrounding
airways and blood vessels. Before immune system clearance, this primary infection
lasts for around 10 days (Ehtisham et al., 1993). During the period of primary infection,
an intense inflammatory infiltrate is observed and this may exist up to 30 days post
infection in the form of chronic granulomatous lesions (Sunil-Chandra, 1991).
Prior to the clearance of the productive infection in the lung, MHV-68 has been found to
spread to the spleen where the virus is concealed in a latent form in B lymphocytes
(Sunil-Chandra et al, 1992a, 1992b). In the spleen, infectious virus is rarely detected.
Detection of latent virus is based on quantitating reactivating cells in an infective centre
assay. This technique has revealed that latently infected cells are present in the first
week of an intranasal infection. The level of latently infected cells peaks during the
second to third week at numbers of 1 in 103/104 splenocytes, before decreasing to steady
numbers of 1 in 106 spleen leukocytes (Sunil-Chandra et al., 1992a, 1992b). Lower
numbers of latently-infected cells are also detected in lymph nodes and bone marrow
(Cardin et al., 1996). Latent infection has also been detected in other cell types
including peritoneal macrophages (Virgin et al., 1999). As mentioned previously, the
virus encoded tRNA-like genes are an invaluable tool by acting as a molecular marker of
latency. During productive infection, these tRNA-like genes are expressed but they are
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also detected in cells of the germinal centres in spleens in the absence of any productive
infection (Bowden et al., 1997). Comparable with all other herpesviruses, latency is a
permanent feature in the host.
Contrary to the spleen, virus cannot be detected in lungs later than 10 days post-infection
using standard biological assays. However, MHV-68 can persist in the lung indefinitely
without any evidence of infection of any other organs such as the spleen. This has been
observed using sensitive PCR analysis of virus DNA in B cell deficient mice
(Usherwood et al., 1996c). Evidence which indicates that both latent and productively
infected cells are present in the lung was achieved by the detection of both linear and
circular forms of the genome (Stewart et al., 1998).
It has been a common notion that latently infected lymphocytes are vital for
gammaherpesvirus persistence. However, Stewart et al., 1998, have now demonstrated
using in situ hybridisation for viral tRNAs, alveolar epithelial cells which are latently
infected. Hence, epithelial tissue in the lung can act as a non-lymphoid reservoir for
gammaherpesvirus persistence and may also be a reservoir for transmission. The lungs
are a completely separate site of virus persistence as they do not need to be constantly
re-seeded from circulating B cells. MHV-68 latency has also been detected in peritoneal
macrophages and dendritic cells (Week et al., 1996, Week et al., 1999a, Week et al.,
1999b, Flano et al., 2000). B cells are clearly a principal site of latency and persistence,
but are not essential for persistence of the virus which can be harboured in other cellular
reservoirs.
Chronic lung infection can be detected in MHC class II deficient mice. These mice
restrain the primary infection in the lung but virus is once more observed by day 20
post-infection and exists for up to 3 months. This has been found with EBV replication
which has been associated with chronic lung disease in humans (Egan et al., 1995 ).
In some instances, such as mice that are less than 4 weeks old or immunocompromised,
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different tissues can be productively infected by virus, including the heart, liver, kidney,
adrenal glands, and the nervous system (Sunil-Chandra, 1991).
1.5.8 Lymphoproliferative Disease
Members of the gammaherpesvirus subfamily are associated with lymphoproliferative
disorders. EBV is the etiologic agent of infectious mononucleosis and is also correlated
with nasopharyngeal carcinoma and Burkitt's lymphoma. KSHV is implicated in the
pathogenesis of KS, a neoplasm frequently detected in AIDS patients (Chang et al.,
1994, Mesri et al., 1996, Renne et al., 1996a, Russo et al., 1997, Boshoff et al., 1997,
Cesarman et al., 1995a).
MHV-68 has been demonstrated to cause chronically infected inbred mice to develop
lymphoproliferative disease (LPD) which has clear similarities to the disease seen in
EBV-infected individuals. 9% of BALB/c mice infected with MHV-68 over a period of
3 years developed lymphoproliferative disease. Of these, 50% displayed high grade
lymphomas. These lymphomas were identified with both lymphoid and non-lymphoid
tissues, for example, the liver and kidney. The tumours contained both B and T cells.
The B cells were light chain restricted which denoted a clonal origin (Sunil-Chandra et
al., 1994a). Cell lines have been derived from mice with LPD, including SI 1, which is a
cell line which originates from B cells and contains virus in the latent episomal form
(Usherwood et al., 1996b).
1.5.9 Immunology of MHV-68 Infection
MHV-68 infection of the lung induces a characteristic inflammatory infiltrate consisting
ofmostly mononuclear phagocytes and lymphocytes (Sunil-Chandra et al., 1992a). Cell
infiltration studies by bronchoalveolar lavage reveal that monocytes appeared early and
peak around day 3 to 4. Reduction in the number ofmonocytes occurs as CD8+ T cells
are detected which peak at day 8 to 10. CD4+ T cells and B cells are undetectable in the
lavage but are seen in lung sections (Sunil-Chandra, NP and Nash, AA, unpublished).
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CD8+ T cells present in the lungs are thought to play a central anti-viral role in the
control of acute infection (Ehtisham et al., 1993, Stevenson et al., 1998). Absence of
CD8+ T cells during the infection in BALB/c mice results in an infection which
continues uncontrolled. CD4+ T cells and anti-viral antibody are detected, however,
depletion of either or both of these only has a trivial effect on viral clearance (Ehtisham
et al., 1993, Usherwood et al., 1996c; Week et al., 1996, Cardin et al., 1996, Stevenson
et al., 1998, Stevenson et al., 1999a). Absence of both T cell subsets led to a severe
infection with infection of other tissues as a result of viral dissemination (Ehtisham et
al., 1993).
Splenomegaly is correlated with the presence of latently-infected B cells in the spleen
during early MHV-68 infection. This was demonstrated in studies with the intranasal
infection of transgenic pMT mice that were deficient in mature B cells and therefore
have no latent infection in the spleen (Usherwood et al., 1996c; Week et al., 1996).
Consequently, these mice did not exhibit any splenomegaly. B cells are critical for
transporting the virus to the spleen (Stewart et al., 1998). There is a role for CD4+ T
cells in the induction of splenomegaly as a result of MHV-68 infection. Splenomegaly
is observed 14 days post infection where cell numbers double with a CD4+ T cell
mediated expansion in B and T cells, CD8+ T cells possessing the greatest elevation. No
splenomegaly is observed in studies with CD4 depleted mice (Usherwood et al., 1996a).
Furthermore, there is a dependency for CD4+ T cells in the nonspecific B cell activation
and polyclonal antibody secretion associated with the viral infection (Stevenson et al.,
1999a) and for the production of the virus-specific antibody response (Stevenson et al.,
1999b). An infectious mononucleosis-like syndrome is detected after 21 days post
infection which is involved with a major expansion of Vp4+ CD8+ T cells (Tripp et al.,
1997, Doherty et al., 1997). CD4+ T cells are important for the expansion of the Vp4+
CD8+ subset and may be involved in generating the ligand which drives this subset
(Flano et al., 1999).
Levels of IL-6, IL-10 and IFN-y rapidly elevate during splenomegaly which may be
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linked with a role for these cytokines in B cell growth and thereby assist viral
persistence (Sarawar et al., 1996, Sarawar et al., 1997, Sarawar et al., 1998). Infected B
cells stimulate the activation of CD4+ T cells which act as helpers during the
proliferation of both infected and non-infected B cells, resulting in B cell expansion.
This positive feedback loop, influenced by B cells and CD4+ T cells, creates the
splenomegaly.
CD8+ T cells have a central role in the decline of infected B cells and thus in the
outcome of splenomegaly. The importance of CD8+ T cells has been demonstrated by
depletion studies (Ehtisham et al., 1993, Week et al, 1996, Stevenson et al., 1999b).
This proposes a vital role for CD8+ T cells in the regulation of latent B cells. It also
suggests that some infected B cells are susceptible to T cell recognition whereas others
escape from this effector response resulting in lifetime persistence of the host. During
EBV latent B cell infection, T cells target type III latency whereas type I latency evades
recognition (Rooney et al., 1985). Different types of latency remains to be elucidated in
MHV-68 infected B cells.
Cytokines, such as IFN-y may have a role in CD8+ T cell control. A study with IFN-y
knockout mice have shown that this lesion had no effect and that IFN-y is not essential
for recovery from acute MHV-68 infection (Sarawar et al, 1997). In contrast, another
group studying IFN-y knockout mice infected with MHV-68 showed that nearly one
third of these mice died (Kulkarni et al., 1997). There have also been studies using mice
with a targeted deletion in the IFN-y receptor a chain (IFN-y R""). These mice still
produce IFN-y but are unable to respond to it. The IFN-y R"" mice can control the lung
infection but show severe pathological changes in their spleens. This immunopathology
is mediated mainly by CD8+ T cells, as the changes are completely reversed in CD8+ T
cell-depleted mice (Dutia et al., 199 /).
Antibodies against MHV-68 first appear in the serum towards the end of the first week
in mice which have been inoculated intranasally (Kulkarni et al., 1997). Mice deficient
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in antibody (pMT mice) resolve the virus from the lung only slightly slower than wild
type mice. However, in the absence of CD8+ and CD4+ cells, the virus reactivates
suggesting antibodies are important in preventing reactivation (Stewart et al., 1998).
Studies using mice with a lesion in the a/p interferon receptor gene (IFN-a/p R_/") have
demonstrated that type I interferons play a central role in controlling the primary
replication of the virus (Kulkarni et al., 1997, Week et al., 1997, Dutia et al., 1999). The
absence of type I interferons seems to allow the virus to replicate to immense levels
which overcome the immune system of the mice. The IRF-1 gene is a transcriptional
transactivator important for the induction of type 1 interferons (Matsuyama et al., 1993,
Kimura et al., 1994). Mice that lack the IRF-1 gene (IRF-l"7") were highly susceptible to
MHV-68 infection and behaved similarly to the IFN-a/p R"/_mice (Dutia et al., 1999).
1.5.10 Therapeutic Strategies
MHV-68 is an important model for investigating the effects of novel therapeutic
strategies against human and animal gammaherpesvirus infection and disease.
Immunotherapies include the effects of novel vaccination strategies, antiviral drugs, and
candidate CTL vaccines.
Vaccination studies have been performed using the MHV-68 gpl50 gene to model the
potential of its EBV homolog as an immunogen in protection against EBV (Stewart et
al., 1999). Mice were vaccinated with a recombinant vaccinia virus expressing MHV-68
gpl50 and then subsequently challenged with a MHV-68 infection. The immunised
mice exhibited greatly reduced splenomegaly, comparable to infectious mononucleosis
in EBV, but did still establish latency (Stewart et al., 1999).
Thymidine kinase is a protein encoded by EBV that will activate the anti-herpetic drug
acyclovir (acycloguanosine) (Pepper et al., 1996). Drug phosphorylation via the
thymidine kinase results in the termination of DNA synthesis. Acyclovir also has an
effect on MHV-68 productive replication. Another MHV-68 sensitive nucleoside
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analogue is 2'-deoxy-5-ethyl-beta-4'-thiouridine (4'-S-EtdU) which has proven to be
much more effective (Sunil-Chandra et al., 1993, 1994b, Barnes et al., 1999). This drug
delays the onset of latency and rapidly controls infection in the lung. An advantage of
these drugs in being only effective against productive replication is that this allows them
to be used as an extremely important tool for deciphering the functional events during
ganmaherpesvirus latency.
Knowledge of CTL epitopes has led to investigations into the possible use of them at
generating protective immunity. During one study, dendritic cells were pulsed in vitro
with defined lytic cycle MHV-68 CTL epitopes and used to immunise mice (Liu et al.,
1999). Subsequent challenge with MHV-68 led to a partial protection against acute
infection in the lungs and a reduction in the level of viral latency. Recently in another
study, mice were primed with a recombinant vaccinia virus and then boosted by a
recombinant influenza virus, both viruses expressing the MHV-68 p56 CTL epitope
(Stevenson et al., 1999c). A marked increase of p56 CTL occurred that led to a massive
reduction in the acute infection in the lungs. However, neither of the immunisation
studies prevented the establishment of latency. These studies did not examine latent
infection. Therefore, the discovery of novel CTL epitopes of latent antigens would be
an ideal vaccination strategy. As previously mentioned, a candidate latent gene, the M2
gene of MHV-68, has been identified as a target for CD8+ T cells (Husain et al., 1999,
Usherwood et al., 2000). M2-specific T cell clones could be used to limit the number of
latently infected cells. Studies using this epitope in MHV-68 infection have potential for
gammaherpesvirus immunotherapeutic applications.
1.6 Viral Immunomodulatory Proteins
Host immune systems are complex machinery which viruses have coevolved to combat
and evade. Large DNA viruses, such as herpesviruses and poxviruses, express proteins
that function to either mimic or modulate the host's immune response (Spriggs et al.,
1996, Smith, 1997a, Mahalingam & Karupiah, 2000, Alcami & Koszinowski, 2000,
Lalani et al., 2000). These viral proteins include chemokine and cytokine elements
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which are devoted to their defence strategy. A large proportion are protein receptors and
secreted proteins with known cellular homologues. However, an ever increasing number
of proteins, in particular viral chemokine-binding proteins and secreted cytokines, exist
with as yet unknown homologues (table 1.6a and 1.6b).
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Table 1.6a. Viral chemokine homologues, receptor homologues, and binding
proteins.
Gene Virus Homologue Mechanisms
Viral chemokine homologues
VM1P-I/K6 HHV-8 MlP-la CCR8 agonist (Endres et al., 1999).
VMIP-II/K4 HHV-8 MlP-la Broad-spectrum CC, CXC,CX3C chemokine agonist (Sozzani et al.,
1998, Chen et al., 1998, Boshoff et al., 1997).
vMIP-III/BCK HHV-8 MIP-ip Not determined (Stine et al., 2000).
U83 HHV-6 MlP-la CC chemokine-like agonist (Zou et al., 1999).
MCK-I/ml31 MCMV CC chemokines CC chemokine-like agonist, promotes viral dissemination (Fleming
et al., 1999).
VCXC-I/UL146 HCMV IL-8 CXC chemokine-like agonist (Penfold et al., 1999).
VCXC-2/UL147 HCMV IL-8 Not determined (Penfold et al., 1999).
Unmapped Stealth virus GRO-a/MGSA Not determined (Martin et al., 1999).
Unmapped MDV IL-8 Not determined (Peng et al., 1995).
vMCC-I/MCI48R MCV MCP-I Broad-spectrum CC and CXC chemokine antagonist (Krathwohl et
al., 1997, Damon et al., 1998, Luttichau et al., 2000)
Viral chemokine receptor homologues
ORF74 HHV-8 CXCR2 Constitutively signalling and agonist-independent receptor
(Arvanitakis et al., 1997).
ECRF3/ORF74 HVS CXCR2 Functional CXC chemokine receptor (Ahuja & Murphy, 1993).
ORF74 MHV-68 CXCR2 In vitro transforming activity (Wakeling et al., 2001).
ORF74, El, E6 EHV-2 CXCR2/CCR1 Not determined (Telford et al., 1995).
U12 HHV-7 CCR Not determined (Nicholas, 1996).
U12 HHV-6 CCR Functional CC chemokine receptor (Isegawa, 1998, Milne et al.,
2000).
U5 HHV-6 CCR Not determined (Gompels et al., 1995).
US28 HCMV CCR1 Functional CC chemokine receptor (Vieira et al., 1998).
UL33 HCMV CCR1 Localises to viral envelope particles (Margulies et al., 1996).
US27 HCMV CCR1 Not determined.
UL78 HCMV CCR1 Not determined.
M33 MCMV CCR1 Important for viral dissemination to salivary glands (Davis-Poynter et
al., 1997).
K2R SPV CXCR Not determined (Massung et al., 1993).
Q2/3L CaPV CCR Not determined (Cao et al., 1995).
Viral chemokine-binding proteins
M-T7 MV IFN-y receptor Binds C, CC, CXC chemokines via a heparin binding site (Lalani et
al., 1997).
M-Tl MV ? Broad-spectrum chemokine inhibitor (Lalani et al., 1998).
S-Tl SFV 9 Broad-spectrum chemokine inhibitor (Graham et al., 1997).
35kDa RPV ? Broad-spectrum chemokine inhibitor (Lalani et al., 1998).
C23L/B29R VV ? Broad-spectrum chemokine inhibitor (Smith & Alcami, 2000).
G3R VaV 9 Broad-spectrum chemokine inhibitor (Smith et al., 1997b).
DIL/H5R CPV ? Broad-spectrum chemokine inhibitor (Smith et al., 1997b).
M3 MHV-68 ? Broad-spectrum chemokine inhibitor (Parry et al., 2000).
CCR - chemokine receptor, CXCR - CXC chemokine receptor, GRO-a - growth-related oncogene a, IFN-y - interferon y, IL-8 -
interleukin-8, MlP-la - macrophage inflammatory protein la, MDV - Marek's disease virus, MCV - Molluscum Contagiosum, SPV
- Swinepox virus, CaPV - Capripox virus, MV - myxoma virus, SFV - shope fibroma virus, RPV - rabbitpoxvirus, VV - vaccinia
virus, VaV - variola virus, CPV - cowpox virus, HHV - human herpesvirus, MCMV - murine cytomegalovirus, HCMV - human
cytomegalovirus, HVS - herpesvirus saimiri, MHV-68 - murine gammaherpesvirus-68.
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Table 1.6b. Viral secreted cytokines and cytokine homologues.
Gene Virus Homologue Mechanisms
Viral secreted cytokines
M-T2 MV, SFV ? Secreted protein that binds TNF (Upton et al., 1991).
CrmB CPV, VaV ? Secreted protein that binds TNF and LT (Alcami et al., 1999).
CrmC CPV, VV ? Secreted protein that binds TNF (Alcami et al., 1999).
CrmD CPV, EV ? Secreted protein that binds TNF and LT (Alcami et al., 1999).
CrmE CPV ? Secreted protein that binds TNF (Alcami et al., 1999).
B15R VV ? Secreted protein that binds IL-lp (Alcami & Smith, 1992).
B18R VV 7 Secreted protein that binds type 1 IFNs (Symons et al., 1995).
BARF1 EBV ? Secreted protein that binds CSF-1 (M-CSF) (Strockbine et al., 1998).
GIF OV 7 Secreted protein that binds GM-CSF and IL-2 (Deane et al., 2000).
MC53, MC54 MCV ? Secreted protein that binds IL-18 and inhibits lL-18-induced IFN-y
VV, EV, CPV,
(Smith et al., 2000c).
D7L ? Secreted protein that binds IL-18 and inhibits IL-18-induced IFN-y
VaV (Novick et al., 1999, Smith et al., 2000c).
LMP1 EBV ? Binds TRAFs. Activation ofTNFR p75, B cell
CllR(VGF) VV
proliferation/activation (Mosialos et al., 1995).
7 Epidermal growth factor-like activity. Epithelial cell proliferation
MGF MV
(Brown et al., 1995).
? Epidermal growth factor-like activity. Epithelial cell proliferation
(Brown et al., 1995).
Viral cytokine homologues
VEGF OV VEGF Stimulates angiogenesis (Savory et al., 2000).
K2 HHV-8 IL-6 Angiogenesis, B cell growth factor (Nicholas et al., 1997, Aoki et al.,
1999, Jones et al., 1999).
BCRF-1 EBV IL-10 Inhibits inflammatory cytokines and IFN-y (Hsu et al., 1990).
vIL-10 OV, EHV-2 IL-10 Inhibits inflammatory cytokines and IFN-y (Fleming et al.,2000).
cmvIL-10 HCMV IL-10 Inhibits inflammatory cytokines and IFN-y (Kotenko et al., 2000).
ORF 13 HVS IL-17 Stimulates T cell proliferation (Yao et al., 1995).
GRO-a - growth-related oncogene a, 1FN - interferon, 1L - interleukin, MlP-la- macrophage inflammatory protein la, MDV -
Marek's disease virus, MCV - Molluscum Contagiosum, SPV - swinepox virus, CaPV - Capripox virus, MV - myxoma virus, SFV -
shope fibroma virus, RPV - rabbitpoxvirus, VV - vaccinia virus, VaV - variola virus, EV - ectromelia virus, CPV - cowpox virus,
OV - orf virus, EBV - Epstein-Barr virus, HHV - human herpesvirus, HCMV - human cytomegalovirus, HVS - herpesvirus saimiri,
TNF - tumour necrosis factor, TNFR - tumour necrosis factor receptor, VEGF - vascular endothelial growth factor, CSF - colony
stimulating factor, GM-CSF, granulocyte macrophage-colony stimulating factor.
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1.6.1 Chemokines
Chemokines are soluble, chemoattractant cytokines which function by trafficking
leukocytes to sites of tissue damage or viral infection. They are small, disulfide-linked
polypeptides, on average about 70 amino acids in length, of which there are over 40
different types. Classification of chemokines are on the basis of conserved structural
features, generating four different subfamilies, termed CXC (or a), CC (or (3), C (y), and
CX3C. The CXC chemokines have a single amino acid separating the first two cysteines
in a canonical motif, for example IL-8R, in contrast to the CC chemokines which have
no amino acid separating the cysteines, for example RANTES. The C subfamily
contains only one member, lymphotactin, which has only a single cysteine in the N-
terminus of the mature protein. Fractalkine is the sole member of the CX3C subfamily
and is distinguished by containing cysteines separated by three amino acids (Greaves et
al., 1997, Bacon et al., 1996, Dairaghi et al., 1998a).
As a large superfamily of proinflammatory proteins, chemokines mediate the activation
and migration of a large variety of immune cells by binding to specific G protein-
coupled, seven transmembrane receptors (GCRs). The GCR superfamily have several
hundred different members specific for a huge array of ligands (Premack et al., 1996).
Following receptor interaction, intracellular calcium and activation of other second
messenger systems determines the signalling effects of chemokines.
The inflammatory response mediated by chemokines is crucial in the clearance of
invading pathogens, therefore, it is expected that in response viruses are likely to move
in their own defence mechanisms to maintain their survival.
1.6.2 Chemokine Elements Encoded by Herpesviruses
Anti-chemokine defence strategies employed by viruses involve the production of
proteins which appear to regulate chemokines and their receptors. Both the beta and
gammaherpesvirus subfamilies encode gene products which contain homology to genes
of known chemokine elements (table 1,6a). The alphaherpesviruses do not appear to
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have incorporated homologs of chemokine elements into the viral genome.
Murine cytomegalovirus (MCMV) is a betaherpesvirus which expresses MCKl/ml31, a
viral-encoded chemokine homologue shown to have functional CC chemokine-like
activity (Saederup et al., 1999, MacDonald et al., 1997). A MCKl/ml31 mutant
MCMV exhibited a lower inflammatory response and virus dissemination to target
organs in comparison to the wild type virus in vivo (Saederup et al., 1999, Fleming et
al., 1999). Additionally, MCMV encodes a chemokine receptor, M33, which is
conserved and co-linear with the CMV UL33 ORF (Davis-Poynter et al, 1997). The
M33 protein was shown to be highly expressed during MCMV infection and in vivo
mice studies have indicated that M33 may be an important factor in trafficking of
infected leukocytes or transmission of virus to the salivary glands (Davis-Poynter et al,
1997). MCMV also encodes a putative CC chemokine within ORF M131 (MacDonald
et al., 1997).
One strain of human cytomegalovirus (HCMV) is predicted to express two CXC
chemokine homologues termed vCXC-1 and vCXC-2. The vCXC-1 homolog has been
demonstrated to bind the IL-8 receptor CXCR2 and to promote neutrophil migration and
degranulation. Furthermore, FICMV has been found to encode four putative chemokine
receptors. The GCRs encoded by HCMV are US28, UL33, US27, and UL78. The
US28 gene product is very similar to the human CCR1 chemokine receptor (Neote et al.,
1993). It has been demonstrated that US28 has the capacity to act as a co-receptor with
CD4 for infection by certain subtypes of HIV (Pleskoff et al., 1997). This property of
US28 extends the cellular tropism inflicted by HIV infection to other CD4 cells. Thus,
HCMV co-infection of HIV positive patients may have an important influence on
whether they progress towards AIDS. The GFP gene has been used to disrupt the US28
gene and these studies revealed it is not required for viral replication in cultured cells
(Vieira et al., 1998). The US28 GCR has been shown to bind CC chemokines and
exhaust the chemokine environment of infected cells in vitro (Bodaghi et al., 1998) and
has also been demonstrated to mediate smooth muscle cell migration (Streblow et al.,
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1999). HCMV infection of smooth muscle cells is linked to vascular disease, therefore,
the US28 chemokine receptor may function to accelerate the disease by promoting the
migration of these cells (Streblow et al., 1999). Immunofluoresence studies on UL33
have demonstrated that UL33 localises to cytoplasmic inclusion structures at late stages
of in vitro HCMV infection, and that the GCR is expressed on membranes of maturing
virions (Marguiles et al, 1997). US27 has been observed to exhibit high similarity with
US28 and a common notion is that US27 was created by a duplication event with US28.
However, the function ofUS27 is presently unknown, likewise with UL78.
Other betaherpesviruses, such as HHV-6 and HHV-7, encode putative chemokine
elements. HHV-6 encodes two potential GCRs, in ORFs U12 and U5 (Isegawa, 1998,
Milne et al., 2000, Gompels et al., 1995). The GCR encoded by U12 is related to ORFs
UL33, M33, and U12 which are encoded within the genomes of HCMV, MCMV, and
HHV-7, respectively. HHV-6 ORF U83 also encodes a putative CC chemokine which
has been demonstrated to act as a functional chemokine (Gompels et al., 1995, Zou et
al, 1999).
Within the gammaherpesvirus subfamily, several members have been shown to encode
potential chemokine elements. Comparative sequence analysis of KSHV identified a
CXC chemokine receptor within ORF 74 which is highly related to the human CXC
chemokine receptors CXCR1 and CXCR2 (Cesarman et al., 1996). KSHV ORF 74 was
also identified using direct hydridisation with an ORF 74/ECRF3 probe (Guo et al.,
1997). The IL-8 protein has been demonstrated to bind to the KSHV ORF 74 GCR
(Arvanitakis et al., 1997). This GCR stimulates signalling pathways linked to cell
proliferation in a constitutive (agonist-independent) manner (Arvanitakis et al., 1997),
thus bringing about some confusion over the reason why ORF 74 has ligands which bind
at all (eg. IL-8). It is possible that ORF 74 may bind specific chemokines which
regulate its signalling activity. A few chemokines including stromal derived factor 1 a
(SDF-la) and IFN-y-inducible protein (IP-10) have been shown to function as inverse
agonists by inhibiting the constitutive signalling activity of ORF 74 in vitro (Geras-
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Raaka et al., 1998). It has recently been demonstrated that KSHV ORF 74 signalling
leads to cell transformation and angiogenesis in KSHV-mediated oncogenesis indicating
that this HHV-8 GCR is a viral oncogene (Bais et al., 1998). KSHV also encodes three
chemokines; vMIP-I, vMIP-II, and vMIP-III. The vMIP-I protein has been
demonstrated to contain strong angiogenic properties and is a selective agonist for the
CCR8 receptor which is expressed mainly on the TH2 subpopulation of CD4 T cells
(Boshoff et al., 1997, Dairaghi et al., 1999, Endres et al., 1999). In contrast, the vMIP-
II protein has been characterised as a general inhibitor of a range of chemokines (Kledal
et al., 1997, Chen et al., 1998, Sozzani et al., 1998). The vMIP-II protein also has the
capacity to inhibit HIV infection with CCR3, CCR5, and CXCR4 receptors as cofactors
(Boshoff et al., 1997).
The HVS genome also contains a GCR, ECRF3, which is co-linear with the ORF 74
chemokine receptors of other gammaherpesviruses (Nicholas et al., 1992). The HVS
ECRF3 gene has been shown to encode a functional receptor for CC chemokines IL-8,
GRO/melanoma stimulating activity (MGSA), and NAP-2 but not for CXC chemokines
(Ahuja & Murphy, 1993).
Equine herpesvirus-2 (EHV-2), a member of the gammaherpesvirus subfamily, contains
four putative chemokine receptors (Telford et al, 1995). Like HVS and HHV-8,
comparative sequence analysis revealed that EHV-2 also encodes an ORF 74 homologue
which has not been functionally characterised. EHV-2 ORF El encodes a GCR which
has high similarity with the human CCR1 chemokine receptor (like HCMV) and been
shown to be a functional chemokine receptor (Camarda et al., 1999). The third putative
chemokine receptor is a duplicate of ORF El and the fourth, ORF E6, has an unknown
function (Telford et al., 1995).
MHV-68, like many of the gammaherpesviruses mentioned above, also contains a
homologue of GCR encoded by ORF 74. If ORF 74 is shown, like HVS and HHV-8
ORF 74, to be a functional IL-8 receptor in transfection experiments, then this would
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suggest that the MHV-68 life cycle could be affected by host chemokines signalling
through the virally-encoded GCR. Thus, there is a possibility that the high grade
lymphomas exhibited by 9% of BALB/c mice infected with MHV-68 (Sunil-Chandra et
al., 1994a) may be influenced either in induction or maintenance by host chemokine
signalling through the viral GCR. However, it is also feasible that ORF 74 may have a
role in the lytic or latent phase of infection. Studies have demonstrated that the MHV-68
ORF 74 has in vitro transforming activity which suggests, like HHV-8 ORF 74, the
MHV-68 GCR homologue may function as a viral oncogene (Wakeling et al., 2001). A
MHV-68 ORF 74 deletion virus for in vivo studies would be invaluable for
understanding the role of ORF 74 in gammaherpesviruses.
1.6.3 Cytokines
Cytokine is the term given for a large, very diverse family of soluble proteins and
peptides which, either under normal or pathological conditions, modulate the functional
activities of individual cells and tissues. These proteins also mediate interactions
between cells directly and regulate processes taking place in the extracellular
environment.
It is very difficult to define a typical cytokine due to the wide diversity of these
molecules. Therefore, there are a number of characteristic features cytokines adhere to
which allow them to be included in the cytokine family. The majority of cytokines are
polypeptides or glycoproteins which are secreted by cells and are usually a relatively
small molecular weight. However, many cytokines appear to have a larger molecular
weight due to formation of homodimers, homotrimers and heterodimers (e.g. interleukin
12 (IL-12)). Cytokines are rarely constitutively expressed but instead are strictly
regulated. Expression normally occurs transiently and is usually in response to an
induction signal at the transcriptional or translational level. The biological activities of
cytokines are mediated by specific cell surface membrane receptors which can be
expressed on virtually all cell types known. Cytokine actions can lead to an increase or
decrease in the rate of cell proliferation, change in cell differentiation state and/or a
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change in the expression of some differentiated functions. Almost all cytokines are
pleiotropic effectors showing multiple biological activities. However, it seems that each
cytokine targets at least one of its many activities at haematopoietic cells. More often
than not, cytokines show stimulating or inhibitory activities and may also act on other
cytokines by synergising or antagonising their actions. Cytokines are not produced by
specialised cells which are organised in specialised glands (like hormones). The fact
that the same cytokine is often produced by several unrelated cell types and cytokines
are secreted suggests that the sites of their expression does not necessarily predict the
site at which they exert their biological function. Cytokines are rarely closely related
among each other in terms of primary sequences but may share functions.
Within the rapidly growing cytokine family, groups include interleukins, colony
stimulating factors, chemokines and interferons. Two different subpopulations of CD4+
T helper cells, termed TH1 and TH2 cells, have been demonstrated in both mouse and
humans (Mosmann et al., 1986, Del Prete et al., 1991). TH1 cells produce type 1
cytokines when activated by an antigen or antigen presenting cells (APC), provide
limited help for B cell responses and effectively activate cell-mediated responses
(Coffman et al., 1988, Hunter et al., 2000). Examples of type 1 cytokines include
interleukin-2 (IL-2), interferon-y (IFN-y), interleukin-12 (IL-12), and tumour necrosis
factor (TNF) (Taniguchi et al., 1993, Waxman et al., 1992, Murray et al., 1985; Nathan
et al., 1983; Murray et al., 1983, Dayton et al., 1992, De Maeyer et al, 1992, Farrar &
Schreiber, 1993, Trinchieri et al., 1993, Van Strijp et al., 1991, Murphy et al., 2000).
TH2 cells produce type 2 cytokines which function to stimulate antibody responses but
inhibit cell-mediated or delayed type hypersensitivity (DTH) responses (Hunter et al.,
2000). Examples of type 2 cytokines include interleukin-4 (IL-4), interleukin-5 (IF-5),
interleukin-6 (IL-6), interleukin-9 (IF-9), interleukin-10 (IF-10), and interleukin -13 (IL-
13) (Howard et al., 1982, Nelms et al, 1999, Swain et al, 1983, Swain, 1985, Kishimoto,
1989, Renauld et al., 1993, Houssiau et al, 1992, Fiorentino et al., 1989, Zurawski & De
Vries, 1994, Zurawski et al., 1993, Murphy et al., 2000).
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The TH1 and TH2 cytokine pattern strongly contributes to the major functional
differences between these two subpopulations of T helper cells. The cytokine pattern
assists the cross-regulation of the differentiation and activation of TH1 and TH2 cells
during an immune response. The type 1 and type 2 cytokines are only some of the wide
variety of cytokines discovered. Many cytokines have an effect on, not only T cells, but
also on other cells such as macrophages, B cells and mast cells.
Homologues of the type 2 cytokines, IL-6 and IL-10, have been found in herpesvirus
genomes (see section 1.6.4). IL-6 is a multifunctional cytokine which performs a
plethora of biological activities. This cytokine regulates immune responses,
haematopoiesis and acute phase reactions, thus playing a central role in host defense
mechanisms (Kishimoto, 1989; Van Snick, 1990; Akira et al., 1993). IL-6 was first
discovered as a T cell-derived lymphokine that induces final maturation of B cells into
antibody producing cells (Muraguchi et al, 1981; Hirano et al., 1985). In addition, IL-6
also acts as an essential factor in activation for resting T cells. In the presence of IL-2,
IL-6 induces the differentiation of mature and immature T cells into cytotoxic T cells
(CTL) (Takai et al., 1988, Okada et al., 1988). IL-10 has a wide variety of functions in
the immune system. This secreted protein was first discovered when it was observed
that the supernatant from activated T cells had an inhibitory effect on the secretion of
cytokines in TH1 cells which included IFN-y, IL-2 and TNF-P (Fiorentino et al., 1989,
D'Andrea et al, 1993, Gerard et al., 1993, Taga et al. 1992). The inhibitory effect on
IFN-y production by IL-10 is indirect and appears to be the result of a suppression of IL-
12 synthesis by accessory cells (D'Andrea et al., 1993). However, reduction of IL-12
synthesis is not the only mechanism whereby IL-10 reduces cytokine synthesis in TH1
cells. It is possible that IL-10 downregulates other co-stimulatory molecules. IL-10 also
has biological effects on a variety of other cell types including macrophages, NK cells,
B cells and mast cells (Mosmann et al., 1994). Recently, IL-10 has been shown to
inhibit the down-regulation of inflammatory chemokine receptors in dendritic cells and
monocytes exposed to an inflammatory microenvironment. This has generated
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functional decoy receptors which are able to mop up chemokines and act in an anti¬
inflammatory manner (D'Amico et al., 2000).
1.6.4 Cytokine Elements Encoded by Herpesviruses
It is not a surprise that, in addition to chemokine elements, the beta and gamma
herpesviruses have been demonstrated to encode potential cytokine elements (table
1.6b). Homologues of cytokine elements are employed to circumvent detection and
combat the host immune defence mechanisms.
Within the EBV genome, human IL-10 exhibits 78% amino acid identity overall to the
protein encoded by the BCRF1 gene. The BCRF1 gene product has a molecular weight
of 17 kD and is produced and secreted during the lytic phase of EBV infection (Hsu et
al., 1990, Stewart & Rooney, 1992; Swaminathan et al., 1993; Ryon et al., 1993;
Stewart et al., 1994). The viral IL-10 shares similar but not identical biological
activities with human IL-10. They both inhibit monocyte/macrophage activities, thereby
inhibiting synthesis of cytokines from these cells. Human IL-10 and BCRF1 also
downregulate IFN-y synthesis by T cells and NK cells which disrupts IFN-y-induced
upregulation ofMHC class II molecules on APC. However, a positive effect is that they
both stimulate proliferation and antibody secretion from human B cells activated through
binding of their CD40 surface antigen (Rousset et al., 1992). Thus, BCRF1 most likely
functions to assist EBV in escaping host surveillance by interfering in the antiviral
effects of IFN-y while facilitating EBV replication through the activation of resting B
cells (Miyazaki et al., 1993).
A viral IL-10 homolog was recently discovered to be encoded by the HCMV ORF
ULllla and termed cmvIL-10 (Kotenko et al., 2000). Although the cmvIL-10 only
exhibits 27% amino acid homology to its human counterpart, it has been shown to bind
the human IL-10 receptor and compete for human IL-10 binding sites (Kotenko et al.,
2000).
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HVS has been shown to encode a number of cytokine elements. Previous work had
isolated a cytokine-like protein termed CTLA-8 from activated T cells, which encoded a
15 kD secreted protein. Comparison of the deduced amino acid sequence of CTLA-8
with others in a sequence database revealed significant homology between CTLA-8 and
HVS ORF 13. CTLA-8, now referred to as interleukin-17 (IL-17), exhibits 57% amino
acid identity overall with its viral homologue (Spriggs, 1994). It has been demonstrated
that the viral IL-17 homologue exhibits pleiotropic cytokine-like activity including the
induction of NFkB and co-stimulation of T-cell proliferation (Yao et al., 1995; Fossiez
et al., 1996). The function of the viral homologue has not been elucidated but it is likely
this protein will have a role in assisting HVS infectivity of T lymphocytes.
KSHV encodes a viral IL-6 homologue which has been shown to stimulate the growth of
KSHV-infected primary infusion lymphoma (PEL) cells, promote hematopoiesis, and
act as an angiogenic factor through the induction of vascular endothelial growth factor
(VEGF) (Nicholas et al., 1997, Aoki et al., 1999, Osborne et al., 1999, Jones et al.,
1999).
No genes with homology to known cytokine elements have been found in MHV-68.
However, given the propensity of the gammaherpesviruses to abduct cytokines, it is
likely that proteins with cytokine functions and properties will be encoded within the
genome. Candidates are the M genes which have no known homologues within the
sequence databases. Analysis of the M genes indicate that the M4 ORF has properties
which are consistent with it functioning as a cytokine.
1.7 Aim
The aim of my project is to functionally characterise the M4 gene and elucidate its role
in the pathogenesis ofMHV-68.
Protein expression would allow the generation of rabbit anti-sera which would be an
invaluable tool in both in vitro and in vivo immunostaining studies to determine the
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expression ofM4. The addition ofM4 protein directly on cells such as epithelial and B
cells would allow us to determine ifM4 has any proliferative effects which would be of
assistance in functional studies. RNA expression studies would provide an indication of
the time post-infection of when the M4 gene is transcribed and whether it can be termed
an immediate early, early, late or a latency gene.
The generation of a M4 recombinant virus and use of this for infections in vivo and in








All DNA sequencing was kindly carried out by Mr. Ian Bennet using a LI-COR DNA
Sequencer 4000 (MWG-Biotech).
2.1.2 Restriction Enzyme Digestion
All restriction enzymes used were purchased from Gibco BRL and used according to the
manufacturer's instructions in the supplied buffers. The standard reaction mix consisted
of 1 unit of a restriction enzyme to lpg of target DNA in the appropriate buffer (total
volume ranging from 20-100pl). All solutions were dispensed into a 1.5ml
microcentrifuge tube and incubated at 37 °C for 2-3 hours.
2.1.3 Dephosphorylation of Linearised DNA
The 5' phosphate of the cut ends of plasmid DNA were dephosphorylated by the
addition of 10 units of calf intestinal alkaline phosphatase (Boehringer) to the restriction
digest reaction mix. This reaction mix was incubated for a further 20min at 37 °C and
stopped by phenol/chloroform extraction as described in 2.1.5.
2.1.4 Ligation of DNA Fragments
Ligation of DNA fragments was performed using T4 DNA ligase (Gibco BRL).
Purified DNA fragments were mixed with the cut DNA vector at ratios in the range of
3:1 - 6:1 respectively in ligase buffer (50mM Tris-HCL [pH 7.6], lOmM MgCh, ImM
dithiothreitol, 5% (w/v) polyethylene glycol-8000 (Gibco BRL)) and lunit of T4 DNA
ligase at a final volume of 20pL This reaction mix was incubated at 4 °C overnight.
2.1.5 Phenol Chloroform Extraction and Ethanol Precipitation
To clean DNA solutions, an equal volume of phenol/chlorotbrm (1:1) solution
(Amresco, USA) was added, vortexed and then centrifuged for 5min at 13,000g\ The
upper phase containing the DNA was removed and aliquoted into a fresh tube containing
an equal volume of chloroform. The tube was again vortexed and centrifuged for 5min
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at 10,000g. The upper phase was removed and aliquoted into a fresh tube containing
1/10 volume of 3M sodium acetate and then 3 volumes of ethanol were added. The tube
was incubated at -20°C for 1 hour to allow the DNA to precipitate. The tube was
centrifuged for 10 min at 10,000g to pellet the DNA. The supernatant was removed and
500pl of 70% ethanol was used to wash the pellet. The tube was centrifuged for 3 min
at 10,000g, ethanol was removed and the pellet was resuspended in 50pl of Tris EDTA
(TE) buffer.
2.1.6 Agarose Gel Electrophoresis
To form a 0.7% TAE gel, 100ml of IX TAE buffer (40mM Tris-acetate [pH7.8] and
ImM EDTA) and 0.7g of SeaKem LE agarose (Flowgen) was added to a microwavable
bottle. Contents were boiled in a microwave for several minutes until the agarose had
dissolved. The solution was left to cool for 20min and then 3pi of lOmg/ml ethidium
bromide (Sigma) was added to the bottle and swirled. The gel solution was poured into
a Minnie the Gel Cicle submarine agarose gel unit HE33 (Hoefer) or a Biorad mini gel
kit and left to set. 2pl of 10X loading buffer (15% w/v ficoll type 400, 0.25%
bromophenol blue, 0.25% xylene cyanol or 0.25% orange G in EEO) was added to the
DNA samples and loaded into the wells of the set TAE gel. lpl of a 1Kb DNA ladder
(Gibco BRL) was added to 15pi of loading buffer and this was added to a well for sizing
the DNA fragments. The gel tank was filled with IX TAE buffer and the gel was
electrophoresed for 1 hour at 70 volts using a Bromma power pack supply (LKB).
DNA bands were visualised using a UV transilluminator.
2.1.7 Extracting DNA from Agarose Gels
DNA separated on agarose gels was extracted by placing the gel slice containing the
DNA into a large well of a 1% TAE gel and covered with PEG solution (20% (w/v) PEG
in IX TAE, 200ng of ethidium bromide (Sigma)). The 1% TAE gel was placed in a
Biorad Mini-sub cell and electrophoresed at 100V for 2 minutes, during which the DNA
moved from the gel slice into the surrounding PEG solution. The PEG solution was
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removed and extracted with phenol chloroform. The DNA was purified and
concentrated from the aqueous phase using a Microcon column (Amicon).
2.1.8 Quantitation of DNA
DNA concentration was quantified using a CECIL spectrophotometer. The buffer in
which the nucleic acid was eluted in was used to zero the machine. The nucleic acid
was diluted from 1/50 - 1/500 and measured at OD260-
Nucleic acid concentration was calculated using the following formula:
DNA concentration (pg/ml) = OD260 x dilution x 50
2.1.9 Colony transformation
BL21(DE3) bacteria (Novagen) were streaked onto LB agar plates (1% bacto tryptone,
0.5% bacto yeast extract, 1% NaCl), 1.5% bacteriological agar (Oxoid Ltd) containing
10-20mM Mg2+' The plates were incubated overnight at 37°C to establish colonies. A
tungsten inoculating loop was used to pick 4 colonies and these were dispersed in 200pl
of TLB (lOOmM KCL, 45mM MnC1.4H20, lOmM CaCl2.2H20, 3mM HAC0CI3, 10
mM K-MES (2[N-morpholino]ethone sulphonic acid, [pH6.3]) by vigorously vortexing
with a rotamixer (Hook and Tucker Ltd) in a 15ml polybutadeine styrene conical tube
(Nunc, USA). The tube was incubated on ice for 30 min. 7pl of DnD solution (1M
dithiothreitol dimethyl sulfoxide, 90% DMSO, lOmM potassium acetate) was added into
the centre of the solution and the tube was swirled for a few seconds and placed on ice
for 15 min. An additional 7pl ofDnD was added, the tube was again swirled gently, and
incubated on ice for 20 min. lpl of pET-22b(+) vector (Novagen) containing the M4
gene (provided by James P. Stewart) was added to the solution and incubated on ice for
10-40 min. The cells were heat shocked by placing the tube in a 42°C water bath for 90
sec and then chilled on ice for 2min. 800pl of SOC medium (2% bacto tryptone, 0.5%
bacto yeast extract, lOmM NaCl, 2.5mM KCL, lOmM MgCf, lOmM MgSC>4, 20mM
glucose) was added to the cells and then they were incubated in the Orbital Shaker
(Porma Scientific Inc., USA) at 37°C for 60 min. The cells were gently centrifuged and
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resuspended in 250pl of SOC medium. The bacteria were plated out on agar plates
composed of LB, bacteriological agar, 10-20mM Mg2+, and 50pg/ml of carbenecillin
(Sigma).
2.1.10 Transformation of Epicurian Coli Ultracompetent Cells
Epicurian Coli ultracompetent cells (Stratagene) were transformed according to
manufacturer's instructions as follows. Cells were thawed on ice and gently mixed by
hand. 50pl of the cells were aliquoted per transformation into each pre-chilled 15ml
polybutadeine styrene conical tube. (3-mercaptoethanol was added to 25mM
concentration to each tube. The contents of the tubes were swirled gently and incubated
on ice for 10 min, swirling every 2min. 2pl of DNA ligation mix was added to each
tube and swirled gently and the tubes were left to incubate on ice for 30min. The tubes
were heat-pulsed in a 42°C water bath for exactly 30sec and left on ice for 2min. 0.9ml
of preheated (42°C) NZY+ broth was added and incubated in the tubes at 37°C for one
hour in the Orbital Shaker. Before plating the transformation mixture, the cells were
concentrated by gentle centrifugation for lOmin and resuspended in 200pl of NZY+
broth. The plates were incubated at 37°C overnight.
2.1.11 Small Scale Purification of Plasmid DNA
Colonies were grown on an agar plate composed of LB, bacteriological agar and
50pg/ml of carbenecillin. A colony was picked containing pET-22b(+) vector with the
M4 gene insert. The colony was inoculated into a universal tube (Bibby Sterilin Ltd,
UK) containing 6ml of LB and 50pg/ml of carbenecillin. The culture was grown
overnight in the Orbital Shaker at 37°C and then centrifuged for lOmin at 500g. The
pellet was resuspended in 200pl of a solution containing 1M glucose, 1M Tris pH8.0,
0.5M EDTA, [pH8.0]. The solution was transferred to a 1.5ml microcentrifuge tube and
400pl of a solution containing 0.2M NaOH and 1% SDS was added. The tube was left at
room temperature for lOmin. 300pl of a solution containing 2.7M potassium acetate,
[pH5.5], was added and the tube was left on ice for lOmin. The tube was centrifuged for
3min in a microcentrifuge (MSE) and 800pl of the supernatant was removed and
aliquoted into a fresh tube. 2.5ju.l of a 20pg/ml stock of RNAse A was added and the
tube was left to incubate at 37°C for 1 hour. DNA was phenol chloroform extracted and
ethanol precipitated as described in section 2.1.5.
2.1.12 Polymerase Chain Reaction (PCR)
PCR reactions were performed using either Taq DNA plymerase (Gibco BRL) or
PfuTurbo DNA polymerase (Stratagene).
A PCR reaction using Taq DNA polymerse was performed in a final volume of lOOpl
containing lpl of primer mixture stock (lOpM each), lpl of lOmM dNTP mixture (lOpl
of each dNTP added to 60pl of diHBO), 3pi of 50mM MgCh, lOpl of 10X PCR buffer,
lpl target DNA (amounts ranged from 1-lOOng) and lpl of Taq DNA polymerase.
A PCR reaction using PfuTurbo DNA polymerase was performed in a final volume of
50pl containing lpl of primer mixture stock (10 pM each), lpl of lOmM dNTP mixture
(lOpl of each dNTP added to 60pl of difBO), lpl target DNA (amounts ranged from 1-
lOOng), lpl ofPfuTurbo DNA polymerase and lOpl of 10X cloned PPU buffer.
An Omnigene PCR machine (Hybaid) was used for the temperature cycles. The
standard PCR cycling program involved an initial stage of denaturation for 3min at 94°C
without Taq DNA polymerase. The hotstart method was used which involved aliquoting
lpl of Taq DNA polymerase to the tubes while holding the temperature of the PCR
mixture at 80°C. 30 cycles were performed of denature for 45s at 94°C, anneal for 45s at
55°C and extend for 2min at 72°C. After the 30 cycles, the tube was incubated for an
additional 5min at 72°C to complete the extension. To allow the Omnigene PCR
machine to cool down, the tube was incubated for 30min at 35°C. The PCR products
were analysed by agarose gel electrophoresis as described in section 2.1.6.
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2.1.13 Calculation of Primer Annealing Temperature
For PCR using Taq DNA polymerase, the annealing temperature for primers was
calculated using the following formula:
annealing temperature (°C) = 4(Bg+Bc) + 2(BA+BT) - 5
For PCR using PfuTurbo DNA polymerase, the annealing temperature for primers was
calculated using the following formula:
annealing temperature (°C) = 4(Bg+Bc) + 2(Ba+Bt)
B equals the number of guanosine (G), cytosine (C), adenine (A) and thymidine (T)
bases in the primer complementary to the target DNA in the first round of PCR.
2.1.14 Calculation of PCR Extension Time
When using Taq DNA polymerase and PfuTurbo DNA polymerase, extension times
were calculated on the basis of 1 minute/kb.
2.1.15 Primers
Oligonucleotides were purchased from MWG biotech. Primers which have bases
complementary to the target sequence during the first cycle of PCR are in italics.
M4A -Within M4 gene (sense)
5' - GCGCGGATCCGACACC7WGNGAAGA TGA TGA TA TTC - 3'
BamWl
5' location on MHV-68 genome: 8617
M4B - Within M4 gene (antisense)
5' - CGCGGAATTCGGTTCTAGAAAGTCA TAAA TCTCAATACC - 3'
EcoRl
5' location on MHV-68 genome: 9786
M4A & M4B product size: 1169bp
Target: MHV-68 genome
PCR conditions with Taq polymerase: 55°C annealing temperature, 2min extension time,
30 cycles.
M4Arev - Within M4 gene (antisense)
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5' - CGCGAATTCGGCAGTCGCATAACCATGTCCACG - 3'
EcoRl
5' location on MHV-68 genome: 9176
M4A & M4Arev product size: 559bp
Target: MHV-68 genome
PCR conditions with Taq polymerase: 55°C annealing temperature, 2min extension time,
30 cycles.
M4Bfor - Within M4 gene (sense)
5' - CGCGGAICCGGTGGACATGGTTATGCGACTGA- 3'
BamHl
5' location on MHV-68 genome: 9156
M4B & M4Bfor product size: 630bp
Target: MHV-68 genome
PCR conditions with Taq polymerase: 55°C annealing temperature, 2min extension time,
30 cycles.
M4pc - Within M4 gene (sense)
5' - GCGCAAGCTTGGTCCGGCCTCA CA TCA T - V
Hindlll
5' location on MHV-68 genome: 8503
M4B & M4pc product size: 1284bp
Target: MHV-68 genome
PCR conditions with pfu polymerase: 40°C annealing temperature, 4min extension time,
20 cycles.
M41F - Left ofM4 gene (sense)
5' - CGCGCTCGAGTGTGGTTACAGTCTGCCACC - 3'
Xhol
5' location on MHV-68 genome: 7833
M41R - Left ofM4 gene (antisense)
5' - AAGCTTGTCGACGAATTCC4CTCA TCTGACTTGCTGCA TAC-3'
HindlU-Accl —-EcoRl
5' location on MHV-68 genome: 8408
M41F & M41R product size: 575bp
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Target: MHV-68 genome
PCR conditions with Taq polymerase: 57°C annealing temperature, 2min extension time,
30 cycles.
M42F - Right ofM4 gene (sense)
5' - GAATTCGTCGACAAGCTTCTAGAATAACTGTACCCTGTTAAG- 3'
fscoRI —AccI—Hindill
5' location on MHV-68 genome: 9780
M42R(2) - Right ofM4 gene (antisense)
5' - GCGCGGATCCTGGTCA CCTCTCGGGTGTTA - 3'
Bamdl
5' location on MHV-68 genome: 10401
M42F & M42R(2) product size: 621 bp
Target: MHV-68 genome
PCR conditions with Taq polymerase: 57°C annealing temperature, 2min extension time,
30 cycles.
M41F & M42R(2) product size: 1172bp
Target: M41F & M41R product and M42F & M42R(2) product
PCR conditions with Taq polymerase: 57°C annealing temperature, 2min extension time,
30 cycles.
M4LH1 - Right ofM4 gene (sense)
5' - GTACTA TA TGGCACCAGC - 3'
5' location on MHV-68 genome: 7786
GFP1 - Within GFP gene (sense)
5' - GCGCGAATTCGTTCA TAGCCCA TA TATGGAG - 3'
GFP2 -Within GFP gene (antisense)
5' - GCGCGAATTCCGCGTTAAGA TACATTGATGAG- 3'
M4LH1 & GFP2 product size: 1600bp
Target: M4KO DNA
PCR conditions with Taq polymerase: 55°C annealing temperature, 2min extension time,
30 cycles.
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GFP1 & GFP2 product size: 1400bp
Target: M4KO DNA
PCR conditions with Taq polymerase: 55°C annealing temperature, 2min extension time,
30 cycles.
MHV76A - Right ofM4 gene (sense)
5' - GCGCGGATCCCA TGTGCTACCTCTGTG - 3'
BamUl
5' location on MHV-68 genome: 7414
MHV76B - Left ofM4 gene (antisense)
5' - GCGCGAATTCGTACCGTCTGAGTGACTG- 3'
EcoRl
5' location on MHV-68 genome: 10914
MHV76A & MHV76B product size: 3500bp
Target: MHV-68 genome
PCR conditions with Taq polymerase: 51°C annealing temperature, 2min extension time,
30 cycles.
M4GFP76 - Right ofM4 gene (antisense)
5' - GCGCGACGCGACTAGCATGAGGA - 3'
5' location on MHV-68 genome: 11191
M4A & M4GFP76 product size: 2574bp
Target: M4 knock in DNA
PCR conditions with Taq polymerase: 55°C annealing temperature, 2min extension time,
30 cycles.
CMV1 - within pEGFP-Cl plasmid (sense)
5' - CCrCGGGATCCGTTCATAGCCCA TA TA TGGA - 3'
Accl
5' location on pEGFP-Cl plasmid (Clontech): 35
SV40-within pFGFP-CI plasmid (antisense)
5' - GCGCAGATCTCGCGTTAAGA TACATTGA TGAG - 3'
Accl
5' location on pEGFP-Cl plasmid (Clontech): 1646
CMV1 & SV40 product size: 1631 bp
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Target: pEGFP-Cl plasmid (Clontech)
PCR conditions with Taq polymerase: 55°C annealing temperature, 3min extension time,
35 cycles.
CMVBam - within pEGFP-Cl plasmid (sense)
5' - CGCGGGATCCGTTCA TAGCCCA TA TATGGA - 3'
BamHl
5' location on pEGFP-Cl plasmid (Clontech): 35
SV40Bgl - within pEGFP-Cl plasmid (antisense)
5' - GCGCAGATCTCGCGTTAAGA TACA TTGA TGAG- 3'
BglU
5' location on pEGFP-Cl plasmid (Clontech): 1646
CMVBam & SV40Bgl product size: 1631 bp
Target: pEGFP-Cl plasmid (Clontech)
PCR conditions with Taq polymerase: 55°C annealing temperature, 3min extension time,
35 cycles.
MAI - Within gpl50 gene (sense)
5' - GGACCATGGGATTTCTGGGGAATCACAACTTAG - 3'
Ncol
5' location on MHV-68 genome: 69,520
MA2 - Within gpl50 gene (antisense)
5' - GCTCTCG/tGGGTAGAAA TGTCTGGAACGG - 3'
Xhol
5' location on MHV-68 genome: 70, 826
MAI & MA2 product size: 1324bp
Target: MHV-68 genome
PCR conditions with Taq polymerase: 50°C annealing temperature, 2min extension time,
25 cycles.
neoF -Within neomycin resistance gene (sense)
5' - GTGCTCGACGTTGTCACTGAA- 3'
neoR - Within neomycin resistance gene (antisense)
5' - CTGATGCTCTTCGTCAGATC - V
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neoF & neoR product size: 257bp
Target: pcDNA3.1/V5/HTS/TOPO plasmid (Invitrogen)
PCR conditions with Taq polymerase: 55°C annealing temperature, 2min extension time,
30 cycles.
Murine p-actin 1 -Within p-actin gene (sense)
5' - TGTGATGGTGGGGAATGGGTCA- 3'
Murine P-actin 2 -Within P-actin gene (antisense)
5' - TTTGATGTCACGCACGATTTC- 3'
Murine P-actin 1 & Murine P-actin 2 product size: 514bp
Target: M4KI cDNA
PCR conditions with Taq polymerase: 55°C annealing temperature, 2min extension time,
30 cycles.
2.1.16 PCR Product Purification
The Wizard PCR Preps DNA Purification System (Promega, USA) was used to purify
the PCR product. lOOpl of direct purification buffer was added to a 1.5ml
microcentrifuge tube containing 30-300pl of the PCR reaction mix. 1 ml of resin was
added to the tube and this was vortexed 3 times over 1 minute. For each PCR product,
one Wizard minicolumn was prepared. The plunger from a 5 ml disposable syringe was
removed and set aside and a minicolumn was placed at the end of the syringe. The
resin/DNA mix was pippeted into the syringe barrel and the syringe plunger was inserted
slowly and gently to push the slurry into the minicolumn. The syringe was detached
from the minicolumn and the plunger was removed from the syringe. The syringe barrel
was reattached to the minicolumn and 2ml of 80% isopropanol was added to the syringe
barrel. To wash the minicolumn the syringe plunger was again inserted into the syringe
barrel and pushed the isopropanol through slowly. The syringe was removed and the
minicolumn was transferred to a 1.5ml microcentrifuge tube. The minicolumn was
centrifuged at 10,000g to dry the resin. The minicolumn was transferred to a new
microcentrifuge tube, 50pl of TE buffer was applied and left for lmin. Centrifugation of
the minicolumn for 20sec at 10,000g was performed to elute the bound DNA fragment
which was stored frozen.
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2.1.17 M4 KO Recombinant Construction
The following PCRs were performed using the standard PCR protocol. A 575bp
flanking sequence to the left of M4, termed M41 was generated by PCR, using primers
M41F and M41R. The M41F and M41R primers contained a Xhol and a Hindlll-Acc\-
EcoKl restriction enzyme site, respectively, at their 5' ends. The same was performed
for a 621 bp right flanking sequence termed M42, using primers M42F and M42R(2).
The M42F and M42R(2) primers contained a EcoKl-Accl-Hindlll and BamHl restriction
enzyme site, respectively, at their 5' ends. Both M41 and M42 PCR products were
analysed on a 0.8% (w/v) agarose gel.
A DNA fragment containing the left (M42) and right (M41) flanking sequence of M4
was generated by PCR via the Hindlll-Accl-EcoRl site, lpl of the M41 and M42 PCR
reactions was used as template DNA in a PCR with the primers M41F and M42R(2) to
generate a DNA fragment of 1172bp which was detected on a 0.8% agarose gel. The
M41/M42 DNA was purified using a PCR wizard clean kit (Promega). The entire PCR
product was cut with Xhol and BamHl restriction enzymes for 3 hours at 37°C and then
purified again. All enzymes used were purchased from GibcoBRL. pKS vector was cut
with the same restriction enzymes and extracted with phenol chloroform using the
standard protocol.
All cloning was performed using standard cloning protocols unless otherwise stated.
The M41/M42 DNA was ligated into the pKS vector cut with the appropriate enzymes.
The ligated vector was transformed into XL 1-blue competent cells (Stratagene) using the
manufacturer's protocol and the resultant colonies were picked and grown overnight in
LB broth. DNA was prepared from mini cultures (5-10ml) using a miniprep kit
(Qiagen) and checked for the correct clone using restriction analysis.
The pKS vector containing the M41/M42 DNA insert was digested with Accl for 4 hours
at 37°C. lpl of alkaline phosphatase (Boehringer Mannheim) was added to the digest
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for the final 20 mins of incubation and extracted with phenol chloroform. The green
fluorescent protein (GFP) gene was obtained by Accl digestion of pAC8 vector (kindly
provided by Dr. Douglas J. Roy). pAC8 was derived from pEGFP-Cl (Clontech) by
deletion of the multiple cloning site. The pAC8/GFP vector was digested with Accl for
3 hours at 37°C. The entire digest was separated on a 0.8% agarose gel and the band
containing the GFP gene was isolated and the DNA was extracted as described in
section 2.1.7.
The GFP DNA was cloned into the corresponding sites in the pKS/M41/M42 and DNA
was prepared using a endotoxin-free maxi-prep kit (Qiagen) according to the
manufacturer's protocol. DNA was quantitated by UV spectroscopy (CECIL). The M4
knock out cassette was cut out from the pKS vector with Xhol and BamHl. This crude
digest was used for transfection.
2.1.18 M4 KI Recombinant Construction
A pUC13 plasmid containing a 1.2kb Pstl fragment from the MHV-68 terminal repeat
(kindly provided by Dr. James P. Stewart) was sequenced to determine the orientation of
the terminal repeat (TR). For our purposes we required the TR to read from left to right.
However, the sequence revealed the TR was reading in the opposite direction. The TR
was cut with Pstl and re-ligated into the pUC13 plasmid. All clones revealed the TR
was ligating from right to left indicating preferential orientation with respect to the lacZ
promoter. To overcome this problem the Pstl fragment was cloned into pUC18 which
contains the multiple cloning site in the opposite orientation to the lacZ. Orientation was
confirmed by restriction analysis.
The following PCRs were performed using the standard PCR protocol. DNA containing
the M4 gene, a 1124bp flanking sequence to the left of M4 and a 1129bp flanking
sequence to the right of M4, were generated by PCR using primers MHV76A and
MHV76B. The MHV76A and MHV76B primers contained 5' BamUl and EcoBA
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restriction enzyme sites, respectively. M4 was digested with BamYll and EcoKl and
cloned into its corresponding site in the pUC18 vector.
The pEGFP-Cl (Clontech) plasmid with the multiple cloning site deleted (kindly
provided by Dr. James P. Stewart) was used as a template for PCR using primers
SV40Bam at the 5' end and CMVBglll at the 3'end (see appendix). The 1.6kb GFP
fragment was digested with BamYll and Bglll and ligated into its corresponding sites in
the pUC18 plasmid. There are two possible orientations which the GFP fragment can
enter. The desired orientation is for the 3' end of GFP containing the Bglll site to ligate
into the BamHI site. The ligations were transformed into E.coli Solopack-Gold cells
(Stratagene) using the manufacturer's standard protocol. Resultant colonies were grown
using the standard protocol and screened using restriction analysis.
DNA from the correct orientation was prepared using a endotoxin-free maxi-prep kit
(Qiagen) according to the manufacturer's protocol. DNA was quantitated by UV
spectroscopy (CECIL). The M4/GFP/TR cassette was excised from the pUC18 vector
with EcoRl and Hindlll. This crude digest was used for transfection.
2.1.19 Extraction ofViral DNA
T175 flasks containing cells and plaques were washed x 2 in PBS and 10ml of extraction
buffer (0.1M EDTA, 0.5% SDS, 0.2M Tris-HCL [pH8.0]) dispensed into the flasks.
Cells were scraped and transferred to 15ml polypropylene conical tubes. The procedure
was continued using pipette tips with ends cut off to prevent shearing ofDNA. 20pg/ml
of RnaseA (Sigma) were added to the tubes and incubated for lhr at 37°C. lOOpg/ml of
proteinase K (Roche) were added to the tubes and incubated at 56°C overnight. The
DNA was extracted using phenol/chloroform x3 and chloroform xl. After every
addition of phenol or chloroform, the tubes were placed on a rotating mixer for 15min
and centrifuged at 3.5K for 15 min at 4 °C. The DNA was precipitated in 2 volumes of
100% ethanol and 0.1 volume of 3M sodium acetate at room temperature. The DNA
were centrifuged as before and the pellets were washed with 70% ethanol x2. Excess
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ethanol was removed and the pellet left to dry for 5min. The DNA was resuspended in
200pl of distilled H2O and quantitated.
2.1.20 Radioactive Labelling of DNA Fragments
DNA radiolabeled with the isoptope P was used to probe Southern and northern blots.
The DNA was labelled using a Random Primed DNA Labelling Kit (Boehringer
Mannheim). 25 ng of DNA in 9 pi of distilled water was incubated for lOmin at 95°C
and cooled on ice. The DNA was added to a 1.5ml microcentrifuge tube containing lpl
of dATP, lpl of dGTP, lpl of dTTP, 2pl of reaction mixture, 5 pi of [32P]-dCTP, and lpl
of Klenow enyme (2 units/pl). The tube was incubated for 40min at 37°C. The labelled
DNA was increased to a volume of lOOpl with TE and purified on a nick column
(Amersham Pharmacia). The column was equilibrated with 3ml of TE and the lOOpl of
labelled DNA was added to the column. 400pl of TE was added and the flow-through
was discarded. Another 400pl of TE was added and the flow-through collected
contained the labelled DNA probe. The probe was denatured with 0.1 volume of 1M
NaOH for 5min at 37°C.
2.1.21 Southern Analysis
5pg of each digested DNA sample and a lkb DNA ladder were loaded and
electrophoresed in a 0.7% agarose gel as described in section 2.1.6 for 3-4hr at 70-80V.
The gel was washed with distilled water, soaked in a 0.5M NaOEl, 1M NaCl solution for
20min x 2, soaked in 0.5M Tris-HCL pH7.5, 1.5M NaCL solution for 20min x 2, and
washed again in distilled water.
2.1.22 Transfer of Nucleic Acids by Blotting
A large Biorad gel kit was used as the blotting apparatus and was fdled halfway with
20X SSC. Two long strips of 3 MM chromatography paper cut to the width of the gel
were soaked with 20X SSC and placed on the gel kit so that the ends were submerged
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into the 20X SSC sitting at the bottom of the kit. The gel was placed back on the paper
with the face downwards. Magnagraph nylon transfer membrane (MSI) cut to the size of
the gel was soaked in 20X SSC and placed on top of the gel. This was followed by two
sheets of 3MM chromatography paper cut to the size of the gel and soaked in 20X SSC,
a stack of blotting paper and a weight. Clingfilm was placed around the edges of the gel
to prevent the paper under and above the gel from touching resulting in the blot short-
circuiting. The nucleic acids are drawn up onto the membrane by capillary overnight.
The nucleic acid on the membrane was immobilised by placing the membrane in a
Stratalinker and exposing to a source of ultraviolet irradiation. The membrane was
wrapped in paper and clingfilm and stored at -80°C.
2.1.23 Southern Blots Probed with DNA
Prior to probing, the nylon membrane was pre-hybridised with a solution containing 6X
SSC and 5% milk (Marvel). The membrane and pre-hybridisation solution was
incubated in a sealed plastic bag or in a hybridisation bottle for 4 hr at 68°C.
To hybridise the membrane with the DNA probe, the pre-hybridisation solution was
replaced with a hybridisation solution containing 6X SSC, 5% milk and the labelled
DNA probe. The membrane, hybridisation solution and labelled probe were incubated
overnight at 68°C.
The membrane was subjected to a series of washes to remove non-specific binding at a
high stringency. The first washes were 2 x 15min at room temperature with a solution
containing 5X SSC, 0.5% SDS. The second washes were 2 x 15min at 37°C with a
solution containing IX SSC, 0.5% SDS. The final washes were 3 x 15min at 65°C with
a solution containing 0.1 SSC, 1% SDS.
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To detect labelled probe, the membrane was covered in clingfdm and placed in a
cassette containing a screen and Kodak Xomat film (Sigma). The cassette was stored
overnight at -80°C. The film was developed using a x-ray developer.
2.2 RNA Studies
2.2.1 Total RNA extraction
The RNAzol B method (Sigma) was used to extract total RNA. 0.2ml of chloroform
was added per 2ml of homogenate in the universal tubes. The tubes were shaken
vigorously but not vortexed and incubated on ice for 5min. The suspensions were
transferred to 1.5ml microcentrifuge tubes and centrifuged for 15min at 12,000g at 4°C.
The top aqueous phase of the tubes were transferred to fresh tubes, an equal volume of
isopropanol was aliquoted into the tubes and the samples were stored for 15min at 4°C.
The tubes were centrifuged for 15min at 12,000g at 4°C and the supernatants were
removed. The RNA pellets were washed once with 75% ethanol by vortexing and
subsequent centrifugation for 8min at 7500g at 4°C. All traces of ethanol were removed
and the pellets were resuspended in lOOpl of RNase-free H2O. Tubes with the same
RNA timepoints were pooled and stored at -80°C.
2.2.2 Quantitation of RNA
RNA concentration was quantified using a CECIL spectrophotometer. The buffer in
which the nucleic acid was eluted in was used to zero the machine. The nucleic acid
was diluted from 1/50 - 1/500 and measured at OD260-
Nucleic acid concentration was calculated using the following formula:
RNA concentration (pg/ml) = OD260 x dilution x 40
2.2.3 Removal ofDNA from RNA Preparations
The Ambion DNase free kit was used. RNA samples were diluted to 2pg/pl. A 0.1
volume of 1 OX DNase I buffer and 4 units of DNase I was added to the RNA samples,
mixed and incubated at 37°C for 30min. A 0.1 volume of the DNase inactivation
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reagent was added to the samples and incubated for 2min at room temperature. The
DNase inactivation reagent was pelleted and left at the bottom of the tube.
2.2.4 Reverse Transcription PCR
2pg of DNase I treated RNA (see section 2.2.3) was added to a total volume of 1 Ojul and
incubated at 70°C for lOmin to denature the RNA. 200ng of random primers
(Gibco/BRL) was added to the reaction and chilled on ice. The following was added to
the reaction mixture containing a final concentration of lx first strand synthesis buffer
(Gibco/BRL), ImM each dATP, dCTP, dGTP, and dTTP (Gico/BRL), 2mM DTT, 200U
of reverse transcriptase (Superscript II RNaseH" Reverse Transcriptase) (Gibco/BRL) in
a final volume of 20pl. The cDNA synthesis reaction was carried out at room
temperature for lOmin, 42°C for 50min, and 70°C for 15min. The samples were cooled
on ice. Typically, l-2pl of the reaction was used as a template in subsequent PCR
reactions.
2.2.5 Northern Analysis
RNA was fractionated on a 1.2% agarose/2.2 M formaldehyde gel. To prepare the gel,
3.6g of agarose and 216.3ml of distilled water were melted and cooled to 55°C. 53.7ml
of formaldehyde and 30ml of 10X formaldehyde gel-running buffer (0.2M MOPS,
pH7.0, 80mM NaOAc, lOmM EDTA, [pH8.0]) were pre-warmed to 55°C and added to
the melted agarose. 20pl of lOpg/ml ethidium bromide was added to the solution before
it was poured into a DNA sub cell gel kit (BioRad). When set, the gel was submerged in
IX formaldehyde gel-running buffer to cover the wells.
For each of the four RNA samples, 5.5pg ofRNA in a total volume of 5.5jul, 1 jlxI of 10X
formaldehyde gel-running buffer, 3.5pl of formaldehyde, and lOpl of formamide were
aliquoted into a 1.5ml microcentrifuge tube. 3pl of a 0.24-9.5Kb RNA ladder (Gibco
BRL) were diluted in the same solution as the RNA samples. The RNA ladder and the
RNA samples were incubated for 15min at 65°C and then cooled on ice. 2pl of
65
formaldehyde gel loading buffer (50% glycerol, ImM EDTA, [pH8.0], 0.25%
bromophenol blue) and 2pl of ethidium bromide were added to all the samples and these
were loaded into the gel wells. The gel was electrophoresed overnight at 35V until the
bromophenol blue had moved 8-1 lcm down the gel. Before blotting, the gel was
washed with a solution containing 50mM NaOH, 150mM NaCl for 30min followed by a
second wash with a solution containing 0.1M TRIS, [pH7.5], 150mM NaCl, for 30min.
Finally the gel was rinsed with milli-Q water and then covered with 20X SSC (3M
NaCl, 0.3M Na3Citrate.2H20, [pH7.0]) for 45min.
RNA was transferred onto a nylon membrane by capillary action as described in section
2.1.22.
2.2.6 Northern Blots Probed with DNA
Prior to probing, the nylon membrane was pre-hybridised with a solution containing 5X
SSPE (0.75M NaCl, 50mM NaH2P04.H20, 5mM EDTA[pH7.4]), 5X Denhardts, 50%
formamide, 0.5% SDS and lOOpg/ml of denatured salmon sperm DNA (Sigma). The
membrane and pre-hybridisation solution was incubated in a sealed plastic bag or in a
hybridisation bottle for 4 hr at 45°C.
To hybridise the membrane with the DNA probe, the pre-hybridisation solution was
replaced with a hybridisation solution containing 5X SSPE, 5X Denhardts, 50%
formamide, 10% dextran sulphate, 5% SDS, 200pg/ml of denatured salmon sperm DNA
and the labelled DNA probe. The membrane, hybridisation solution and labelled probe
were incubated overnight at 45°C.
The membrane was subjected to a series of washes to remove non-specific binding at a
high stringency. The first washes were 2 x 15min at room temperature with a solution
containing 5X SSPE, 0.5% SDS. The second washes were 2 x 15min at 37°C with a
solution containing IX SSPE, 0.5% SDS. The final washes were 2 x 15min at 55°C with
a solution containing 0.1 SSPE, 1% SDS.
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Bound probe was detected by autoradiography as previously described.
2.3 Protein Expression and Purification Studies
2.3.1 Expression of pET-22b(+) Vector
One colony containing the pET-22b(+) vector with M4 insert was picked from a freshly
streaked agar plate composed of LB, bacteriological agar and 50pg/ml of carbenecillin.
The colony was inoculated into 10ml of LB and 50pg/ml of carbenecillin in a universal
tube. The culture was incubated in the Orbital Shaker for 5 hours at 37°C until ODgoo
reached between 0.4 and 1. A 500pl aliquot of the culture was removed for the
uninduced control and stored as the timepoints below. IPTG from a lOOmM stock was
added to the culture to a final concentration of ImM and the incubation was continued
for 3 hours.
To study the timecourse of target protein expression after induction, 500pl aliquots were
saved at 60min timepoints following IPTG addition. The cells were collected by
centrifugation and the supernatant was discarded. The cell pellet was resuspended in
50pl of SDS gel sample buffer (2% SDS, 4% glycerol, 0.125M Tris-HCL, [pH6.8],
0.004% bromophenol blue, 5% P-mercaptoethanol) and kept frozen at -20°C. When all
the timepoints were collected, they (including the uninduced control) were ran on a
SDS-polyacrylamide gel as below. The tube was placed on ice for 5 min and the cells
were harvested by centrifugation at 500g for 5 min. The cells were resupended in 0.25
culture volume of cold 50 mM Tris-HCL [pH8.0] at 25°C and centrifuged as above. The
supernatant was removed and the cells were stored as a frozen pellet at -70°C.
2.3.2 Expression of pGEXl Vector
One colony containing the pGEXl vector with M4 insert was picked from a freshly
streaked agar plate composed of LB, bacteriological agar and 50pg/ml of carbenecillin.
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The colony was inoculated into 10ml of LB and 50pg/ml of carbenecillin in a universal
tube. The culture was incubated in the Orbital Shaker overnight and diluted 1 in 10 in
5nrl of LB the next morning. The diluted culture was grown at 37°C until ODeoo reached
between 0.4 and 1. A 500jLtl aliquot of each culture was removed for the uninduced
control and these cells were collected by centrifugation and the supernatant was
discarded. The cell pellet was resuspended in 50pil of SDS gel sample buffer (2% SDS,
4% glycerol, 0.125M Tris-HCL, [pH6.8], 0.004% bromophenol blue, 5% p-
mercaptoethanol) and kept frozen at -20°C. IPTG from a lOOmM stock was added to
the cultures to give a final concentration of 0.5, ImM, and 1.5mM and the incubation
was continued for 3 hours. 1.5ml of each culture was transferred to a sterile micro¬
centrifuge tube and centrifuged at low speed for 5min. The pellet was resuspended in
300p.l of PBS, 1% Triton-XlOO (Sigma), ImM PMSF, and 1% Aprotinin. Cells were
lysed by adding an equal volume of a 50% suspension of silica lysis beads/PBS to the
resupended pellet contained in the micro-centrifuge tube. The tube was vortexed three
times for 15sec and centrifuged at full speed. The supernatant was transferred to a fresh
tube and the pellet was stored at -80°C. lOpl of sample buffer were added to lOpl of
each supernatant and proteins were separated by SDS-PAGE. The excess supernatants
were stored at -80°C.
2.3.3 Purification of GST Fusion Protein
Small scale purification of GST fusion protein for SDS-PAGE gels was as follows.
50jli1 of a suspension of Glutathione-Sepharose (Pharmacia Biotech) was equilibrated
with four changes of PBS. The suspension was added to 500pl of supernatant collected
from the protein expression of the pGEXl vector with the M4 gene. This was incubated
at room temperature for 5min then 1ml of PBS/1% Triton X100 was added. The tubes
were centrifuged at a low speed for 30sec and the supernatant was carefully removed
and discarded. The pellet was washed twice with PBS and then resuspended in 50pl of
SDS-PAGE sample buffer. The pellet containing the silica beads stored from the protein
68
expression of pGEXl vector procedure was also resuspended in 150pl of sample buffer.
lOpl of each resuspension were loaded onto a SDS-PAGE gel.
Large scale purification of GST fusion protein for preparation of antigen for rabbits was
performed using Glutathione-Sepharose (Pharmacia Biotech) according to
manufacturer's instructions.
2.3.4 SDS-polyacrylamide Gel Electrophoresis (SDS-PAGE)
The bacterial cell lysates suspended in SDS gel sample buffer were heated for 5min at
95°C. If the gel was to be visualised by Coomasie Blue staining (see section 3.1.5), low
molecular weight protein markers (Pharmacia Biotech) were used. If the gel was for
western blotting "Rainbow" markers were used (Amersham). Both kinds of markers
were also heated alongside the cell lysate samples. Samples were electrophoresed using
a vertical slab gel system (Biorad). The main separating gel was composed of 15%
acrylamide:bisacrylamide, 375mM Tris-HCl [pH8.7], 0.1% SDS, 0.7mg/ml ammonium
persulphate, and 0.08% TEMED (Sigma). The stacking gel was composed of 5%
acrylamide:bisacrylamide, 125mM Tris-HCl [pH6.8], 0.1% SDS, 0.8mg/ml ammonium
persulphate and 0.2% TEMED. Gels were electrophoresed at 200V for 30 min or until
the dyefront had reached the bottom of the gel.
2.3.5 Coomasie Blue Staining
Coomasie stain (0.25% Coomasie Blue R250, 10% acetic acid, 45% methanol) was used
to visualise the proteins on the SDS-PAGE gel by incubating the gel in the stain for 30
min. The gel was destained by incubating in Coomasie destain (10% acetic acid, 20%
methanol) overnight until the background cleared.
2.3.6 Western Blotting
3 layers of 3MM chromatography paper [16 x 16cm] (Whatman) were soaked in blotting
buffer (48mM Tris, 39mM glycine, 20% methanol) and placed on a Semi-Dry
Electroblotter (Ancos, Denmark). The nitrocellulose membrane (Sartorius AG,
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Germany) was cut to the size of gel, soaked in blotting buffer and placed on the paper.
The gel was removed from the plates, placed on the nitrocellulose membrane and
covered with another 3 layers of 3MM paper soaked in blotting buffer. The
electroblotter was electrophoresed at 120mA for 1 hour. The nitrocellulose blot was
placed in 5% dried skimmed milk in PBS for 30min on a shaker, rinsed in PBS, and
placed in monoclonal anti-polyHistidine antibody (Sigma) overnight at 4°C. The blot
was washed in 5 changes of 1% dried milk in PBS over 30min. It was then placed in
anti-mouse IgG biotin conjugate (Sigma) diluted with 1 % dried milk in PBS for 1 hour
at room temperature with shaking. The blot was washed as before and incubated in
streptavidin-alkaline phosphatase conjugate (Boehringer Mannheim) for up to 1 hour at
room temperature with shaking. The blot was washed as before and was developed with
alkaline phosphatase substrate tablets (Sigma). The process was stopped by rinsing the
blot in water.
2.3.7 Purification of Anti-M4 Serum
Anti-M4 serum were purified using MAbTrap G (Pharmacia LKB) according to the
manufacturer's instructions. The protein concentration of the purified anti-M4 sera was
measured using the Bio-Rad Protein Assay as per manufacturer's instructions.
2.3.8 Analysis of Protein from Mammalian Cell Supernatant
His-bind resin (Novagen) was used to purify the expressed protein containing the His tag
from COS-7 cell supernatant. 500pl of resin were added to 50ml of supernatant and
centrifuged end over end at 4°C overnight. After removal of supernatant, the resins were
boiled with SDS-PAGE sample buffer and proteins were analysed by western blotting
with a monoclonal anti-His antibody (Sigma).
2.3.9 Immunoprecipitation
[35S] labeled cell lysates and supernatants were precleared by incubating with 200pl
sepharose 4B (Pharmacia) in RIPA buffer end over end overnight at 4 °C in screw
capped microfuge tubes. 20pl of antibody was added to each sample incubated
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overnight at 4 °C. 40pl of 50% (v/v) protein A sepharose (Sigma) in RIPA buffer was
added to the samples and incubated end over end for 4 hours at 4°C. The protein A
sepharose was centrifuged at low speed and the pellets were washed 5 X with 500pl of
RIPA buffer. To analyse the precipitate, 40pl of sample buffer were added to each
pellet and boiled for 2min at 100°C. The protein A sepharose was centrifuged and 50%
of each sample buffer was loaded on a long 12% SDS-PAGE gel. The gel was
electrophoresed overnight at 40V and Coomasie stained and destained as described in
section 2.3.5. To reduce the exposure time a scintillant was incorporated into the gel
which resulted in photon production by the radiation emitted from the isotope. The gel
was submerged in En3hance (DuPont), placed on a shaker for 30min. and rinsed in tap
water for 30min. The gel was dried in a gel dryer (Biorad) and developed as described
in 2.1.23.
2.4 Cell and Virus Culture
2.4.1 Tissue Culture
Baby hamster kidney (BHK-21) cells were propagated as a monolayer anchored to a
T175 flask (Nunc). Cells were seeded at 2 x 106 cells with BHK growth medium
(Glasgow modified Eagle medium (GMEM) (Gibco BRL) supplemented with 10% (v/v)
tryptose phosphate broth (TPB) (Gibco BRL) and 10% new born calf serum (NBCS)
(Harlan Sera Lab), 70pg/ml penicillin (Merck BDH), lOpg/ml streptomycin (Sigma) and
2mM L-glutamine (Merck BDH). Cells were incubated at 37°C in 5% CO2 until
confluent.
COS-7 cells were grown in with Dulbecco's modified Eagle medium (DMEM) (Gibco
BRL) containing 10% Foetal calf serum (FCS) (Globepharm), 70pg/ml penicillin,
lOpg/ml streptomycin and 2mM L-glutamine.
CI27 cells were grown in T175 flasks (Nunc) seeded at 2 x 106 cells as for COS-7 cells.
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293 cells were grown in T175 flasks (Nunc) seeded at 2 x 106 cells with DMEM
containing 5% Foetal calf serum (FCS) (Globepharm), 70pg/ml penicillin, lOpg/ml
streptomycin and 2mM L-glutamine.
Cell monolayers were harvested by washing with 10ml of versene solution (0.02%
ethylenediaminetetra acetic acid (EDTA) and 1% phenol red, [pH 7.1-7.3] in sterile
PBS) and then incubating with 8ml of Trypsin/EDTA solution (GibcoBRL) until
monolayers peeled from the plastic surface. Cells were dislodged by tapping the flask
and cell aggregates were broken by pipetting the cells up and down. 12ml of growth
medium were added to the trypsinised cells, cell suspension were transferred to a
universal tube and the cells were pelleted by centrifugation at 500g for 5min. The
supernatant was discarded and the cells were resuspended in 20ml fresh medium ready
to be seeded into flasks. The cells were vortexed for 10-20 sec to ensure complete
resuspension. The appropriate volume of cells was added to a T175 flask and incubated
at 37°C in 5% C02.
2.4.2 Mammalian Cell Quantification
The number of viable mammalian cells were quantified using a haemocytometer
counting chamber. A 1:1 dilution of cells was prepared with 0.1% Trypan blue (0.1%
trypan blue (Gurr) in PBS) and dispensed onto a well of the haemacytometer. The cells
within the centre square and the four large corner squares were counted. Cells touching
the upper and right hand perimeter lines were ignored and those touching the left hand
and lower perimeter lines were counted. Viable cells appeared unstained whereas dead
cells stained blue.
2.4.3 Storage and Retrieval of Cells
To store cell lines, cells were reuspended at 106 cells/ml in freezing solution (10%
dimethyl sulfoxide (DMSO) in foetal calf serum). 1ml aliquots were transferred into
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cryovials and frozen slowly in a -80°C freezer overnight. The cryovials were then
transferred to liquid nitrogen tanks, -180°C, for long term storage.
To retrieve cell lines, cells were thawed rapidly by placing the cryovial in a 37 °C water
bath. The thawed cell suspension were transferred to a universal tube and 9ml ofmedia
were added drop by drop using a pasteur pipette, with constant swirling of the tube.
Cells were centrifuged and transferred into a T25 flask (Nunc).
2.4.4 Electroporation of Cells
Cells for transfection are required to be -80% confluent to increase the transfection
efficiency. Cells were harvested by trypsinisation and resuspended at 2 x 106 cells/ml in
their standard growth medium. 1ml of cells was transferred to a electroporation cuvette
(Equibio). DNA to be transfected in a range of 5-15pg was added to the cells and mixed
by pipetting. The cuvette was placed into the electroporator machine (Equibid) and
transfected either using a single pulse (260V for 18msec, 1050pF capacitance) or a
double pulse (first pulse 600V, 25mF capacitance, 99Q, 0.1s delay, second pulse, as
single pulse). Electroporated cells were resuspended immediately in 10ml medium, split
between 2 wells of a 6 well plate (Nunc) and incubated in a 5% CO2 incubator at 37°C.
The medium covering the wells was changed after 24 hours and selective agents applied
if required.
2.4.5 Generation of a Stable Mammalian Cell Line
To generate a stable cell line expressing M4 protein, three cuvettes containing
(i) COS-7 cells and 5pg pcDNA3.1/V5/His TOPO vector (Invitrogen) with the M4 gene,
(ii) COS-7 cells and 5pg pcDNA3.1/V5/His TOPO vector only, (iii) COS-7 cells only,
were transfected using a single pulse. Cells were incubated in a 5% CO2 incubator at
37°C for 3 days. Cells were harvested and resuspended in 10ml of medium containing
Geneticin (G418 Sulphate) (GibcoBRL) at 400pg/ml. Cells were plated into 6-well
plates and replaced with selective medium twice a week until foci could be identified.
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After four weeks the antibiotic resistant cell foci were ring cloned. Ring cloning
involved removing the medium from the well and placing a sterile ring (cut from the
base of a Gilson pipette tip) with a coating of silicon grease around a focus of cells.
Cells were harvested by washing with versene and trypsinisation. Cells were transferred
into a well of a 6-well plate and grown in selective medium. Confluent cells were
harvested and grown in T25 flasks.
2.4.6 Transfection of M4KO DNA and MHV-68
To generate a M4KO virus, four cuvettes containing BHK cells and different ratios of
M4KO cassette to MHV-68 DNA were set up as follows:, (i) 15pg: 10pg, (ii) lOpg:
lOpg, (iii) lp.g: 10pg, (iv) no DNA were electroporated using a single pulse.
Transfected cells were incubated in a 5% CO2 incubator at 37°C overnight. Cells were
rinsed with medium and overlayed with 5ml of agar (2% Seakem plaque agarose
(Flowgen) melted in PBS mixed with an equal volume of medium). Cells were
incubated in a 5% CO2 incubator at 37°C.
2.4.7 Transfection of M4KI DNA and MHV-76
To generate a M4KI virus, four cuvettes containing BHK cells and different ratios of
M4KI cassette to MHV-76 DNA were set up as follows, (i) 10pg: 5pg, (ii) lOpg: lOpg,
(iii) 5pig: Opg, (iv) no DNA were electroporated using a double pulse. Transfected cells
were incubated in a 5% CO2 incubator at 37°C overnight. Cells were rinsed with
medium and overlayed with 5ml of agar (2% Seakem plaque agarose (Flowgen) melted
in PBS mixed with an equal volume of medium). Cells were incubated in a 5% CO2
incubator at 37°C.
2.4.8 Radiolabelliug Cells with [35S] Methionine
BHK cells which were sub-confluent and growing exponentially in 6 well plates were
infected with 5-10 pfu/cell of MHV-68 virus in 500jal medium or mock-infected. After
1 hour at 37°C the virus or mock-infecting medium was removed and 2ml of fresh
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medium were added to each well. At 4 hour post-infection the medium was removed
and cells were rinsed in medium containing 20% normal methionine and 2% serum
(lOmls GMEM, 40ml methionine and serum free medium (Gibco BRL), 2mM L-
glutamine). 200pCi [ S] methionine (Amersham) were added to each well in a total
volume of 1ml. Wells were incubated overnight at 37°C. Supernatants were removed
from each well and stored. Cells were harvested in 1ml RIPA buffer (20 mM Tris,
[pH7.2], 0.15 M NaCl, 1% (v/v) Triton X100 (Sigma), 1% (w/v) deoxycholate, 0.1%
(w/v) SDS). Both cell lysates and supernatants were kept at -80 °C and used for
immunoprecipitation.
2.4.9 Preparation of Mouse Splenic Lymphocytes for MACS
The spleen was placed in a 60mm Petri dish containing 5ml of RPMI 1640 medium
(Gibco BRL) supplemented with 10% FCS, 70pg/ml penicillin, lOpg/ml streptomycin,
50pM P-mercaptoethanol (ME) (Sigma) and 2mM L-glutamine. Cells were teased out
using a sterile scalpel and transferred to a universal. Another 5ml of media were used to
rinse the remaining cells from the Petri dish. Cells were centrifuged for 5min at 500g,
and resuspended in 10ml of media. After cell clumps had sedimented, the single cell
suspension was removed by decanting, layered onto 10ml of histopaque (Sigma) and
centrifuged for 20min at 3000g with no brake. The lymphocytes were removed from the
interface and transferred to a universal containing 15ml of media. They were
centrifuged for lOmin at 900g, resuspended in 20ml of media and centrifuged for a
further lOmin at 500g. After resuspension in 20ml of media, lymphocytes were counted
using a haemocytometer.
The MACS (Miltenyi Biotec) column was prepared (see below) while lymphocytes were
washed and counted. Cells were washed with ice cold 1% FCS in PBS and resuspended
in the same buffer at 5xl07cells/450pl. 60pl of CD43 microbeads (Miltenyi Biotec)
were added to 5xl07cells and incubated for 15min in a 4°C cold room or fridge.
75
Meanwhile the column was prepared. The column was placed by the magnet and filled
with 70% alcohol using the 3 way tap and a syringe which filled from bottom up. A 23
gauge needle was fitted onto the column and the ethanol was allowed to flow through.
The column was washed with at least 15ml of ice cold 1%FCS/PBS and kept full of
buffer until it was ready for use.
15ml of 1%FCS/PBS were added to the CD43 microbeads and cells and centrifuged for
5mins at 500g, 4°C. Cells and beads were resuspended in 1ml of 1%FCS/PBS and
loaded onto the column. The flow through were collected and the column was washed
with 15ml of ice cold 1%FCS/PBS. The flow through were centrifuged, resuspended in
medium and counted.
2.4.10 Alamar Blue Assay
2xl05 cells were added per well of a 96 well flat bottomed plate (Iwaki). AlamarBlue
(Serotec) was added to each well to a final concentration of 10% (v/v). Different
concentrations of supernatants were added to triplicates of wells containing cells. The
absorbance of the cultures was measured at a wavelength of 570nm and the background
absorbance measured at 600nm was subtracted from this reading. The plates were
incubated at 37 °C in a CO2 incubator for 3 days with absorbance measurements taken
using a Dynatech MR 5000 (Dynex) every 24 hours.
2.4.11 [3H] Thymidine Assay
lOOpl of a cell suspension containing 2x105 cells was aliquoted into a total volume of
200pl in a 96 well flat bottomed plate (Iwaki). Different concentrations of supernatants
were added to triplicates of wells containing B cells. The plates were incubated at 37 °C
in a CO2 incubator. After 48 hours, lpCi of [3H] thymidine was added to each well and
incubation was continued for 24 hours in a CO2 incubator. Cells were harvested onto
filtermats using a cell harvester (TOMTEK). The incorporated radioactivity of each cell
sample was read using a 1450 Microbeta liquid scintillation counter (Wallac).
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2.4.12 MHV-68 Stock Preparation
BHK-21 cells were grown up to the numbers required, trypsinised, and resuspended to
107 cells/ml in a 50 ml tube. MHV-68 was added to the cells at a multiplicity of
infection (MOI) of 0.001 pfu/cell. The tube was incubated with shaking for 1 hour at
37°C. The cells were seeded at 3x106 cells/flask and incubated for 4-5 days in 5% CO2
at 37°C until 100% cytopathic effect was observed. A cell scraper was used to remove
any remaining cells from the plastic surface of the flasks. The media was pipetted into
50ml falcon tubes. The flasks were rinsed with a very small amount of media to ensure
all cell debris was removed. The 50ml tubes were centrifuged at 2000g for 20min at 4°C
and the supernatant was removed. A total of 5-6ml of ice cold PBS were used to
resuspend all the cells. Resuspended cells were pipetted into a Dounce homogeniser
(Wheaton) which was used to disrupt the BHK cells. Cells in the homogeniser were
transferred to a 50ml tube and the tube was centrifuged at 2000g for 20min at 4°C. The
supernatant was removed and kept on ice. The pellet was resuspended in 1ml of ice cold
PBS, homogenised and centrifuged again as above. The second supernatant was pooled
with the first supernatant. The pellet was stored at - 80°C until the virus stock was
titrated in the supernatant. The supernatant was dispensed into 0.2 and 0.5ml volumes
and stored at -80°C. Infective virus was measured by plaque titration using BHK-21
cells.
2.4.13 Plaque Purification of Recombinant Viruses
Cells which were infected with virus and had undergone homologous recombination
with the recombinant DNA cassettes formed plaques expressing the green fluorescent
protein (GFP). Green plaques were visible by fluorescence microscopy using a UV
filter (excitation at 450nm). Pasteur pipettes were used to pick plaques by piercing the
agar and removing the agar directly above the plaque of interest. Agar containing the
plaque was dispensed into 1ml of medium, sonicated x 3 in a sonicating water bath for
about 20sec and freeze/thawed to disrupt the cells
To purify the green virus from wild-type, the picked plaque suspensions were serially
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diluted from 10"1 to 10~6. 1 x 106 CI27 cells were added and tubes were incubated for
lhr at 37 °C with shaking to allow adsorption. Cells were aliquoted into a well of a 6
well plate and incubated in a 5% CO2 incubator at 37°C. After 24 hours, the media on
the monolayer was replaced with an agar overlay. After 3-5 days, green plaques were
picked and the dilution procedure repeated. This process was repeated at least 3 times.
2.4.14 Infection of Cells for RNA Transcript Analysis
Four T175 flasks containing BHK-21 cells at 107 cells/flask grown up in Glasgow's
media were used. To distinguish immediate early and early RNA transcribed post¬
infection, cyclohexamide and the antiviral compound 2'deoxy-5'ethyip-4'thiouridine
(4'-S-EtdU) (GlaxoWellcome Laboratories, Kent) (Rahim et al., 1996) were used
respectively. The medium from one flask was decanted and 10ml of Glasgow's media
containing 100pg/ml of cyclohexamide was added to cover the cells prior to infection.
This flask set up for immediate early RNA was incubated for 30mins with 5% CO2 at
37°C, and then the solution was removed. The flasks set up for immediate early, early,
and late RNA were infected with MFIV-68 at 5x107 pfu/cell in 5ml of Glasgow's media
containing lOOpg/ml of cyclohexamide, 2pg/ml of 4'-S-Etdu and only virus,
respectively. The fourth flask was used for mock infection and contained only 5 ml of
Glasgow's media. All the flasks were incubated with 5% CO2 at 37°C. After lhr, the
Glasgow's media were increased in all 4 flasks to a total of 30 ml/flask containing their
respective inhibitors. 8hr post-infection, the flask containing the immediate early RNA
was harvested. The flasks containing the early RNA, late RNA and mock infected cells
were harvested 24hr post-infection. To harvest the RNA, the media in all flasks was
decanted and the cells covering the plastic surface were carefully washed with 20ml of
ice cold PBS/flask. 3ml of RNAzol B (Sigma) were added to each flask to remove the




BALB/c females were used, age 3 to 4 weeks on arrival from B & K Universal Ltd
(Grimston, Aldborough, Hull, UK).
2.4.16 Administration of Virus to Mice via Intranasal Route
Mice were inoculated intranasally with 4 x 105 pfu of virus in a 40gil infusion. Prior to
administration mice were lightly anaesthetised using halothane. Virus dilutions were
made in sterile phosphate buffered saline immediately prior to use and were kept on ice
until the inoculation.
2.4.17 Sampling of Mice
Mice were killed in a CO2 chamber and relevant organs removed by dissection.
2.4.18 Assay for Infective Virus
If required, sample organs were allowed to thaw and then homogenised individually in
lml of ice cold supplemented GMEM using glass homogenisers. Cell suspensions were
transferred back to their cryovials and refrozen at -70°C. Freeze/thawing samples
increases cell lysis and infective virus release.
Tissue homogenates were thawed rapidly at 37°C and centrifuged at 1100g for 5 minutes
at 4°C to pellet cell debris. Homogenates or virus samples were then diluted in a bijou
and 2xl06 BHK-21 cells added. The samples, in a final volume of 4ml of supplemented
GMEM, were incubated at 37°C for one hour on a shaker, to allow virus adsorption.
After incubation, the samples were vortexed, then the volume split between two 60mm
Petri dishes containing 2ml supplemented GMEM to form duplicates. The suspensions
were gently swirled to evenly mix and distribute the cells. All Petri dishes were
subsequently incubated at 37°C with 5% CO2 for 4 days. Following this incubation, the
BHK cell monolayers were fixed by removing supernatant from the plates using a 25ml
pipette and replacing it with 3ml of 10% formal saline. The plates were then incubated
for a minimum of 15 min at room temperature. In a fume hood, the formal saline was
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poured off and around 5ml of 0.1% toluidine blue was added to each plate to stain the
monolayer. After 20 min the stain was poured off and the plates were rinsed in water
and allowed to air dry.
The number of plaques per plate was quantitated using a microscope and the virus titre
per organ was calculated.
2.4.19 Assay for Infective Centres
Splenocyte suspensions were obtained and counted as previously described. 1 x 107, 1 x
106 and 1 x 105 cells were pipetted in duplicate into 60mm Petri dishes containing 6ml
of RPMI medium and 1 x 106 BHK-21 cells. 1ml of each splenocyte suspension was
refrozen for subsequent infectious virus titration. Plates were incubated for 5 days at
37°C with 5%C02. After this period monolayers were fixed as described above.
Numbers of infective centres/plate was quantitated using a microscope and the infective
centre titre was calculated per 107 splenocytes and per spleen.
2.4.20 One Step Growth Curve of Virus
BHK-21 cells at 80% confluency in a 24 well plate were infected with virus at 5 pfu/cell
and allowed to absorb for 1 hour at 37°C in 5% CO2 incubator. Unbound virus was
removed from the wells, each well was washed three times with medium and 1.5ml of
medium were aliquoted into each well. The 0 hour timepoint was harvested in duplicate
and stored at -70 °C and the 24 well plates were incubated at 37°C in 5% CO2 incubator.
Thereafter, wells were harvested in duplicate at appropriate timepoints and stored at -70
°C. The virus was released from the cells by freeze/thawing at -70 °C three times and
titrated as described in section 2.4.19.
2.4.21 Histopathology
After euthanasia of mice by CO2 asphyxiation, the lungs were perfused in situ via the
trachea with 10% neutral buffered formal saline. Portions of the spleen were also fixed
in 10% buffered formal saline and the tissues were processed routinely into paraffin
80
wax-embedded sections. These were stained with hematoxylin and eosin, and examined
by light microscopy.
2.5 Immunological Studies
2.5.1 Flow Cytometric Analysis of Cells
Reagents:
1% formal-saline - 10% formal-saline solution diluted 1/10 v/v with sterile PBS
FACS buffer - PBS with 1% BSA and 0.1% Sodium Azide (w/v)
All antibody working stocks diluted in FACS buffer
2.5.2 Immunostaining and Flow Cytometry
Flow cytometric analyses were carried out on splenocytes prepared or cultured as
previously described. 1 x 106 cells were pipetted into micro-test tubes and the cells were
pelleted at 370g for 5 min at 4°C. The cells were re-suspended by agitation and 30pl of
primary antibody was added to the appropriate tubes which were then incubated for 20
minutes on ice. Following incubation the cells were pelleted by centrifugation as above
and the supernatants were removed by aspiration. Each aliquot of cells was washed 3
times with ice-cold FACS buffer. 200pl of the buffer was added to each tube containing
a re-suspended cell pellet and the cells were re-pelleted by centrifugation. 30pl of
secondary antibody was added to the cells if required. Following addition of the
secondary antibody, the cells were incubated on ice for 20 min and then washed as
before. Finally, the cells were fixed by addition of 200pl of 1% formal-saline to all tubes
and analysed using a FACStar (Becton Dickinson) FACS scanner.
2.5.3 Immunofluorescence
BFIK cells were infected overnight with MHV-68 at a multiplicity of infection (MOI) of
10 and plated into a 6 well plate. The cells were resuspended at 106/ml and 200pl
aliquots were spread onto biobond slides using a cytocentrifuge. Slides were washed
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with PBS for 2 min and blocked with lOOjul of 5% pig serum in PBS/slide overnight.
Slides were washed in PBS + 0.05% Tween 20 and then washed again in PBS alone.
The primary antibody, rabbit anti-M4, were diluted in PBS + 2% pig serum and lOOpl
were added to the cells in 1:50, 1:100 and 1:500 dilutions. The cells were incubated for
lhr at 37°C and washed x 3 in PBS + 0.05% Tween 20. The secondary antibody, FITC-
labelled swine anti-rabbit was diluted to 1:50 in PBS + 2% pig serum and 1 OOjul were
added to each slide. The cells were incubated for lhr at 37°C and washed x 3 in PBS +








When first provided with the opportunity to characterise and explore the function of a
novel gene, an initial aim would be protein expression. M4 is a novel gene which has
never been characterised and expressed in an expression system. Protein expression
would allow for the generation of antisera which would be an invaluable tool in both in
vitro and in vivo immunostaining studies. RNA expression studies would provide vital
clues to the function of this gene as it would provide an indication of the time post¬
infection of when M4 is transcribed and whether it can be termed an immediate early,
early, late or a latency gene.
This has been successfully demonstrated with many novel genes including a HHV-6
candidate for a chemokine homolog, U83 (Zou et al., 1999). The U83 gene was cloned,
expressed in a bacterial expression system and the purified protein was used to generate
antisera. Immunostaining studies with the antisera revealed the expression pattern of
U83 in infected cells and additionally demonstrated that U83 is a late gene (Zou et al.,
1999). M3, a putative chemokine of MHV-68 was initially characterised by northern
blot analysis which revealed M3 is an early-late gene (Simas et al., 1999, van Berkel et
al., 1999). RNA expression studies have also revealed which stage of viral infection
other MHV-68 genes are expressed, including ORF 50 which was identified as an
immediate-early gene (Liu et al., 2000).
3.1.1 Analysis of the M4 Peptide Sequence
The DNA sequence of the M4 gene revealed no homology to known proteins (Virgin et
al., 1997). To further analyse the M4 gene for potential motifs and domains that may
provide a clue to the function of the gene, the M4 sequence was translated from base
position 8409 to 9785 into its corresponding 459 amino acids using the University of
Wisconsin Genetics Computer Group Sequence Analysis Software (UWGCG 9.0,
Devereux et al., 1984) (see figure 3.1.1a). Seven potential N-glycosylation sites and a
heparin sulphate binding domain were identified in the half of the peptide nearest the C-
terminus. A hydrophobicity plot of the amino acid sequence was generated which
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revealed a signal sequence at the N-terminus of the M4 gene (figure 3.1.1b). The signal
sequence indicates that the M4 protein is secreted. Heparin sulphate binding domains
are found in many cytokines, this indicates that the M4 protein may function as a
potential cytokine (Handin & Cohen, 1976, Webb et al., 1993).
3.1.2 M4 Protein Expression Using the pET System
The pET-22b(+) vector was chosen to express the M4 protein because the system allows
stringent control of expression. The target gene is inserted under the control of the
bacteriophage T7 promoter and is cloned using hosts that do not contain the T7 RNA
polymerase gene, thereby eliminating the possibility of plasmid instability due to the
production of proteins which are toxic to the host. Expression of the gene is induced by
providing a source of T7 RNA polymerase in the host cell. Futhermore, the vector
contains a hexahistidine tag which is expressed in the C-terminus of the target protein
allowing for detection and purification. The M4 gene was amplified via PCR (as
described in 2.1.12) using primers M4A and M4B to produce a PCR product of 1.3kb in
length. The M4 product was ligated into the pET-22b(+) vector using the EcoRl and
BamHl restriction enzyme sites designed within the primers. The ligated vector was
transformed into BL21(DE3) bacteria using the colony transformation procedure as
described in section 2.1.9. Once transformed colonies were shown by restriction
enzyme digest to be positive for the M4 gene, the pET-22b(+) vector was induced with
isopropyl-P-D-thiogalactopyranoside (IPTG) which induces T7 RNA polymerase to
transcribe the gene as described in section 2.3.1. The proteins in induced whole cell
lysates were visualised using Coomasie-stained SDS-PAGE gel, however, no induced
protein was observed. To eliminate the possibility that the protein was present but in
minimal amounts such that it was not visible, a more sensitive technique was used.
Western blotting was performed as described in section 2.3.6 using two different
antibodies, rabbit anti-MHV-68 polyclonal anitibody and mouse anti-his monoclonal
antibody, as detecting agents (see figure 3.1.2). Normal rabbit serum and a control
monoclonal antibody were used as negative controls and a pET-22b(+) vector containing
the gpl50 gene (provided by J.P. Stewart) was used as a positive control. Also, different
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Figure 3.1.1a Amino acid sequence of the M4 gene.
I MVGTQPRFLV KIHQKFYWA1 RDDLI1HGGY KRSGLTSSFA LVAMGPLGRP
51 WAASFGFFFL AVVSLATPTP GEDDDIPVKI HRLTFVKGLV PDVTGGSSYY
10I VCVYPSRKLF CTPTRWKDLS RFLNSETLNQ VCSART1YSV VPVEMLR1IS
151 LPLPPEIKSI VGGS1RSQYV SFPTFSETLNQ AKLP1WKSFA NLKVSMKFRS
201 SQWEVAFSVV SKTDYAITYW AEIPGFLIHE SAT1NL1NQP LLALYADLHV
251 DMVMRLTDKF 1YCQTYTLQQ KNLTDPRTGK RPTSSVL1PS PHVKNCQIRR
301 RNETHFVDTC SSAWDNYTSE AHNISRNSSS RGSNATQLVN ITANPCTLPT
351 LWDNWPCYTN YRSSPVPE1V 1HEN1LLEGR A1Y11YHQ1G LFDQPRLCVA
401 TFWMSKEETL LMQLDYPCEV SVEKKGKKFF IKSVVSMYHA 1SMVTF1WEY
451 G1E1YDFLE
The M4 DNA sequence, base position 8409 to 9785, was translated into 459 amino acids.
The 7 predicted N-glycosylation sites are shown in green letters. The heparin sulphate

































Figure 3.1.2 M4 protein expression from pET-22b (+) vector.
a) a-MHV-68 antibody
1 2 3 4 5
gp150-
b) normal rabbit antibody
















Lane 1: purified gp150 protein
Lane 2: M4/pET-22b(+)in BL21(DE3), -IPTG
Lane 3: M4/pET-22b(+)in BL21(DE3), +IPTG
Lane 4: gp150/pET-22b(+)in BL21(DE3), -IPTG
Lane 5: gp150/pET-22b(+)in BL21(DE3), +IPTG
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M4 gene was cloned into pET-22b(+) vector and induced with isopropyl-p-D-
thiogalactopyranoside (IPTG) in BL21(DE3) cells. Whole cell lysates were
electrophoresed on a 12% SDS-PAGE gel and western blotted with a) a-MHV-68
antibody, b) normal rabbit antibody, c) a-his antibody and d) normal mouse antibody.
pET-22b(+) vector containing the MHV-68 gp150 gene and purified gp150 protein were
used as controls.
dilutions of both antibodies and conjugates were used for the western blotting (not
shown in figure 3.1.2). No M4 protein expression was visualised by western blotting.
Both rabbit anti-MHV-68 and mouse anti-his antibodies bound to the gpl50 protein
which demonstrated that recombinant protein was being induced and that his tagged
protein could be detected by the anti-his antibody. This also demonstrated that the anti-
MHV-68 antibody was detecting antigens.
A further explanation for the lack of M4 protein detected was that the protein was
expressed and present but in a very low amount such that it was undetectable by SDS-
PAGE gel and western blotting. Therefore, the small scale purification method as
described in the pET system manual (Novagen) was performed on induced whole cell
lysates. However, no recombinant protein could be detected by western blotting.
Another possible reason for lack of M4 expression would be the introduction of a
mutation into M4 during the PCR amplification and cloning. Three clones of the M4
DNA contained in the pET-22b(+) vector were sequenced for mutations. A T7 primer
was used and the first 500 bases of the gene was sequenced. The sequenced stretch of
DNA of one M4 clone was aligned with the M4 DNA sequence using the University of
Wisconsin Genetics Computer Group Sequence Analysis Software (UWGCG 9.0,
Devereux et al., 1984). Accurate sequence of the first 500 bp of the M4 gene was
obtained which revealed that no mutations were present. While it was possible that
mutations had occurred further downstream, these clones should still have produced a
product. The likelihood that a mutation accounted for the lack of protein was therefore
small because a) three individual clones were tested for expression and it was unlikely
that all three had mutations, and b) sequencing showed all three clones were intact up to
500 bp.
Another explanation was that low amounts of M4 protein expression may have been
transcribed before the induction, and this may be toxic to the BL21(DE3) bacteria. This
is caused by low levels of T7 polymerase being produced even in the absence of IPTG.
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A final possible explanation for the lack of M4 protein expression was that ampicillin
selection used during the induction procedure was being lost in the culture and bacteria
had arisen which lack the M4 gene and have overgrown the bacteria which did contain
the gene. Therefore, when the induction procedure was initiated, there were few
bacteria in the culture which contained the pET-22b(+) vector and the M4 gene.
To overcome the problem of toxicity, another strain of bacteria which provides
additional stability to target genes, termed BL21(DE3)pLysS were used. This strain
contains a plasmid that encodes a small amount of T7 lysozyme which inhibits T7 RNA
polymerase (Moffatt & Studier et al., 1987, Studier, 1991). The BL21(DE3)pLysS
bacteria were transformed and induced as before but this time the selective antibiotic
was changed to carbenecillin. Carbenecillin, like ampicillin, is degraded by P-lactamase
which is encoded by a gene within the pET-22b(+) vector. However, this antibiotic is
degraded much slower and is more stable in cultures by being less sensitive to low pH.
Therefore, in place of ampicillin, carbenecillin helps prevent overgrowth of culture with
bacteria which lack the M4 gene-containing plasmid. Once again, western blotting with
rabbit anti-MHV-68 and mouse anti-His antibodies did not detect M4 protein
expression. In another strategy to try and overcome the potential toxicity of the M4
gene, the BL21(DE3)pLysS bacteria were grown up in a culture containing a higher
concentration of carbenecillin and the medium was replaced twice prior to induction.
During the induction, the culture was incubated at 30°C instead of 37°C. Even with
these changes to the induction protocol no M4 protein expression was detected by
western blotting.
3.1.3 M4A and M4B Protein Expression Using the pET System
Since we were unable to express the whole of the M4 protein, we decided to split the
1.3kb M4 gene in half and attempt to express the two separate fractions. Therefore,
primers were designed and used to amplify the two fragments. The first half of the gene
from nucleotide 8617-9176 nearest the 5' end, termed M4A, were amplified via PCR
using primers M4A and M4ARev to produce a PCR fragment of 559bp. The second half
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of the gene from nucleotide 9156-9786 nearest the 3' end, termed M4B, were amplified
via PCR using primers M4BFor and M4B to produce a PCR fragment of 630bp (figure
3.1.3). The two halves of the M4 gene were cloned into the pET-22b(+) vector, re-
transformed into the BL21(DE3)pLysS bacteria and induced. Again Coomasie-stained
SDS-PAGE gels and western blotting with mouse anti-his antibody and rabbit anti-
MHV-68 antibody did not detect any induced protein.
Once more the M4A and M4B DNA contained within the pET-22b(+) vector was
sequenced to check for mutations. Accurate sequences were produced of the first 342bp
and 502bp ofM4A and M4B, respectively.
3.1.4 M4A and M4B Protein Expression Using the pGEX System
pGEXl is a fusion-protein expression vector that expresses the cloned gene as a fusion
protein to glutathione-S-transferase (GST). The GST protein acts as a control as it can
be detected as a 27kD band on a SDS-PAGE gel. This new approach was used to
express the M4 protein. The procedure involved the re-cloning ofM4A and M4B into a
different expression vector termed pGEXl. The M4A and M4B-containing pGEXl
vectors were transformed into XL-2 ultracompetent bacteria (Stratagene) and were
induced. Coomasie-stained SDS-PAGE gel detected induced protein bands in the 50kD
region for M4A whole cell lysates (not shown). The expression of the M4A protein was
confirmed by western blotting using rabbit anti-GST antibody as shown in figure 3.1.4.
The predicted sizes of the M4A and M4B proteins are 20kD, thus the protein bound to
the 27kD GST would appear at a molecular weight of 47kD. In the case of M4B, we
were unable to detect an induced band in the 47kD region by western blotting using
rabbit anti-GST antibody.
3.1.5 Generation of Antisera
The M4A protein was purified on large scale and used to generate antisera in two
rabbits, termed IG54 and IF55. The rabbits were immunised via a subcutaneous
injection. The initial inoculation contained 20mg of M4A protein purified using the
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GST sepharose column (see section 2.3.3) homogenised with 1ml of TiterMax Gold
(CytRx Corporation) and this solution was equally split between the two rabbits. Both
rabbits were boosted three times with four week intervals. Each boost consisted of lOmg
of M4A protein per rabbit. After four months from the initial inoculation, serum was
obtained from blood samples from the rabbits and tested for anti-M4 activity.
3.1.6 Anti-M4 Activity of Antisera
The antisera was used to detect the M4A protein expressed in the pGEX system by
western blotting (as described in section 2.3.6). A variety of different concentrations of
sera, including neat sera, was used. The antisera bound to the M4A fusion protein,
however, we were unable to show that this was due to M4 and not GST recognition (not
shown).
An immunoprecipitation approach (as described in section 2.3.9) was used as this was
likely to be more sensitive. The late proteins of MHV-68 infected BHK cells were
labelled with [35S] methionine and both the pre-immune rabbit serum and anti-M4 rabbit
serum were used for immunoprecipitation with the cell lysate and cell supernatant. The
immunoprecipitated proteins were separated on a SDS-PAGE gel as shown in figure
3.1.6. The immunoprecipitation revealed that the anti-M4 sera bound to a protein in the
range of 46kD in the lane containing the infected cell lysate. This observation confirms
the predicted size of the 44kD M4 protein. In the same lane, the anti-M4 sera also
bound to two unknown bands of ~80kD and ~94kD not bound by the pre-immune anti¬
sera. In the lane containing the infected cell supernatant, the anti-M4 sera precipitated a
diffuse band of ~60kD. No proteins of these sizes were precipitated from the mock-
infected cell lysates and supernatant. These studies show that the anti-serum bound
specifically to proteins produced following MHV-68 infection. The intracellular 46kD
protein is the expected size for M4 and is likely to be the M4 protein. The extracellular
60kD protein is likely to be a processed form. The "fuzzy" appearance suggests that it is
processed possibly by the addition of sugars. The 80kD and 94kD proteins may be
dimers but at present this is unknown.
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Figure 3.1.3 Generation of M4A and M4B DNA fragments.















The M4 gene cut to generate two DNA fragments; M4A and M4B, using PCR
with tour primers (black arrows).
Figure 3.1.4 M4A protein expression.
i) anti-GST antibody ii) control rabbit serum
A. GST dimer, 60 kDa
B. M4A fusion protein, 46 kDa
C. GST monomer, 27 kDa
M4A gene was cloned and expressed in the pGEX-1 vector. The M4A protein was
bound to GST beads and eluted with glutathione. The eluted protein was
electrophoresed on a 12% SDS-PAGE gel and western blotted with i) anti-GST antibody
and ii) control rabbit serum.
Figure 3.1.6. Radio-immunoprecipitation of antisera.














BHK cells were infected with MHV-68 and radiolabeled with [35S]-methionine and
incubated overnight at 37°C. The cells were lysed in RIPA buffer and the lysates
pre-cleared by incubating with sepharose. Lysates were incubated with i) pre-
immune rabbit anti-sera or ii) rabbit anti-M4 sera and precipitated by mixing with
protein A sepharose. The sepharose beads were washed, resuspended in SDS-
PAGE sample buffer and electrophoresed through a 12% SDS-PAGE gel.
An attempt was made to use the anti-M4 sera as a tool to reveal the subcellular
localisation of the M4 protein within MHV-68-infected BHK cells. An
immunofluorescence approach (as described in section 2.5.3) was used involving a wide
variety of serum concentrations. However, this approach was unsuccessful as the anti-
M4 sera did not appear to bind to any of the infected cells, whereas our positive control,
rabbit anti-MHV-68 polyclonal antibody, worked well.
3.1.7 M4 Protein Expression Using a Eukaryotic System
Since M4 is predicted to have a role as an immunomodulatory protein, functional studies
such as the addition ofM4 protein directly on cells would allow us to determine if M4
has any proliferative effects. The M4 protein expressed in the pGEXl bacterial
expression system (see figure 3.1.4) was only the first half of the protein and purification
gave rise to poor yields, therefore being insufficient for functional studies. Furthermore,
since the sera generated against M4 had weak activity, the use of the whole M4 protein
as an antigen to produce antisera would be more useful. More success may be gained
from utilising a eukaryotic mammalian expression system to express the entire M4 gene
along with the benefits of eukaryotic post-transcriptional modifications.
The M4 gene was cloned into the pcDNA3.1/V5/His-TOPO plasmid using an Invitrogen
TOPO TA cloning kit. The M4pc and M4B primers were used to amplify the M4 gene
and the product was cloned into the vector as described in the Invitrogen manual. The
pcDNA3.1/V5/His-TOPO plasmid does not direct the orientation of the gene insert,
therefore the M4 gene could ligate in either orientation. The plasmid and gene were
transformed into Stratagene XL-2 ultracompetent cells, resultant colonies were picked,
grown overnight in liquid culture and DNA was extracted using a Qiagen miniprep kit.
Restriction digest analysis using BamWl and HindlU were required to determine if the
M4 gene had inserted in a manner so that it was reading left to right as shown in figure
3.1.7. The digests revealed that colonies either contained the M4 gene which had
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inserted in the wrong orientation or that they contained an unknown DNA fragment of
the same size as the M4 gene. The latter could not be explained except that a possible
mutation may have occurred in either one of the two BamRl sites which would prevent
us recognising and detecting the M4 gene cloned in the right orientation. The BamRl
restriction enzyme appeared to cut the DNA once but not twice. If the mutation had
occurred at the BamHI site near the 5' end of the M4 gene then the DNA would be
unviable as the expression of M4 would terminate extremely early. However, if the
mutation had occurred at the 3' end of the M4 gene then this would still allow us to use
the plasmid for our studies as the entire M4 gene would still be expressed. Four samples
containing the unknown DNA were sequenced. This revealed that the DNA was the M4
gene in the correct orientation and there were no mutations in the BamRl site at the
5'end of the gene. This would allow us to assume that the mutation had occurred at the
BamRl site at the 3' end of the M4 and therefore would not pose a problem in our
studies.
A large preparation of a sequenced pcDNA3.1/V5/His-TOPO plasmid containing the
M4 gene was grown in bacteria and DNA was extracted using a Qiagen Endofree
maxiprep kit. 10pg of the plasmid was transfected into 2 x 106 COS-7 cells (as
described in section 2.4.5). The COS-7 cells were grown with selective medium until
foci could be identified. After four weeks the antibiotic resistant cell foci were
harvested and grown to a confluent monolayer.
The expression of M4 from the pcDNA3.1/V5/His-TOPO plasmid in the COS-7 cells
was examined by making use of the hexahistidine sequence present at the 3' end of the
protein. From the observation that the M4 protein contains a secretory signal, the His
bind resin beads were used to purify the M4 protein from the cell supernatant (as
described in section 2.3.8). Western blotting of the purified protein elutes using an anti-
His antibody, the anti-M4 sera, and anti-MHV-68 polyclonal antibody did not detect an
expressed protein. A large amount of non-specific protein was observed on the blots,
therefore an attempt was made to remove these proteins. 0.05% Triton X-100 and
91
protein sepharose 4B were added to the supernatant to remove the non-specific proteins.
Although these alterations did remove some of the unwanted proteins, we did not detect
the expression of M4. To check if the M4 gene and the pcDNA3.1/V5/His-TOPO
plasmid was still present in the COS-7 cells, DNA was extracted from the cells using a
Qiagen DNeasy kit. PCR was performed on the DNA using the M4A and M4B primers
within the M4 gene, and neoF and neoR primers within the neomycin resistance gene.
We were unable to detect the M4 gene but were able to detect the neomycin resistance
gene present in the plasmid by PCR (data not shown). Since the M4 gene appeared to
have been rejected by the COS-7 cells, we decided to pursue a transient transfection
approach. The pcDNA3.1/V5/His-TOPO plasmid containing the M4 gene was
transfected in a similar manner into an alternative cell line, 293 cells. Cell supernatants
were collected at 24 hour intervals over 72 hours post-transfection. Once again the His
bind resin beads were used to purify the M4 protein from the cell supernatant (as
described in section 2.3.8). However, no eluted M4 protein was visualised by western
blotting.
3.1.8 Transcription of M4 During Productive Infection
In order to further characterise the M4 gene, RNA expression studies would be
beneficial by demonstrating in which phase of the MHV-68 lifecycle the M4 gene is
transcribed. As previously mentioned, herpesvirus proteins are produced by genes
which are categorised into one of four types; immediate early, early, late, and latency
genes, depending on the time post-infection the genes are expressed. MHV-68 infected
cells were harvested for immediate early, early and late RNA which was separated on a
formaldehyde gel (as described in section 2.2.5). Northern blotting was performed and
the RNA was hybridised with a M4 DNA probe. The developed X-ray film revealed
that the M4 RNA was expressed early and late as a 1,3kb transcript during the MHV-68
lifecycle as shown in figure 3.1.8. The gpl50 gene is a late gene so therefore, acting as
a control, a gpl50 DNA probe was used to detect the gpl50 RNA transcript of 1.6kb in
the lane containing the late expressed RNA. This was to confirm that the inhibitors used
had worked and no leakage ofRNA had occurred.
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M4 gene was cloned into the pcDNA3.1A/5/His-TOPO plasmid. To screen for the
M4 gene cloned in the correct orientation, restriction digest analysis was performed.
The BamHI and Hind\\\ restriction enzyme sites present in the DNA sequence of
both gene and plasmid were used to determine the correct orientation. The BamHI
and Hind\\\ restriction enzyme bands are shown by blue and red lines respectively.
The M4 gene is shown by the yellow bar. The orientation of the M4 gene is shown
by the pink arrow. The pcDNA3,1A/5/His-TOPO plasmid is shown by the black bar.
Figure 3.1.8 Northern analysis of M4 transcript expression.





Lane 1: 8 hr P.I. + cyclohexamide
Lane 2: 24 hr P.I. + 4'-S-Etdu
LaneS: 24hrP.I.
Lane 4: OhrP.I.
MHV-68 infected cells were harvested for immediate early, early and late RNA using the
appropriate inhibitors (see section 2.4.14) and electrophoresed on a formaldehyde gel (see
section 2.7 5) Northern blotting was performed and the RNA was hybridised with a M4
DNA probe. The blot was stripped and re-probed with a gp150 DNA probe. I he 18S RNA
subunit is shown indicating equal loading of RNA in all lanes.
3.2 Expression Discussion
Immunomodulation proteins are employed by viruses as an immune evasion strategy
(Spriggs et ah, 1996, Alcami & Koszinowski, 2000, Lalani et ah, 2000, MeFadden &
Murphy, 2000, Tortorella et al., 2000). The discovery of M4, a unique gene ofMHV-68
(Virgin et ah, 1997) suggests that this gene is present to give an advantage to the virus
and may be involved in the combating the host's defence mechanisms. Several
approaches have been taken to investigate the role of the MHV-68 M4 gene including
expression of the protein and transcriptional analysis.
3.2.1 Analysis of the M4 Peptide Sequence
The protein sequence of M4 was analysed using the University of Wisconsin Genetics
Computer Group Sequence Analysis Software (UWGCG 9.0, Devereux et ah, 1984)
which revealed the M4 gene had seven potential N-glycosylation sites and a heparin
sulphate binding domain in the half of the peptide nearest the C-terminus. A
hydrophobic signal sequence was detected at the N-terminus of the M4 gene by plotting
the amino acid sequence on a hydrophobicity plot. Heparin sulphate binding domains
are a common characteristic of cytokines and may be involved in the interaction between
M4 protein and its receptor (Handin & Cohen, 1973, Webb et ah, 1993). These
properties lead us to speculate that the M4 gene may be a viral-encoded cytokine.
Cytokines are diverse multifunctional proteins and many viruses harbour their own
cytokines (Spriggs et ah, 1996, Alcami & Koszinowski, 2000). A number of viral
encoded secreted proteins act by interfering with host cell signal transduction pathways
and innate responses. The EBV IL-10 homologue has been shown to mimic human IL-
10 activities including the downregulation of IFN-y synthesis by T cells and NK cells
(Hsu et al., 1990). The M4 protein may be expressed as a secreted glycosylated protein
and exert cytokine signalling by binding to its receptor via its heparin sulphate binding
domain in the extracellular environment during MHV-68 infecton.
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3.2.2 Expression of the M4 Protein and Generation of an Antibody
The expression of the whole M4 protein has been difficult during the project, a major
obstacle being the apparent toxicity of this gene to its host cell. Initially, the expression
of M4 was attempted in the pET-22b(+) plasmid, a plasmid containing a hexahistidine
fusion tag. Fusion protein vectors are advantageous as they contain a tag of known size
and biological function that can greatly simplify subsequent isolation, purification and
detection. An advantage with the pET expression system is that the histidine tag is small
and poorly immunogenic. The pET-22b(+) plasmid is under the control of the
bacteriophage T7 promoter and expression is induced by providing a source of T7 RNA
polymerase in the host cell, and thus the pET system is a tightly controlled system.
Nevertheless, the expression of M4 was not successful in BL21(DE3) bacteria. The
rationale for switching the bacterial host strains was that the BL21(DE3) strain were for
general purpose expression whereas the BL21(DE3)pLysS strain was generated for
high-stringency expression. The BL21(DE3)pLysS strain provides additional stability to
target genes by harbouring a compatible plasmid which contains a gene which produces
small amounts of T7 lysozyme. T7 lysozyme is a natural inhibitor of T7 RNA
polymerase (Moffatt & Studier, 1987; Studier, 1991) by binding to small amounts of T7
RNA polymerase which have leaked before the induction procedure, thus inhibiting
transcription and thereby reducing toxicity. However, the BL21(DE3)pLysS strain
showed no evidence of improving M4 protein expression. Even when the M4 gene was
cut in half to generate M4A and M4B, there was no evidence of protein expression. The
first 500bp of the M4 gene was sequenced which revealed no mutations were present.
However, the possibility of premature termination of the M4 gene cannot be ruled out as
mutations may have occurred further along the sequence.
One difficulty with the pET system is that the pET-22b(+) vector does not contain a
marker which is easily visible. The pGEXl expression system has an inbuilt control in
terms of being able to detect the 27kD GST protein on a SDS-PAGE gel. Furthermore,
any mutation in the M4 gene would not affect expression of the GST as it is 5' to the
inserted gene. However, if the gene fused to GST is toxic then this might prevent
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expression of the GST.
Expression of the M4A fusion protein in the pGEXl system was detected by a shift of
the GST protein band from a molecular weight of 27kD to 47kD visualised on a
Coomasie gel, and by western blotting using an anti-GST antibody. Compared to M4A,
the M4B fusion protein was not successfully expressed in the pGEXl system and this
may be explained by toxicity. Furthermore, there may be motif influences in M4B not
detected by amino acid analysis that inhibit expression. The M4A protein was purified
using a GST sepharose column and protein elution yields were relatively low.
Another system was used to attempt to create alternative yields of the M4 protein and a
stable mammalian cell line. Protein expressed in a mammalian system may be less toxic
and have the same biologically activity as the native protein. The M4 gene was cloned
into the pcDNA3.1/V5/His-TOPO eukaryotic expression system, a fast one step cloning
strategy for the direct insertion of fresh Taq polymerase-amplified PCR product. This
system also has the advantage that the plasmid contains a histidine tag and a V5 epitope
for detection of the protein. However, expression of the plasmid containing M4 in
mammalian cells was not successful following selection of G418 resistant clones. PCR
analysis indicated the M4 gene had been lost while the neomycin resistance gene was
retained which allowed the cells to persist under the selective medium. An explanation
of the rejection may be that the M4 gene was toxic to the COS-7 cells. However,
transient transfection of the plasmid into an alternative cell line, 293 cells, did not
improve M4 expression. If time had permitted, the pVR1255 plasmid is an alternative
vector which could have been used as it has been successfully used to express MHV-68
proteins that could not be expressed in other vectors (Atkin, 2000, Wakeling et al,
2001).
The M4 gene was shown to be toxic in both bacterial pET and mammalian pcDNA3
expression systems. The toxicity in bacteria may be caused by low-level readthrough
transcription from the plasmid promoter (Brown & Campbell, 1993). Using an
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alternative strain of bacteria that reduces toxicity did not appear to have any effect on
protein expression. Expression of eukaryotic proteins can have a deleterious affect on
prokaryotic cells and may cause problems in protein export machinery (Martin et al.,
1989). However, an attempt to express the protein in mammalian cells was not fruitful.
A disadvantage of using mammalian cells as the host is that the manipulated cells can be
genetically unstable which was shown in this case.
M4 protein expression is fundamental for functional characterisation studies. A major
aim would be to find the receptor ligand for the M4 protein and use the M4 protein for
binding studies. Alternative host expression systems include yeast cells and cultured
insect cells. The advantage of the yeast system is that it lacks detectable endotoxins and
only 0.5% of native proteins are exported, thereby, simplifying the isolation of secreted
product. Also, large scale production of proteins is easily achieved and it is a relatively
inexpensive process (Buckholz, 1993, Fleer, 1992, Sreekrishna et al., 1989). However,
glycosylation in yeast is not identical to mammalian systems and, thus, there may be
differences in the biological activity of the protein. Cultured insect cells containing the
Baculovirus vector have processing mechanisms similar to eukaryotic cells and have
high level expression of product (Miller, 1993). However, there is a diminutive amount
of information known about the glycosylation mechanisms and the product is not always
fully functional. Nevertheless, a recombinant baculovirus system was successfully used
to express the M3 protein (Parry et al., 2000).
3.2.3 Anti-M4 Activity of Antisera
The M4A protein was used as an antigen to raise antisera in rabbits. The antisera were
tested against western blots of the M4A protein expressed in the pGEX system. The
antiserum bound to the M4A fusion protein but did not detect any protein by western
blot in MHV-68 infected lysates. Since the binding to the fusion protein could be due to
M4 and not GST recognition, we decided to pursue the more sensitive
radioimmunoprecipitation approach. In radiolabelled MHV-68-infected cell lysates, the
antisera bound to a protein of 44kD, the predicted size of M4, and an unknown protein
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band size of ~80kD. Furthermore, the antisera precipitated an unknown protein of
~60kD in radiolabeled infected cell supernatant which had a "fuzzy" appearance
indicative of a processed protein with variable molecular weight. Several different
protein complexes may form between M4 and unknown protein molecules within the
cell as well as being secreted into the supernatant. Further experiments are required to
reveal the nature of these unknown proteins.
The subcellular localisation of the M4 protein within MHV-68-infected BHK cells was
investigated using the antiserum generated against M4. Immunofluorescence studies
revealed that the antiserum did not detect the presence of M4 in the infected cells.
Interestingly, the M4 sequence harbours a secretory signal and the immunoprecipitation
studies have demonstrated that a certain proportion of M4 is secreted. Therefore, it is
possible that a large amount of the M4 protein may be secreted and therefore not enough
protein is retained within the infected cell to be detected by the antisera. Further studies
using inhibitors such as tunicamycin which blocks steps in glycosylation and thus block
secretion of proteins could be used as an alternative strategy (Elbein, 1984).
Although the generation of an antiserum against M4 has been successful, the fact that it
did not bind M4 protein on western blots or detect antigen in infected cells suggested
that it was a weak antiserum and without further purification, the antibody was not
useful for further studies. The presence of the GST protein attached to the M4A protein
may have resulted in a stronger antibody being raised against the GST rather than the
M4A protein. In retrospect, the GST protein could have have been removed before
using the fusion protein as an antigen. Also, it may have been possible to remove the
anti-GST antibodies from the rabbit serum using a purification column containing the
GST and then add the serum to another column containing the M4 fusion protein to bind
and thus purify the anti-M4 antibodies. However, time did not permit us to grow and
purify large quantities of GST and M4 fusion protein to test this strategy.
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3.2.4 Transcription ofM4 During Productive Infection
Northern analysis was used to examine the in vitro transcription of M4 during
productive infection. M4 RNA transcripts were expressed early and late as a 1.3kb
transcript during the MHV-68 lifecycle. To distinguish immediate early and early RNA
transcribed post-infection, the inhibitory compounds cyclohexamide and 2'deoxy-
5'ethyip-4'thiouridine (4'-S-EtdU) (Rahim et al., 1996) were used respectively.
Cycloheximide suppresses viral protein synthesis and 4'-S-EtdU blocks viral DNA
replication. Early genes require the translation of immediate early transcripts for
expression while late transcripts require viral DNA synthesis for transcription (Roizman
& Sears, 1996). Another MHV-68 early-late gene detected by northern analysis is the
M3 gene which has been shown to be a functional chemokine binding protein (van
Berkel et al., 1999, Parry et al., 2000, van Berkel et al., 2000). The finding that M4 is
expressed early is consistent with it having an immunomodulatory role. If time had
permitted, it would be have been interesting to characterise the mRNA structure of M4.
Rapid amplification of cDNA ends (RACE) and S1 nuclease protection could have been
used to map the 5' and 3' ends of the M4 transcript as was performed with the






4.1 Recombinant Virus Results
The study of mutant and recombinant viruses in which specific genes have been
mutated, deleted or inserted are fundamental in elucidating the function of viral genes.
Herpesviruses harbouring mutated genes have been discovered and isolated on the basis
of altered plaque phenotype (Ejercito et al., 1968). The invaluable use of recombinant
DNA technology has now permitted the generation of specific recombinant viruses.
The molecular biology studies of gammaherpesviruses have had major set backs due to
the inability of these viruses to grow permissively in cell cultures. MHV-68 does not
encounter this problem, being replication efficient in cell culture. This property allows
us to take advantage of MHV-68 and utilise it for genetic manipulation studies of viral
genes. The M genes have an unknown function. However, with the crucial assistance of
recombinant virus technology, possible functions have been attributed to some of these
genes (Simas et al., 1998, Clambey et al., 2000). MHV-68 recombinant viruses have
been extremely useful in our understanding of the virus-host interactions which occur
with this infection (Clambey et al., 2000; Hoge et al., 2000; Simas et al., 1998; van Dyk
et al., 2000).
A recombinant virus only lacking a functional M4 gene has not been generated. In order
to determine the function of M4 we had two strategies. Our first strategy was to
construct an MHV-68 virus which lacked the entire M4 gene, a M4 "knock out" (KO)
virus. It has been shown previously with gammaherpesviruses including MHV-68, that
these viruses do not tolerate recombination events very well (Simas et al., 1998).
Therefore, if our first strategy failed we had an alternative plan with the use of MHV-76
as a tool. As previously described (see section 1.5.6), MHV-76 appears to be a deletion
mutant ofMHV-68 which lacks the first l-9538bp as shown in figure 4.1 (Macrae et al.,
2001). Thus, it does not encode Ml, M2, M3, the viral tRNAs and crucially for our
purposes, M4. An opportunity was present to generate MHV-76 which contained the
entire M4 gene, a M4 "knock in" (KI) virus. Generation of either of these recombinant
viruses would be a critical tool for our functional studies. Essentially our aim would be
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Left hand regions of the MHV-68 and MHV-76 genome are shown in the diagram.
The MHV-76 genome lacks the first 1-9583bp of the MHV-68 genome (Macrae et al.,
2001). The M4 gene is shown by the pink arrow. Terminal repeats (TR) are shown
by orange bars. M1-M3 genes are shown by yellow arrows. The complement
regulatory protein (crp) is shown by the red arrow. The 8 viral tRNAs are numbered
1-8.
to explore the pathogenesis of the recombinant virus in vivo. Mice would be infected
with the purified recombinant virus and analysed by titration of infective virus in the
lung and reactivation of latent virus in the spleen and mediastinal lymph nodes (MLN)
in comparison with the wild type virus.
4.1.1 M4 Knock-Out Recombinant (M4KO) Virus Cloning Strategy
The cloning strategy used to generate a M4 knock out recombinant (M4KO) virus is
outlined in figure 4.1.1. Our aim was to delete the M4 gene from the MHV-68 genome
and insert in its place a cassette encoding the green fluorescent protein (GFP) via
homologous recombination. The GFP gene was originally derived from the jelly fish
Aequoria victoria (Zolotukhin et al., 1996) and is now a widely used marker due to its
ability to emit a green fluorescence upon excitation by UV light of maximum 488nm
wavelength. The green fluorescence is expressed during productive viral replication as a
result of the gene being under the control of the constitutive CMV immediate early
(CMVIE) promoter. Due to the ease of detection of the GFP gene, this tool has been
widely used in the construction of recombinant herpesviruses (Prichard 1999, Duboise
1996).
A three-step cloning strategy as depicted in figure 4.1.1 was used to generate the M4
recombinant construct. Flanking regions ofDNA directly after each end of the M4 gene
were amplified by PCR. The M41F and M41R primers were used to amplify a flanking
region to the left of M4 and the M42F and M42R(2) primers were used to amplify a
flanking region to the right ofM4. The flanking regions were ~600bp in length to allow
for homologous recombination. The PCR products were connected together using
complementary base pairs to form a single PCR product which flanked both sides of M4
using the M41F and M42R(2) primers. The M4 flanking DNA PCR product was
purified and cut with BamHl and Xhol and ligated into corresponding sites in the
pBluescript II KS+ (pKS) vector. The ligation mix was used to transform competent
E.coli and resultant colonies were picked and grown up in liquid culture. The plasmid
DNA was extracted and analysed for the correct construct by restriction digestion
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analysis. The correct plasmid construct containing the M4 flanking regions was digested
with Accl. A construct (kindly provided by Dr. D. J. Roy) containing the GFP gene
flanked by the CMVIE promoter and the Simian virus 40 polyadenylation signal
(SV40pA), was amplified from the plasmid pEGFP-Cl using primers CMV1 and SV40.
The pEGFP-Cl multiple cloning site, which is situated at the 3' end of the GFP coding
region, was excised prior to amplification, which assisted subsequent cloning of the GFP
gene. The plasmid was digested with Accl and ligated into the corresponding Accl sites
within the M4 flanking DNA in the pKS+ vector and transformed into competent E. coli,
grown up and analysed as described previously. Restriction digest analysis was used to
determine the GFP cassette was in the same transcriptional orientation as the M4
flanking DNA. The M4KO construct consisted of the pKS+ vector containing the GFP
gene flanked with DNA which flanked the left and right hand of the M4 sequence. A
large scale preparation of the M4KO plasmid was made using a Qiagen endofree maxi-
prep kit. The M4KO plasmid was digested with BamHl and Xhol to remove the M4KO
cassette from the pKS+ vector to avoid a recombination event which might lead to the
entire plasmid being incorporated into the MHV-68 genome.
BHK cells were co-transfected with 15pg of MHV-68 DNA and lOpg of the excised
M4KO cassette. The cells were overlaid with agar 24 hours post-transfection. At four
days post-transfection, wild type virus plaques were observed using the light microscope
and green fluorescent plaques were visible using a UV microscope.
4.1.2 Purification of M4KO Virus
Plaque purification was used to isolate wild type MHV-68 plaques from the recombinant
plaques (see section 2.4.13). Green plaques were picked with a Pasteur pipette and
serially diluted and plated with a cell line, CI27, which forms a more easily detectable
plaque in comparison to BHK cells. Six rounds of plaque purification were performed
which did not appear to increase the purification of the green virus. The CI 27 cells were
replaced with apSVl cells. This is a murine embryo fibroblast cell line which lacks the
type I interferon receptor (kindly provided by Dr. J. P. Stewart). Previous studies have
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shown that MHV-68 plaques more efficiently in this cell line than in BHK or CI27 cells
(A. Macrae, personal communications).
4.1.3 PCR ofM4KO Virus
Virus DNA was extracted from cells infected with a single isolated green plaque and
analysed by PCR. The positions of the primers used are in figure 4.1.3. Primers
M4LH1 and GFP2 were used to detect whether the recombinant construct had
recombined in the correct region of genome, GFP1 and GFP 2 were used to detect the
presence of the GFP gene, and M4LH1 and M4Arev were used to detect the presence of
M4. The PCR failed to demonstrate homologous recombination between the MHV-68
genome and the M4 knock out recombination construct had occurred in the desired
manner as seen in figure 4.1.1. The M4LH1 and M4Arev primers amplified the 1.3kb
M4 gene, thereby demonstrating the presence ofM4. GFP 1 and GFP2 primers revealed
that the 1.6kb GFP gene had recombined into the MHV-68 genome. However, PCR
with M4LH1 and GFP2 primers demonstrated the GFP gene recombination had not
occurred in the correct region and had not disrupted and removed the M4 gene.
Time limitations did not permit us to perform a Southern analysis with the recombinant
DNA which would have revealed the exact location of the non-homologous
recombination.
4.1.4 M4 Knock In Recombinant (M4KI) Virus Cloning Strategy
Since our attempt to generate MHV-68 without the M4 gene had been futile, we adopted
our alternative plan to utilise MHV-76 by generating MHV-76 with the M4 gene
inserted. The three step cloning strategy is shown in figure 4.1.4a. A 1.2kb Pstl
fragment of the MHV-68 terminal repeat had previously been cloned into a pUC13
plasmid (Efstathiou et al., 1990b). Restriction analysis revealed that the terminal repeat
was opposite to our desired orientation. We attempted to switch the orientation of the
terminal repeat by standard cloning methods but the fragment appeared to harbour
preferential orientation and we were unsuccessful. Therefore, we cut the terminal repeat
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The M4 gene left (L) and right (R) flanking regions were amplified via PCR using Taq
polymerase. The L and R products were joined via PCR to produce one DNA
fragment and cloned into the BamHI and Xho\ restriction sites of the pBluescript II KS+
pKS+ vector. The GFP gene was inserted between the left and right flanking DNA
using the Accl restriction site. L - left flanking DNA of M4, R - right flanking DNA of
M4, GFP - green fluorescent protein.
Figure 4.1.3 PCR of M4K0 virus.
M3
Lane
1 1|il KO DNA + M4LH1/GFP2
2 2)il KO DNA i M4LH1/CFP2
3. 3nl KO DNA + M4LH1/GFP2
4. 4pl KO DNA + M4LH1/GFP2
5. 6|il KO DNA + M4LH1/GFP2
6. 10(al KO DNA + M4LH1/GFP2
7. No DNA + M4LH1/GFP2
8. 10nl KO DNA + GFP1/GFP2
9 4pl KO DNA + GFP1/GFP2




1. MHV68 DNA + M4LH1/M4Arev
2. No DNA + M4LH1/M4Arev
3 KO DNA + M4LH1/M4Arev
~1 3kb
i) Diagram of homologous recombination event between the M4 knock-out
recombinant construct and the MHV-68 genome. Green knock-out recombinant virus
plaques were picked and propagated in BHK cells. DNA was extracted from one
sample as described in section 2.1.19 PCR was performed on a range of dilutions
of DNA using ii) M4LH1, GFP1 and GFP2 primers and iii) M4LH1 and M4Arev
primers and Taq polymerase. Primer positions are shown in i) as black arrows. L -




from pUC13 using Pstl and re-cloned the fragment into a pUC18 plasmid. In contrast to
pUC13, our desired orientation for the terminal repeat fragment in pUC18 was
successfully achieved The correct orientation in pUC18 was demonstrated by restriction
analysis. Our next step was to amplify by PCR using primers MHV76A and MHV76B,
a 2.6kb fragment from the MHV-68 genome containing the M4 gene and flanking DNA.
The MHV76A and MHV76B primers were designed to harbour BamWl and EcoKl
restriction sites respectively. The two restriction enzymes were used to cut the purified
PCR product and the pUC18 plasmid. The M4 gene and flanking DNA were cloned into
the pUC18 plasmid containing the terminal repeat. The same GFP gene used for the M4
knock out virus (see section 4.1.1) was amplified as previously described, cut with
BamUl and BglW and cloned into the corresponding site in the pUC18 plasmid.
Restriction digest analysis was used to determine that the GFP cassette was in the same
transcriptional orientation as the terminal repeat and the M4 gene. A large scale
preparation of the M4 knock in (KI) plasmid was made using a Qiagen endofree maxi-
prep kit. The M4KI plasmid was digested with Hindlll and EcoBd to remove the M4KI
cassette from the pUC18 plasmid.
BFIK cells were co-transfected with 10pg of MHV-76 DNA and lOpg of the excised
M4KI cassette. The cells were overlaid with agar 24 hours post-transfection. At four
days post-transfection, wild type virus plaques were observed using the light microscope
and green fluorescent plaques were visible using a UV microscope (figure 4.1.4b).
4.1.5 Purification ofM4KI Virus
As previously described with the purification of the M4KO virus, plaque purification
was used to isolate wild type MHV-76 plaques from the M4KI recombinant plaques (see
section 2.4.13). Green plaques were picked with a Pasteur pipette and serially diluted
and plated with BHK cells. However, in contrast to our method with the M4KO virus,
only one round of plaque purification was performed before we analysed the
recombinant virus by PCR.
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4.1.6 PCR ofM4KI Virus
Virus DNA was extracted from cells infected with a single isolated green plaque using a
Qiagen DNeasy kit and analysed by PCR. The positions of the primers used are in
figure 4.1.6. Primers M4A and M4GFP76 were used to detect whether the recombinant
construct had recombined in the correct region of genome, and M4A and M4B were
used to detect the presence of M4. The PCR demonstrated homologous recombination
between the MHV-76 genome and the M4 knock in recombination construct had
occurred in the desired manner as seen in figure 4.1.6. The M4A and M4GFP76 primers
amplified the expected 2.8kb fragment indicating that homologous recombination had
been successful. The M4A and M4B primers amplified the 1.3kb M4 gene, thereby
demonstrating the insertion ofM4.
4.1.7 Southern Analysis of M4KI Virus
Now we had evidence that the generation of the M4KI virus had been successful, we
performed another two rounds of plaque purification. At this point, the recombinant
virus had been purified to the standard that no wild type plaques were visible under the
light microscope. PCR does not detect the purity of the recombinant virus, however, a
Southern analysis would inform us if wild type virus was present. MHV-68, MHV-76,
and the M4KI virus were propagated on BHK cells and their DNA was extracted as
described in section 2.1.19. lpg/lane of each viral DNA digested with either BamHI,
Bglll or EcoRI, were electrophoresed on two 0.7% TAE gels alongside 5pg of lkb DNA
molecular weight markers. The gel was blotted overnight by capillary transfer to nylon
membranes as described in section 2.1.22 and fixed by UV cross-linking. Each blot was
hybridised with a different 32P-labelled DNA probe corresponding to either (a) the first
590bp of M4 or (b) Hindlll G fragment of the MHV-68 genome. The restriction
enzyme maps of the left hand end of MHV-68, MHV-76 and the M4KI virus and
expected band sizes with the two different probes arc detailed in figure 4.1.7a. The
hybridised southern blots are shown in figure 4.1.7b and the band sizes that distinguish
the three different viruses are confirmed. The blot hybridised with the M4 probe
confirmed again that the M4 gene is only present in MHV-68 and the M4KI virus and
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the generation of the M4KI virus had been successful. Hybridisation with the HindHIG
probe revealed that the M4KI virus stock was pure due to the inability to detect wild
type MHV-76. It was apparent from the blots that the probes detected a series of ladder¬
like DNA fragments which may alter the sizes of some of the bands. These fragments
have previously been detected and is a result of the viral genome harbouring variable
copies of 1.2kb terminal repeats (Efstathiou et al., 1990).
4.1.8 Transcript Expression of M4K1 Virus
Before we used the M4KI virus for in vivo studies, it was essential to establish M4
transcript expression. Whole RNA was extracted using a RNeasy kit (Qiagen) from
BHK cell monolayers infected overnight with either MHV-68, MHV-76 or M4KI
recombinant virus. The RNA preparations was DNasel treated (as described in section
2.2.3) to remove any viral or cellular DNA. Complementary DNA (cDNA) was reverse
transcribed from RNA (as described in section 2.2.4) and used for PCR with the M4A
and M4Arev primers and p-actin as seen in figure 4.1.8a. The M4A and M4Arev
primers amplified M4 DNA present in the MHV-68 and M4KI cDNA but not in the non-
infected or MHV-76 cDNA. DNasel treated RNA was also used for PCR to establish
that the M4 DNA detected was not present in the samples before cDNA preparation.
The P-actin primers were used as a housekeeping control to show that RNA was present
in all samples.
In addition, northern blotting was used to analyse M4 RNA expression. The DNasel
treated RNA from the previous experiment was electrophoresed on a formaldehyde gel,
blotted onto a nylon membrane and hybridised with a M4 DNA probe (as described in
section 2.2.6). The northern analysis confirmed the RT-PCR results by showing the M4
DNA probe had bound the M4 transcript of 1.3kb in the MHV-68 and M4KI RNA but
not the MHV 76 RNA (figure 4.1,8b).
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The M4 gene and flanking regions were amplified via PCR using Taq polymerase. The
M4 PCR product was cloned into the BamHI and EcoRI restriction sites of the pUC18
plasmid containing the terminal repeat (TR). The GFP gene was inserted between the
TR and M4 gene using BamHI and BglU restriction sites. TR -terminal repeat, F -
flanking regions of M4, GFP - green fluorescent protein.
Figure 4.1.4b M4KI virus plaque.
BHK cells were co-transfected with MHV-76 DNA and M4KI cassette. Cells were overlaid
with agar 24 hours post-transfection. At four days post-transfection, green fluorescent
plaques were visible using a UV microscope.





1. KI4 virus DNA + M4A/M4B
2. KI5 virus DNA + M4A/M4B
3. KI6 virus DNA + M4A/M4B
4. KI7 virus DNA + M4A/M4B
5. KI8 virus DNA + M4A/M4B
6. KI9 virus DNA + M4A/M4B
7. MHV-68 DNA + M4A/M4B
8. No DNA + M4A/M4B
iii)
Lane
1. KI4 virus DNA + M4A/M4GFP76
2. KI5 virus DNA + M4A/M4GFP76
3. KI6 virus DNA + M4A/M4GFP7R
4. KI7 virus DNA + M4A/M4GFP76
5. KI8 virus DNA + M4A/M4GFP76
6. KI9 virus DNA + M4A/M4GFP76
7. MHV-68 DNA + M4A/M4GFP76
8. no DNA + M4A/M4GFP76
~1 3kb
i) Diagram of homologous recombination event between the M4KI construct and the
MHV-76 genome. Six green knock-in recombinant virus plaques (KI4-KI9) were picked
and propagated in BHK cells. DNA was extracted using a Qiagen DNeasy kit. PCR was
performed using ii) M4A and M4B primers and iii) M4A and M4AGFP76 primers and Taq
polymerase. Primer positions are shown in i) as black arrows. TR - terminal repeats,
GFP - green fluorescent protein, Kl - knock-in virus.















































Restriction maps of the left hand region of the MHV-68, 76 and MKI virus. The
predicted band sizes are shown for restriction digests of wild type virus and
recombinant virus DNA digested with one of three enzymes, SamHI, BglW or
EcoRI. Band sizes are detected using probes for the M4 gene and the HindlllG
fragment. TR - terminal repeat, Kl - knock-in.
Figure 4.1.7b Southern analysis of MHV-68, MHV-76 and M4KI
virus.
MHV-68, MHV-76 and M4KI recombinant virus were propagated on BHK cells
and DNA was extracted as described in section 2.1.19. 5pg of each viral DNA
were digested overnight with either BamH\, BglII or EcoRI. 1pg/lane of viral
DNA were electrophoresed on two 0.7% TAE gels alongside 5pg of 1kb DNA
molecular weight markers. The gels were blotted overnight by capillary transfer
to nylon membranes as described in section 2.1.22 and fixed by UV cross-
linking. Each blot was hybridised with a different 32P-labelled DNA probe
corresponding to either (a) the first 590bp of M4 or (b) Hindlll G fragment of the
MHV-68 genome. TR - terminal repeat, Kl - knock-in virus.
Figure 4.1.8a Reverse transcription PCR of M4KI virus.











5. Non-infected Dnase treated RNA
6. MHV-68 Dnase treated RNA
7. MHV-76 Dnase treated RNA
8. M4KI Dnase treated RNA
9. no DNA









Reverse transcription-PCR (RT-PCR) was performed using Taq polymerase with A)
M4A and M4ARev primers, and B) p-actin primers. Products are electrophoresed on a
0.8% agarose gel. Kl - knock in, cDNA - complementary DNA
Figure 4.1.8b RNA expression of M4KI virus.
12 3 4
Lane 1: mock-infected RNA
Lane 2: MHV-68 RNA
Lane 3: MHV-76 RNA
Lane 4: M4KI RNA
BHK cells were infected with either MHV-68, MHV-76 or M4KI virus overnight. RNA
was extracted using RNAzolB (Sigma) and 5f.ig/lane of RNA was electrophoresed on
a formaldehyde gel overnight. The gel was blotted with nylon membrane and
hybridised with the M4 gene.
4.1.9 Growth ofM4KI Virus
The growth characteristics in vitro of the M4KI virus were established using the one step
growth curve method (as described in section 2.4.20). MHV-68, MHV-76 and the
M4KI virus stocks were titrated simultaneously on the same BHK-21 cells prior to the
experiment to provide a reliable comparison between the three viruses. 2 x 105 BHK
cells were infected per timepoint at 5 pfu/cell. Cells were harvested at 0, 4, 8, 12, 20,
24, 30, 36, 48, 60 and 72 hour post-infection and titrated on BHK-21 cells (as described
in section 2.4.18). The one step growth curves of MHV-68, MHV-76 and the M4KI
virus are shown in figure 4.1.9. As reported previously, MHV-68 replicated efficiently
and attained maximal titres at around 60 hours post-infection and the growth kinetics of
MHV-76 was similar to MHV-68 (Sunil-Chandra, 1991, Macrae et al., 2001). The
growth curves demonstrated there is no difference in the growth of the M4 KI virus in
vitro on BHK-21 cells compared to MHV-68 and MHV-76. Therefore, the addition of
the M4 gene in MHV-76 does not result in a significant difference in its ability to
replicate in vitro.
4.1.10 Mouse Infection Studies with M4KI Virus
BALB/c mice were infected intranasally with 4xl05 pfu of either MHV-76, MHV-68 or
M4KI virus. Four mice were infected for each timepoint with one of the three viruses.
Lung titrations, as described in section 2.4.18, were performed on lungs taken from mice
on days 2, 6, 10, and 14 and graphed in figure 4.1.10a. As reported previously, MHV-76
is cleared more rapidly than MHV-68 from the lung (Macrae et al., 2001). The lung
titration graph A reveals that the M4KI virus infects the lung with the same
pathogenicity as MHV-76. On day 2 the M4KI virus appears to titrate to higher levels
than MHV-76. The lung titration experiment was repeated with lungs on early timepoint
days 1, 2, 3, 4, and 6 as shown in figure 4.1.10a, graph B. Due to limited availability of
mice, in this instance only three mice were infected for each timepoint with one of the
three viruses. In both graphs A and B, M4KI titre was significantly higher than MHV-
68 (P<0.05, Student's t-Test) on day 2 indicated by *. On graph B but not on graph A,
MHV-76 titre was significantly higher than MHV-68 (P<0.05, Student's t-Test) on day
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2 indicated by No significant difference was observed across the other time points
used.
Infective centre assays, as described in section 2.4.19, were performed on spleens taken
from mice on days 6, 10, 14, 18, 21, and 31 (see figure 4.1.10b and table 4.1.10). This
assay revealed, during all timepoints, that M4KI infective centres were undetectable in
the spleen and there were no signs of reactivating virus in comparison to MHV-76 and
MHV-68. To investigate which site within the mouse the level of M4KI virus became
reduced, inhibited or undetectable, infective centre assays were performed on pooled
mediastinal lymph nodes (MLN) of four mice on days 3, 6, 8, and 13. Infective virus
assays were performed (as described in section 2.4.18) on the pooled MLNs to ensure
that any infective centres detected were not a result of lytic virus plaques. Plaques
which formed as a result of the infective virus assay were deducted from the number of
infective centres (see figure 4.1.10c and table 4.1.10). Infective centres were
demonstrated in the MLNs for the M4KI virus on day 3 and were severely reduced to
just above detection levels on days 6 and 8. By day 10, no infective centres were
detectable in the MLNs for the M4KI virus. In stark contrast, MHV-68 infective centres
were not detectable on day 3 but rose to a high level from day 6 onwards. MHV-76
infective centres were detected at a high level during days 3 and 8, moderate levels on
day 6 and were severely reduced on day 13. The assays showed that M4KI virus
infective centres are much reduced in the MLNs in comparison to MHV-76 and MHV-
68 and are not detectable in the spleen.
Splenomegaly has previously been observed in MHV-68 but not in MHV-76 spleens
(Macrae et al., 2001). It was interesting to examine any changes which may have
occurred in the spleen with M4KI infection in comparison to MHV-68 and MHV-76.
Prior to the infective centre assays, all spleens were weighed and the number of cells
were counted. The spleen weights and cell counts are shown in figure 4.1.1 Od, in graph
A and B, respectively. The weights and cell counts of M4KI spleens were not
significantly different (P<0.05, Student's t-Test) from MHV-76. The MHV-68 spleen
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weights on days 14, 18, 21, and 31 are significantly higher than MHV-76 and M4KI
(P<0.05, Student's t-Test ) indicated by * in graph A. This is corroborated by the
finding that MHV-68 spleen cell counts on days 18 and 21 are significantly higher than
MHV-76 and M4KI (P<0.05, Student's t-Test ) indicated by ~ in graph B. From this
data, as would be expected, splenomegaly was not observed in the M4KI spleens. In
addition, the pooled MLNs were examined for differences in cell counts, the average
number of cells per MLN is shown in figure 4.1.10e. MHV-68 MLN cell counts
appeared higher in days 3, 6, and 8, however, they were much lower on day 13.
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Figure 4.1.9 One Step Growth Curve of M4KI Virus In Vitro.
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The growth kinetics of MHV-68, MHV-76 and M4KI virus were titrated on BHK-21
cells. The standard errors are shown by the black bars.










































Lungs were taken from mice infected with either MHV-68, MHV-76, or M4 Kl virus on days
2, 6, 10, and 14 post-infection and titrated on BHK-21 cells (see graph A). The experiment
was repeated (see graph B) with lungs taken from mice on days 1, 2, 3, 4, and 6 post¬
infection. In both graph A and B, M4 Kl titre was significantly higher than MHV-68 (P<0.05,
Student's t-Test ) on day 2 indicated by * On graph B but not on graph A, MHV-76 titre
was significantly higher than MHV-68 (P<0.05, Student's t-Test) on day 2 indicated by
No significant difference was observed across the other time points used









Infective centre assays (described in section 2.4.19) were performed on spleens of mice
infected with either MHV-68, MHV-76, or M4KI virus on days 6, 10, 14, 18, 21 and 31
post-infection. The number of infective centres/107 splenocytes are presented in the
graph and table 4.1 10. All titres for the three viruses were significantly different from day
10 onwards (P<0.05, Student's t-Test).
Figure 4.1.10c Mediastinal lymph node infective centre assay of
















Infective centre assays (described in section 2.4.19) were performed on pooled
mediastinal lymph nodes (MLN) of mice infected with either MHV-68, MHV-76, or M4KI
virus on days on days 3, 6, 8, and 13. Infective virus assays (described in section 2.4.20)
were performed on the MLNs, data were deducted from infective centre data and
presented in the graph and table 4.1.10. The data represents the pooled MLNs of four
mice.






















Spleens were taken from mice infected with either MHV-68, MHV-76, or M4KI virus
on days 6, 10, 14, 18, 21, and 31 post-infection. The weights and cell counts of
spleens were measured. Weights and cell counts of M4KI spleens were not
significantly different (P<0.05, Student's t-Test ) from MHV-76. MHV-68 spleen
weights on days 14, 18, 21, and 31 are significantly higher than MHV-76 and M4KI
(P<0.05, Student's t-Test) indicated by * in graph A. MHV-68 spleen cell counts on
days 18 and 21 are significantly higher than MHV-76 and M4KI (P<0.05, Student's t-
Test) indicated by ~ on graph B.



















Mediastinal lymph nodes (MLNs) were taken from mice on days 3, 6, 8 and 13 pooled
and counted as shown in graph. The data represents the pooled MLNs of four mice
and is the average number of cells/MLN
Table 4.1.10 Spleen and MLN Infective Centre Assay Data
Day pi
Mouse Number of IC/107Splenocytes
number
MHV-68 MHV-76 M4KI
6 1 2 1 0
2 3 1 0
3 7.5 1.5 0
4 37 1 0
10 1 305 4 0
2 380 6.5 0
3 615 3.5 0
4 2700 29.5 0
14 1 75 2.5 0
2 425 2 0
3 240 1.5 0
4 210 1 0
18 1 265 1.5 0
2 140 1 0
3 170 1 0
4 175 1 0
21 1 66 3.5 0
2 33 8.5 0
3 45 1 0
4 50.5 1 0
31 1 13.5 1 0
2 2 1 0
3 16 1 0
4 14.5 1 0
Day pi
No. of IC-IV/107MLN Cells
MHV-68 MHV-76 M4KI
3 0 1590 330
6 120 40 5
8 1825 440 5
13 1430 5 0
pi - postinfection, IC - infective centres, IV - infective virus
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CHAPTER FOUR RESULTS
4.1.11 FACS Analysis of M4KI Infected Cells
In order to examine the effect of the M4KI virus on B cell activation in the cells of the
MLN and spleen, Fluorescent-Associated Cell Sorting (FACS) analysis was used. The
cells were extracted from spleens and MLNs of mice infected with either MHV-68,
MHV-76, or M4KI. 5 x 105 cells were used for each FACS sample and antibodies were
incubated and washes were performed as described in section 2.5.2. CD19 directly
conjugated to PE was used to detect the total number of B cells present and CD69
directly conjugated to FITC was used to observe differences in B cell activation. CD69
is an activation marker on B cells and T cells. The double stain was used to quantitate
the number of activated B cells. FACS analysis was performed on cells from mice
infected on days 6, 10, 14, 18, 21, and 31 post-infection. Data (not shown) did not
indicate any overall differences in na'ive and activated B cells between MHV-68, MHV-
76 and M4KI during all timepoints.
4.1.12 Lung and Spleen Histopathology
The histopathology of MHV-76 infected lungs and spleens has revealed there is a more
rapid development of lung inflammation compared to MHV-68 (Macrae et al., 2001).
As a result, the histological examination of the M4KI virus infected lungs and spleens
was of interest during the in vivo studies. Lungs were taken from MHV-68, MHV-76,
and M4KI mice on days 4, 6, 8 and 10 post-infection. Spleens were taken from MHV-
68, MHV-76, and M4KI mice on days 4, 6, 8, 10, 14 and 21 post-infection. Lungs were
fdled with and spleens were placed in formaldehyde solution as described in section
2.4.21. Slide sections were made of these organs and they were analysed under a light
microscope (kindly performed by Dr. David Brownstein). As previously observed, the
lungs of MHV-76 had a more elevated inflammation during days 4 and 6 in comparison
to MHV-68 (Macrae et al., 2001). These characteristics were also observed in the M4KI
infected lungs as shown in figure 4.1.12a. Perivascular infiltrate inflammatory cells
were detected around the blood vessels on day 4 ofMHV-76 and M4K1 lungs. On day
6, the inflammatory cells had increased from round the blood vessel and the infiltration
can be seen to spread to the lung airways. By day 8 and 10, the infection had reduced
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and cleared. Germinal centre formation was detected in all infected spleens on day 8
and 10. As previously observed, the number and size of germinal centres in MHV-68
infected spleens were larger and peaked by day 14. However, this was not exhibited by
MHV-76 and M4KI infected spleens as shown in figure 4.1.12b. No differences were
observed between MHV-76 and M4KI infected lungs and spleens during all timepoints.
4.1.13 PCR and Southern Analysis of M4KI Infected Organs
In view of the fact that no latent virus could be detected by infective centre assay in the
spleens of M4KI virus infected mice, it would be of interest to examine whether
lungs,spleens and mediastinal lymph nodes (MLNs) harboured the virus in long term
infected mice. Furthermore, it would be particularly important to show if the M4KI
virus had trafficked from the MLNs to the spleen. A Qiagen DNeasy kit was used to
extract DNA from the lungs, MLNs, and spleens of three month old mice infected with
either MHV-68, MHV-76 or M4KI virus. Duplicate mice were used for each virus.
PCR was performed on lpg of extracted lung, MLN, spleen, and kidney DNA with the
M4A and M4B primers to detect the M4 gene. 15pl of each lOOpl PCR sample were
electrophoresed on a 0.7% TAE gel and Southern blotted onto a nylon membrane and
fixed by UV cross-linking as described in section 2.1.21 and 2.1.22. The membrane was
hybridised with a 32P-labelled M4 DNA probe which did not indicate the presence of the
M4 gene in any of the extracted DNA samples. The M4 probe bound to the positive
control, a PCR of MHV-68 genomic DNA, but did not bind any of the DNA extracted
from MHV-76 and MHV-68 organs. It has previously been demonstrated by PCR
analysis that MHV-76 and MHV-68 persist long term in the spleen and lung of infected
mice (Stewart et al., 1998, Macrae et al., 2001). The lack of detection of the M4 gene in
MHV-76 and MHV-68 infected lungs and spleens would suggest there was a sensitivity
problem.
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4.1.14 Cell Proliferation Studies
The M4 protein is is an secreted protein which may have an immunomodulatory
function. Given the nature of MHV-68 infection it is plausible that this protein may
exert a growth effect on splenic cells. BHK-21 cells were infected for 24 hours with 5
pfu of either MHV-68, MHV-76, M4KI, and mock virus. Supernatants from the cells
were collected, centrifuged at high speed to remove debris, and kept frozen. B cells and
non-B cells were extracted from the spleens of wild type BALB/c mice and used with
the supernatants for an alamar blue assay and a [ H] thymidine assay as described in
section 2.4.10 and 2.4.11. However, all the supernatants, including the control mock,
appeared to inhibit the growth of the cells. It is possible that this was a result of the
supplements used in the growth medium for the BHK-21 cells. Therefore, an alternative
approach was to use another cell line, CI27 cells, that did not require supplements to the
growth medium. CI27 cells were infected as before and supernatants were used for the
same assay. Different supernatant concentrations were used at 0%, 5%, and 10% of the
total culture volume. The amount of incorporated tritiated thymidine by the cells was
measured. MHV-68, MHV-76, and M4KI supernatants stimulated the proliferation of B
cells and non-B cells in comparison to the mock supernatant (see figure 4.1.14).
However, no differences were observed in the level of proliferation between the three
viruses.
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Figure 4.1.14 Cell Proliferation Assay.








Proliferation studies were performed on A) B cells and B) non-B
cells (described in section 2.4.11). Three concentrations (0%, 5%,
and 10%) of virus-infected cell supernatant were used. The
amount of tritiated thymidine ([3H] TdR) incorporated by the cells
was measured by a scintillation counter.
4.2 Recombinant Virus Discussion
The generation of a mutant virus is a desirable way to explore the function of the gene of
interest in its natural host environment. The advent of recombinant DNA technology
and PCR has allowed the generation ofmutants to be a more specific process. However,
before recombinant DNA technology existed, mutant herpesviruses were isolated by
phenotyping and this was initiated by herpes simplex virus (HSV). Classical approaches
in creating mutant HSV include altered plaque phenotype (Ejercito et al., 1968), drug
resistance (Kitt et al, 1964), host-range properties (Aurelian, 1964), and temperature-
sensitive mutants (Brown et al., 1973). Targeted disruption of alphaherpesvirus and
betaherpesvirus genes has been shown to be extremely beneficial in elucidating the
functions of the genes (Balan et al., 1994, Vieira et al., 1998). There has been some
success in the generation of gammaherpesviruses with disrupted genes, however, more
difficulties have been encountered with the manipulation process (Borza & Hutt-
Fletcher, 1998, Wang & Hutt-Fletcher, 1998). Recognition of homologous
recombinants is facilitated by the use of a visual marker. For our studies, we took
advantage of the GFP cassette, a green fluorescence emitting protein under the control of
a constitutive promoter (Zolotukhin et al., 1996). This marker has been successfully
used in a number of recombinant studies (Vieira et al., 1998, Prichard 1999, Duboise
1996). An alternative visual marker which has been successfully used is the P-
galactosidase gene (Simas et al., 1998, van Dyk et al., 2000, Clambey et al., 2000).
Selectable markers that we could have made use of include the neomycin resistance gene
(Grassman & Fleckenstein, 1989), the HSV-1 thymidine kinase gene (Post et al., 1981),
the hygromycin phosphotransferase gene (Marchini et al., 1992), and the E.coli
guanosine phosphoribosyl transferase (gpt) gene (Greaves et al., 1995),
As mentioned previously, murine models of both human alphaherpesvirus and
betaherpesvirus infection exist which are invaluable for recombinant virus studies.
There are many advantages in using mouse models, including the vast amount of genetic
information already known about them and their cost efficiency. MHV-68 is a
gammaherpesvirus which infects mice and can grow permissively in tissue culture,
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unlike EBV and KSHV, and can be utilised for the generation of recombinant viruses for
in vivo studies. The MHV-68 model has recently be used to generate recombinant
viruses, including viruses lacking the Ml and cyclin D genes (Simas et al., 1998,
Clambey et al., 2000, Hoge et al., 2000, van Dyk et al., 2000). It is clear that an
important series of experiments will involve "knocking out" the MHV-68 genes of
interest one by one and analysing their pathogenesis in the virus's natural host.
4.2.1 Knocking M4 Out of MHV-68
A GFP recombination construct encoding homologous flanking regions to the M4 gene
was used to target the disruption of the MHV-68 M4 gene. The excised GFP construct
with M4 flanking regions was co-transfected with MHV-68 DNA into cells and
produced green fluorescent plaques, indicative of the recombinant virus. A number of
wild type (non-green) plaques were visible, therefore, rounds of plaque purification were
performed until only recombinant plaques were observed. PCR analysis was performed
on recombinant viral DNA extracted from cells that had been infected with a single
isolated green plaque. This revealed that the M4 gene was present and the
recombination event had not disrupted the M4 gene. If time had allowed, Southern
analysis could have been performed with the recombinant viral DNA to detect the exact
location of the non-homologous recombination. However, for my particular project
objective, it would have been time consuming and may not necessarily have revealed
any useful information.
A recombinational "hot-spot" has been proposed at the left hand end of the MHV-68
genome (Adler et al., 2000, Roy, unpublished observation, Wakeling, 2001). It is
possible that the non-homologous recombination which occurred in this instance may
have been in this "hot spot". Furthermore, like HVS, this region of the MHV-68
genome is a potential site for the virus origin of replication resulting in a more accessible
part of the genome (Bowden et al., 1997, Grassman & Fleckenstein, 1989).
115
Another possibility for the failure of the homologous recombination is that the 600bp
flanking regions were not long enough to allow such an event to take place. With
hindsight, increasing the flanking regions to 2-3kb may have resulted in a successful
homologous recombination. However, this may not have altered matters as it has been
demonstrated that even with 2kb flanking regions homologous recombination does not
necessarily occur (Wakeling, 2001).
Interestingly, homologous and non-homologous recombination may have occurred
simultaneously but the non-homologous recombination event conferred a growth
advantage to that particular virus. Therefore, during the time spent purifying the green
virus, the non-homologous recombinant virus may have competed out the homologous
recombinant virus.
4.2.2 Knocking M4 Into MHV-76
Despite the problems encountered, it would still be invaluable to generate a recombinant
virus for in vivo studies. The alternative strategy used was the addition of the M4 gene
into MHV-76, a deletion mutant of MHV-68 that lacked a number of left hand genes
including M4 (Macrae et al., 2001). The M4 "knock-in" recombination construct was
used to insert the M4 gene into the left hand end of the MHV-76 genome via
homologous recombination. Once again green fluorescent plaques were observed
indicating recombination had been successful. The green plaques were purified and
upon lack of wild type detection, PCR analysis was performed immediately on the
recombinant viral DNA to ensure a homologous recombinant virus was not competed by
a non-homologous recombinant alternative. PCR analysis indicated homologous
recombination had been successful and a Southern analysis was performed on the M4KI
virus to ensure purity of the virus. Southern analysis revealed that all of the bands which
distinguished MHV-68, MHV-76, and M4KI virus were present. As previously
observed, the laddering effect of the DNA is indicative that the specific DNA being
probed for is adjacent to the terminal repeats which consists of repetitive DNA
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(Efstathiou et al., 1990b). It was apparent from the bands on the Southern blot that
laddering may alter the sizes and visibility of some of the bands.
Before pursuing in vivo studies, it was necessary to ensure the M4KI virus was
transcribing the M4 gene. This was confirmed by two methods. RT-PCR was
performed on cDNA prepared from RNA extracted from M4KI infected cells. In
addition, northern analysis was performed on the M4KI RNA. Both these methods
detected M4 transcript expression. Moreover, the transcript was indistinguishable in
size from MHV-68 indicating wild type transcription.
The growth kinetics of the M4KI virus in vitro were analysed and compared to MHV-68
and MHV-76 using a single step growth curve over 72 hours post-infection. MHV-68
replicated efficiently and attained maximal titres at around 60 hours post-infection and
the growth kinetics of MHV-76 were similar to MHV-68 (Sunil-Chandra, 1991, Macrae
et al., 2001). The addition of the M4 gene in MHV-76 did not alter the virus's ability to
replicate in vitro. This does not implicate a major role for M4 during in vitro
replication.
One of the major aims of the project was to perform in vivo studies with a M4
recombinant virus. During MHV-68 infection of the lungs, virus titres peak at around
day 7 and are cleared by day 10 by the immune system (Ehtisham et al., 1993). In a
similar experiment with MHV-76, the virus is cleared more rapidly from the lung in
comparison to MHV-68 (Macrae et al., 2001). It was of interest to observe the effects of
the M4KI virus on the productive replication in lungs. Mice were infected with either
MHV-76, MHV-68 or M4KI virus and the virus titres in the lungs were analysed at
various times post-infection by plaque assay. The M4KI virus replicated productively in
vivo with the same overall kinetics as MHV-76. Therefore, the presence of the M4 gene
did not reduce or increase the clearance of the virus from the lungs in comparison to
MHV-76 and, furthermore, did not restore the kinetics and productive infection to that
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observed with MHV-68. This indicates that the difference between MHV-76 and MHV-
68 is not due to lack ofM4.
Splenomegaly is characteristic of MHV-68 infection but, interestingly, during MHV-76
infection this is dramatically reduced and a lower number of infective centres are
observed (Suni-Chandra et al., 1992, Macrae et al., 2001). This suggests a role for the
genes at the left hand end of the MHV-68 genome in splenomegaly and B cell latency.
It is not clear which of the genes are involved, therefore, the effects of the M4KI virus
on splenomegaly were observed and compared to MHV-76 and MHV-68. The spleens
of mice infected with either MHV-76, MHV-68 or M4KI virus were assayed for the
presence of virus at various times post-infection. The characteristic splenomegaly and
infective centres were observed with MHV-68 infection and a significant reduction was
observed with MHV-76 infection. The M4KI-infected spleen weights and cell counts
were similar to MHV-76. Interestingly, splenomegaly was not observed with M4KI-
infected spleens and no infective centres were apparent at any time post-infection.
These observations raised two important issues. Firstly, at which point within the mouse
does the level of M4KI virus became reduced, inhibited or undetectable. Secondly, is
the virus present in the spleen but at such low numbers that the sensitivity of the
infective centre assay cannot detect it. The MLNs are involved with the trafficking of
virus to the spleen. Therefore to investigate these issues, infective centre assays were
performed on the mediastinal lymph nodes in addition to the spleen. In contrast to
MHV-68 and MHV-76, M4KI virus infective centres were much reduced in the MLNs
and were not detectable by day 10. It is apparent that the addition of the M4 gene into
MHV-76 results in a dramatic reduction in the latent infection of MLNs and infection is
undetectable in the spleen by infective centre assay. Thus, the M4 gene product has a
role in inhibiting the movement of the virus from the MLNs to the spleen and may
interfere in the establishment of latency. It is possible that the M4 gene is involved in
and may inhibit reactivation from latency. However, M4 has been shown to be a lytic
transcript in Sll cells, thus the protein is not likely to be latency-associated (Husain et
al., 1999).
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MHV-76 and MHV-68 maintain long-term persistence in the spleen and lung and this
has been shown by PCR analysis (Sunil-Chandra et al., 1992, Stewart et al., 1998,
Macrae et al., 2001). The M4KI infective centre studies suggest that the vims may not
infect or establish latency in the spleen. However, if the M4KI vims is present in the
spleen it remains to be determined whether the virus is cleared or persists. PCR analysis
was performed on organs of M4KI infected mice at 3 months post-infection and was
unable to detect presence of the viral DNA in any of the organs. However, MHV-68 and
MHV-76 infected organs were used as positive controls and the PCR could not detect
the presence of viral genome either which suggests there is a sensitivity problem. Either
the DNA extraction process is not efficient or very low amounts of viral DNA are
present. The PCR analysis is sensitive to 1-10 copies of the viral genome in lpg of high
molecular weight DNA.
A histopathological study shows that greater inflammatory response occurs in the lungs
of MHV-76 infected mice than in MHV-68 infection (Macrae et al., 2001). Since the
M4KI virus appears to have significant differences in splenomegaly and latent infection
of B cells when compared to MHV-76, a histopathological study was performed. The
study revealed there was no difference in the inflammatory response in the lungs of
MHV-76 and M4KI virus. No differences were observed in the histopathology of
MHV-76 and M4KI spleens.
The M4 gene is predicted to be a putative viral-encoded cytokine and thus may have a
immunomodulatory role involving B cell proliferation. The presence of the M4 gene in
MHV-76 may influence the role of B cells in trafficking of the vims. Thus, B cell
activation of MLN and spleen cells was analysed by FACS analysis and this revealed
there were no significant differences in B cell activation between the three vimses.
Furthermore, M4KI virus supernatant did not appear to stimulate the growth of splenic B
cells and non-B cells in vitro compared to that ofMHV-76.
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With hindsight, during the generation of the M4KI virus, a control M4KI virus should
have been generated which would have only contained the GFP selectable marker. This
would ensure that the M4KI virus phenotype alteration is not a result of the
neighbourhood effect of the GFP gene and instead due to the M4 gene.
Rescue viruses are vitally important in determining whether the phenotypic alterations of
a recombinant virus is due to the specific recombination event or a random mutation
elsewhere in the genome. In the MHV-68 Ml and cyclin D "knock-out" virus studies,
restoration of the removed DNA sequence demonstrated that no additional mutations
were present in the MHV-68 genome (Clambey et al., 2000, Hoge et al., 2000). In the
MHV-76 studies, the deleted sequences at the left hand end of the genome was restored
to determine whether the differences observed between MHV-76 and MHV-68 were due
to this missing region (Macrae et al., 2001).
If time had permitted, the generation of a M4 rescue virus would be invaluable to
determine if the phenotypic effects of the M4KI virus were due to the presence of the
M4 gene. The M4 rescue virus would remove the M4 gene at the left hand end of the
M4KI virus and be compared to wild type MHV-76 in vivo and in vitro.
4.2.3 Recombinant Virus Strategies
Although the generation of a M4 "knock-in" virus was successful and beneficial for our
studies, it would have been desirable to achieve the initial goal of a M4 "knock-out"
virus. Ultimately, a system that distinguished homologous from non-homologous
recombination would be favourable. The purification of recombinant green plaques
from wild-type plaques was time consuming and unsuccessful, thus bypassing this
procedure would be of great assistance.
Cosmid libraries have been used as an alternative approach in generating recombinant
viruses (Cunningham & Davison, 1993; de Wind et al., 1990; van Zijl et al., 1988).
Advantages of this system are that entire virus genomes are cloned into overlapping
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cosmid clones and genes of interest are directly manipulated within bacteria.
Overlapping cosmids are linearised and the intact mutant virus genome can be
reassembled by homologous recombination of the individual genomic fragments in
permissive cells. This system does not require insertion of a selectable marker thus
eliminating the possibility of neighbourhood effects on the DNA surrounding the gene
of interest. A disadvantage to this system is that repetitive sequences such as terminal
and internal repeats tend to be unstable in bacteria (Gray & Kaerner, 1984; Quinn &
McGeoch, 1985; Weller etal., 1985).
Recently, there has been a heightened interest in the use of bacterial artificial
chromosome (BAC) technology in generating herpesvirus recombinants. The
advantages of the BAC system are that they can harbour up to 300kb of DNA, are easy
to handle, less time consuming and are relatively stable. Large virus genomes, including
HSV, EBV, pseudorabies virus, MCMV, and HCMV, have been inserted into single
BACs thus allowing the genetic manipulation of viral genes using bacterial
recombination machinery (Messerle et al., 1997, Horsburgh et ah, 1999, Delecluse et
al., 1998, Smith & Enquist, 1999, Borst et al., 1999). BACs containing the viral
genomes are maintained in Escherichia coli and viral progeny are produced via
transfection of the BAC plasmid into eukaryotic cells. This system has been used to
produce a MHV-68 BAC which will facilitate the generation of MHV-68 recombinants
(Adler et al., 2000). An ORF 4 recombinant virus and its revertant virus have been
generated using this BAC system (Adler et al., 2000). Similar to the cosmid system,
repetitive sequences are unstable in the BAC system and this was shown by spontaneous
recombination events which occurred within the internal and terminal repeats of the






5.1 Conclusion and Potential Function of M4
Many viral immunomodulatory proteins exist to subvert the host's immune response
(Spriggs, 1996, Alcami & Koszinowski, 2000, Lalani et al., 2000, McFadden &
Murphy, 2000, Tortorella et al., 2000). A number of these proteins are encoded by viral
genes with sequence homology to cellular genes. Their existence suggests that at some
point viruses abducted and modified genes from the host that would be of benefit for
themselves. However, there are many viral genes without sequence similarity to cellular
genes. Viral genes with no cellular homologues may be examples of genes with as yet
unidentified homologs in the host.
The MHV-68 M4 gene is a novel gene with an unknown function (Virgin et al., 1997).
It is likely that MHV-68 harbours the M4 gene to assist its own survival and may
function to evade the host immune response. The M4 gene is predicted to encode a
secreted cytokine with an immunomodulatory role and is an example of a gene that may
have an unidentified cellular homologue.
The initial characterisation of the M4 gene of MHV-68 is demonstrated in this thesis.
Sequence analysis revealed that the M4 gene has seven potential glycosylation sites and
a heparin sulphate binding domain. A secretory signal exists near the N-terminus of the
M4 gene. The half of the M4 protein nearest the N terminus was expressed and used as
an antigen in rabbits to raise antibody production. The antibody bound to a protein of
~44kDa, the predicted size of the M4 protein. M4 transcriptional analysis in vitro
revealed that M4 is expressed as a 1.3kb transcript during the early and late phase of
MHV-68 lytic infection. The M4 gene was inserted into MHV-76, a deletion mutant of
MHV-68, to generate a M4 knock-in (M4KI) virus. Growth kinetics studies in vitro
revealed the M4KI virus growth curve is similar to MHV-68 and MHV-76. In vivo
mouse studies revealed that the M4KI virus replicates in the lung with the same kinetics
as MHV-76. M4 KI virus infective centres were much reduced in the mediastinal lymph
nodes in comparison to MHV-76 and MHV-68, and were not detectable in the spleen.
Thus, it appears that the M4KI virus inhibits the trafficking of the virus from the
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mediastinal lymph nodes to the spleen. Generation of a rescue virus would confirm
whether this anti-pathogenic effect is due to the addition of M4 or a random mutation
elsewhere in the genome.
Since commencing the writing of my thesis, further studies in our laboratory with the
M4KI virus have revealed additional data. Recently, it has been demonstrated that mice
deficient in the type I interferon receptor (IFN-a/(3 R"A) are highly susceptible to MHV-
68 infection compared to wild type mice (Dutia et al., 1999). MHV-76 infection of the
type I IFN R knock-out mice reveals that this virus is more pathogenic than MHV-68
and results in a lethal disease (A. Townsley, personal communications). Interestingly,
the same experiment using the M4KI virus results in a non-pathogenic infection, that is,
addition of the M4 gene disrupts the pathogenicity observed with MHV-76 infection (A.
Townsley, personal communications). Furthermore, genes present in MHV-68 and not
in MHV-76, candidates being the left hand end genes, clearly interfere with the type I
interferon system. These experiments provide evidence for an anti-pathogenic role for
M4.
The anti-pathogenic mechanism by which the M4 protein functions is unknown. It is
possible that the M4 protein may function as a natural killer cell activator or a non¬
specific T cell activator. Clearly, M4 on its own is a disadvantage to the virus as viral
clearance is accelerated. This indicates that M4 must interact with another virus protein
absent in MHV-76. A candidate gene is the M3 gene that encodes a chemokine binding
protein and may be involved in downregulating the immune response (Parry et al., 2000,
van Berkel et al., 2000). During virus infection, the M3 and M4 genes may co-operate
to evade the host's immune response. A M3 and M4 double knock-in virus would be
most beneficial in elucidating the interactions between the two genes. Deleting the M4
gene from MHV-68 would still be desirable as the virus would still retain the other M
genes. A M4 knock-out virus is likely to exhibit a different phenotype from the M4KI
virus. The recent generation of a MHV-68 BAC will be of much assistance in achieving
this aim (Adler et al., 2000). During MHV-68 infection, B cell proliferation is clearly
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important. FACS analysis and proliferation studies of B cells did not reveal any
association between M4 and B cell growth. Also, the M4KI virus appeared to inhibit
viral persistence. Hence, it is possible that M4 has a role in downregulating B cell
infection.
In conclusion, M4 is a potential cytokine that may harbour an anti-pathogenic function
in vivo. The mechanism by which M4 functions remains to be elucidated. Its role in the
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Appendix 1. Cell lines.
Cell lines Properties
Baby Hamster Kidney cell
line (BHK-21)
Immortal fibroblastoid cell line (Stoker
& MacPherson, 1961).
COS (COS-7) SV40 transformed fibroblastoid cell line
(Gluzman, 1981).
293 Human fibroblastoid cell line (Graham
etal., 1977).
apSV1 Murine embryo fibroblast cell line which
lacks the type I interferon receptor
(kindly provided by Dr. J. P. Stewart).
C127 (ATCC CRL 1616) Mouse epithelial cell line derived from
a mammary carcinoma (Lowy et al.,
1978).
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Appendix 2. pET-22b(+) vector.
DET-22b seauence landmarks
T7 promoter 361-377
T7 transcription start 360
pe/fl coding sequence 224-289
Multiple cloning site 158-225
Histidine coding sequence 140-127
T7 terminantor 26-72































BS11107 t(298S) ' I
Tth111 1(2960) 1 BspG 1(2741)
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Appendix 3. pGEX1 vector.
pGEX1 vector (Pharmacia)
Ptac- promoter
Ampr: ampicillin resistance gene


















pBluescript II KS(+) vector (Stratagene)
f1 (+) origin: f1 origin of replication
ColE1 origin: origin of replicationLacI: Certain sequences of the Lacl gene have
been deleted, non-functional.
LacZ: Provides a-complementation for blue/white colour selection. An inducible lac
promoter upstream from the lacZ gene permits fusion protein expression with the p-
galactosidase gene product.
MCS: Multiple cloning site
ampR: Ampicillin resistance gene
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Appendix 5. pcDNA3.1/V5/His TOPO vector.
PCR
Product
L«rilllr I'SiSf-OStoJBoSlcj (fl OC-Q ^ Q. ctj coUJ tS ^ S? >< Q <<3 ta I V5 epitope
pcDNA3.1A/5/His TOPO vector (Invitrogen)
Pcmv- CMV immediate-early promoter
T7: T7 promoter
His6: polyhistidine tag sequence
BGH pA: bovine growth hormone polyadenylation signal
fl ori: f1 origin of replication
SV40 ori: SV40 early promoter and origin
neomycin: noomycin resistance gene
SV40 pA: SV40 polyadenylation signal
ColE1: origin of replication
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Appendix 6. pUC18 vector.
2622 Aafll £coO109 2674
2501 Sspl
2299 Xmn\





















Ser Ser Ser Val Pro Gly Asp Pro
TCG AGC TCG GTA CCC GGG GAT CCT
J I I I ..J
I -J I J L




Ser Thr Cys Arg His Ala Ser
TCG ACC TGC AGG CAT GCA AGC
1 L J I
Xba\ Sal I Pstl Sphl H/ndlll
Acrl
Hmcll
Leu Ala Leu Ala
TTG GCA CTG GCC
pUC18 vector (Stratagene)
Lacl: Certain sequences of the Lacl gene have been deleted, non-functional.
LacZ: Provides a-complementation for blue/white colour selection. An inducible lac promoter
upstream from the lacZ gene permits fusion protein expression with the p-galactosidase gene
product.
ampr: Ampicillin resistance gene




Anti-rabbit IgG biotin conjugate. 1: 80000 - Western Sigma
Anti-mouse IgG biotin conjugate. 1:80000 - Western Sigma
Monocolonal anti-polyHistidine clone HIS-1. 1: 500 - Western Sigma
Anti-GST polyclonal antibody. 1:100 - Western Stewart,
unpublished
Anti-MHV-68 polyclonal antibody.
Raised against MHV-68 infected rabbit kidney





FITC-labelled swine anti-rabbit. 1:50 - IF Dako
Hamster monoclonal antibody to mouse CD69
conjugated to FITC.
1:50 - FACs Serotec
Rat monoclonal antibody to mouse CD19
conjugated to PE.
1:20 - FACs TCS Biologicals
Control hamster IgG conjugated to FITC. 1:85 - FACs TCS Biologicals
Control rat IgG conjugated to PE. 1:85 - FACs Pharmingen
IF - immunofluorescence, FACs - Flow Cytometric Analysis
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